Processing 00000000.tx.1: Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders F. 

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "very-long-chain acyl-CoA dehydrogenase protein"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and"

Phrase: "mRNA expression in deficient fibroblasts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C1515670:mRNA Expression [Genetic Function]
   760   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "is"

Phrase: "a potential therapy for fatty acid oxidation disorders F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0039798:therapy [Functional Concept]
   742   C0087111:Therapy [Therapeutic or Preventive Procedure]
   742   C1363945:Therapy [Finding]
Processing 00000000.tx.2: Djouadi1, F. 

Phrase: "Djouadi1,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.3: Aubey1, D. 

Phrase: "Aubey1,"

Phrase: "D."
Processing 00000000.tx.4: Schlemmer1, J.P.N. 

Phrase: "Schlemmer1,"

Phrase: "J.P.N."
Processing 00000000.tx.5: Ruiter2, R.J.A. 

Phrase: "Ruiter2,"

Phrase: "R.J."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "A."
Processing 00000000.tx.6: Wanders3, A.W. 

Phrase: "Wanders3,"

Phrase: "A.W."
Processing 00000000.tx.7: Strauss3 and Jean Bastin1,* 1INSERM U393, Hpital Necker-Enfants Malades, Paris 75015, France, 2Laboratory for Genetic Metabolic Diseases, Academic Medical Centre, 1105AZ Amsterdam, The Netherlands and 3Vanderbilt Children's Hospital, Nashville, TN 37232, USA * To whom correspondence should be addressed at: INSERM U393, Hpital Necker-Enfants Malades, 149, rue de Svres, 75015 Paris, France. 

Phrase: "Strauss3"

Phrase: "and"

Phrase: "Jean Bastin1,"

Phrase: "* 1INSERM U393,"

Phrase: "Hpital Necker-Enfants Malades,"

Phrase: "Paris 75015,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0030561:Paris [Geographic Area]
   861   C0331677:Paris [Plant]
   861   C1824032:PARIS [Gene or Genome]
   827 E C1824369:PARI [Gene or Genome]

Phrase: "France,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016674:France [Geographic Area]

Phrase: "2Laboratory for Genetic Metabolic Diseases,"

Phrase: "Academic Medical Centre,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0000872:Academic medical centre [Health Care Related Organization,Manufactured Object]
   901   C0565990:Medical center [Health Care Related Organization,Manufactured Object]
   901   C1552471:Medical Center [Health Care Related Organization,Manufactured Object]
   827   C0205099:Center [Spatial Concept]
   827   C0205476:Medical [Functional Concept]
   827   C1510747:Academic [Organization]
   827   C1550724:academic [Idea or Concept]
   827   C3242376:academic [Intellectual Product]

Phrase: "1105AZ Amsterdam,"

Phrase: "The Netherlands"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0027778:The Netherlands [Geographic Area]
           Netherlands

Phrase: "and"

Phrase: "3Vanderbilt Children's Hospital,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   901   C0020017:Children's hospital [Health Care Related Organization]
   827   C0019994:Hospital, NOS [Health Care Related Organization,Manufactured Object]
   827   C1510665:Hospital [Qualitative Concept]
   743 E C1609061:Hospitals [Intellectual Product]

Phrase: "Nashville,"

Phrase: "TN 37232,"

Phrase: "USA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: "*"

Phrase: "To whom correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282413:Correspondence [Intellectual Product]

Phrase: "should"

Phrase: "be"

Phrase: "addressed at"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0376649:Address [Intellectual Product]
   799   C1442065:Address [Spatial Concept]

Phrase: ":"

Phrase: "INSERM U393,"

Phrase: "Hpital Necker-Enfants Malades,"

Phrase: "149,"

Phrase: "rue de Svres,"

Phrase: "75015 Paris,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0030561:Paris [Geographic Area]
   861   C0331677:Paris [Plant]
   861   C1824032:PARIS [Gene or Genome]
   827 E C1824369:PARI [Gene or Genome]

Phrase: "France."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016674:France [Geographic Area]
Processing 00000000.tx.8: Tel: +33 144495161; 

Phrase: "Tel"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0254343:TEL [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C0796520:TEL [Gene or Genome]
  1000   C3272379:TEL [Intellectual Product]

Phrase: ":"

Phrase: "+33 144495161"

Phrase: ";"
Processing 00000000.tx.9: Fax: +33 147348514; 

Phrase: "Fax"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085205:Fax [Manufactured Object]
  1000   C1549619:FAX [Conceptual Entity]
  1000   C1880669:Fax [Manufactured Object]

Phrase: ":"

Phrase: "+33 147348514"

Phrase: ";"
Processing 00000000.tx.10: Email: bastin{at}necker.fr Received May 19, 2005; 

Phrase: "Email"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]

Phrase: ":"

Phrase: "bastin{at}necker.fr"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C2348513:Fr. [Conceptual Entity]
   812   C3538902:FR [Gene or Genome]

Phrase: "Received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "May 19,"

Phrase: "2005"

Phrase: ";"
Processing 00000000.tx.11: Revised July 19, 2005; 

Phrase: "Revised July 19,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1527075:Revised [Therapeutic or Preventive Procedure]

Phrase: "2005"

Phrase: ";"
Processing 00000000.tx.12: Accepted August 2, 2005  ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  Inherited defect in very-long-chain acyl-CoA dehydrogenase (VLCAD), a mitochondrial enzyme catalyzing the initial step of long-chain fatty acid -oxidation (FAO), is one of the most frequent FAO enzyme defects. 

Phrase: "Accepted August 2,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1272684:Accepted [Qualitative Concept]
   827   C1548435:Accepted [Idea or Concept]

Phrase: "2005  ABSTRACT TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Inherited defect in very-long-chain acyl-CoA dehydrogenase (VLCAD),"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C1457869:Defect [Functional Concept]
   742   C1861101:DEFECT [Disease or Syndrome]
   716   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   716   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]

Phrase: "a mitochondrial enzyme catalyzing"

Phrase: "the initial step of long-chain fatty acid -oxidation (FAO),"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C1261552:Step [Conceptual Entity]
   742   C1704379:Step [Functional Concept]
   742   C1705117:Step [Quantitative Concept]
   742   C2825408:Step [Manufactured Object]

Phrase: "is"

Phrase: "one of the most frequent FAO enzyme defects."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0205447:One [Quantitative Concept]
Processing 00000000.tx.13: VLCAD deficiency is associated with clinical manifestations varying in severity, tissue involvement and age of onset. 

Phrase: "VLCAD deficiency"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "is"

Phrase: "associated with clinical manifestations"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0205210:Clinical [Qualitative Concept]
   770   C0205319:manifestations [Functional Concept]
   770   C1280464:manifestations [Qualitative Concept]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "varying in severity,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0439793:Severity [Qualitative Concept]
   790   C2983285:Severity [Intellectual Product]
   718 E C0205082:Severe [Qualitative Concept]

Phrase: "tissue involvement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1314939:Involvement [Functional Concept]

Phrase: "and"

Phrase: "age of onset."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0206132:Age of Onset [Quantitative Concept]
           Onset Age
   790   C0001779:Age [Organism Attribute]
Processing 00000000.tx.14: The molecular basis of VLCAD deficiency has been elucidated but therapeutic approaches are quite limited. 

Phrase: "The molecular basis of VLCAD deficiency"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   756   C1853126:MOLECULAR BASIS [Idea or Concept]
   738   C1527178:Basis [Functional Concept]
   738   C1874451:Basis [Pharmacologic Substance]
   706   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]

Phrase: "has"

Phrase: "been"

Phrase: "elucidated"

Phrase: "but"

Phrase: "therapeutic approaches"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0449445:Approaches [Spatial Concept]
   861   C1292724:Approaches [Functional Concept]

Phrase: "are"

Phrase: "quite"

Phrase: "limited."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0439801:Limited [Functional Concept]
  1000   C3542948:Limited [Intellectual Product]
   966 E C1549649:Limit [Idea or Concept]
   966 E C2349209:Limit [Conceptual Entity]
Processing 00000000.tx.15: In this study, we tested the hypothesis that fibrates, acting as agonist of peroxisome proliferator-activated receptors (PPARs), might stimulate FAO in VLCAD-deficient cells. 

Phrase: "In this study,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "we"

Phrase: "tested"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]

Phrase: "the hypothesis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1512571:Hypothesis [Idea or Concept]

Phrase: "that fibrates,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1449704:Fibrates [Organic Chemical,Pharmacologic Substance]

Phrase: "acting as agonist of peroxisome proliferator-activated receptors (PPARs),"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   833   C0166418:Peroxisome Proliferator-Activated Receptors [Amino Acid, Peptide, or Protein,Receptor]
   822 E C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   770   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   744   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   744   C0752063:Peroxysome [Cell Component]
   744   C1879547:Activated [Activity]
   744   C2984308:Peroxisome [Functional Concept]
   744   C2987634:Agonist [Pharmacologic Substance]
   711   C0079613:ACT [Therapeutic or Preventive Procedure]
   711 E C1515877:Activate [Functional Concept]

Phrase: "might"

Phrase: "stimulate"

Phrase: "FAO"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1158366:fatty acid oxidation [Molecular Function]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0030011:Oxidation [Molecular Function]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: "in VLCAD-deficient cells."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   793   C0007634:Cells [Cell]
   793   C3282337:Cells [Cell]
   760 E C1269647:Cell [Cell]
   760 E C1704653:Cell [Medical Device]
   760 E C1948049:Cell [Spatial Concept]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
Processing 00000000.tx.16: We demonstrate that addition of bezafibrate or fenofibric acid in the culture medium induced a dose-dependent (up to 3-fold) increase in palmitate oxidation capacities in cells from patients with the myopathic form of VLCAD deficiency, but not in cells from severely affected patients. 

Phrase: "We"

Phrase: "demonstrate"

Phrase: "that addition of bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1883712:Addition [Functional Concept]

Phrase: "or"

Phrase: "fenofibric acid in the culture medium"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0060179:fenofibric acid [Organic Chemical,Pharmacologic Substance]
   753   C0001128:Acid [Chemical]
   753   C0202406:Acid [Laboratory Procedure]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "a dose-dependent"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C1512045:Dose-dependent [Quantitative Concept]
   861   C0178602:Dose [Quantitative Concept]
   861   C0851827:Dependent [Qualitative Concept]
   861   C0869039:Dose [Quantitative Concept]
   861   C1114758:Dose # [Clinical Attribute]
   861   C1701901:Dependent [Qualitative Concept]
   861   C3244310:dependent [Functional Concept]

Phrase: "("

Phrase: "up to 3-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332462:Fold [Spatial Concept]
   861   C1880834:FOLD [Phenomenon or Process]

Phrase: ")"

Phrase: "increase in palmitate oxidation capacities"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   760   C0030011:Oxidation [Molecular Function]
   760   C0030233:palmitate [Lipid]
   760   C0442805:Increase [Functional Concept]
   760   C3503116:palmitate [Biomedical or Dental Material,Lipid]
   726   C1516240:Capacity [Quantitative Concept]
   704 E C1517378:Gain [Quantitative Concept]

Phrase: "in cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "from patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with the myopathic form"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0348078:Form [Qualitative Concept]
   861   C0376315:Form [Manufactured Object]
   861   C1522492:Form [Functional Concept]

Phrase: "of VLCAD deficiency,"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "but"

Phrase: "not in cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   790   C0007634:Cells [Cell]
   790   C1518422:Not [Functional Concept]
   790   C3282337:Cells [Cell]
   756 E C1269647:Cell [Cell]
   756 E C1704653:Cell [Medical Device]
   756 E C1948049:Cell [Spatial Concept]

Phrase: "from severely affected patients."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0522476:affected patients [Qualitative Concept]
   827   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.17: Complete normalization of cell FAO capacities could be achieved after exposure to 500M bezafibrate for 48h. 

Phrase: "Complete normalization of cell FAO capacities"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1882115:Normalization [Research Activity]

Phrase: "could"

Phrase: "be"

Phrase: "achieved after exposure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0274281:Exposure, NOS [Injury or Poisoning]
   790   C0332157:Exposure [Clinical Attribute]

Phrase: "to 500M bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "for 48h."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1442464:48H [Temporal Concept]
Processing 00000000.tx.18: Cell therapy of VLCAD deficiency was related to drug-induced increases in VLCAD mRNA (+44 to +150%; P<0.001), protein (1.52-fold) and residual enzyme activity (up to 7.7-fold) in patient cells. 

Phrase: "Cell therapy of VLCAD deficiency"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   760   C0302189:Cell Therapy [Therapeutic or Preventive Procedure]
   739   C0007634:Cell [Cell]
   739   C0039798:therapy [Functional Concept]
   739   C0087111:Therapy [Therapeutic or Preventive Procedure]
   739   C1269647:Cell [Cell]
   739   C1363945:Therapy [Finding]
   739   C1704653:Cell [Medical Device]
   739   C1948049:Cell [Spatial Concept]
   726   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]

Phrase: "was"

Phrase: "related to drug-induced increases"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   806   C0458082:Drug-induced [Functional Concept]
   760   C0013227:Drug [Pharmacologic Substance]
   760   C0205263:Induced [Functional Concept]
   760   C0439849:Related [Qualitative Concept]
   760   C0442805:increases [Functional Concept]
   760   C0445223:Related [Finding]
   760   C1254351:Drug [Pharmacologic Substance]
   726 E C0163712:Relate [Organic Chemical]
   704 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   704 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]

Phrase: "in VLCAD mRNA (+44 to +150%"
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   884   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   884   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   861   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   840   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   821   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   821   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   821   C1980013:Very long chain [Qualitative Concept]
   790   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   790   C0205166:Long [Qualitative Concept]
   790   C0337112:Chain [Manufactured Object]
   790   C0442824:Very [Qualitative Concept]
   790   C1524075:Chain [Idea or Concept]
   790   C1706317:Long [Qualitative Concept]

Phrase: "; P<0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: ","

Phrase: "protein (1.52-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0332462:Fold [Spatial Concept]
   812   C1880834:FOLD [Phenomenon or Process]

Phrase: ")"

Phrase: "and"

Phrase: "residual enzyme activity"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   901   C0243102:enzyme activity [Molecular Function]
   827   C0014442:Enzyme [Enzyme,Organic Chemical]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]
   743 E C0014445:enzymes [Functional Concept]

Phrase: "("

Phrase: "up to 7.7-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0332462:Fold [Spatial Concept]
   827   C1880834:FOLD [Phenomenon or Process]

Phrase: ")"

Phrase: "in patient cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.19: Bezafibrate also diminished the production of toxic long-chain acylcarnitines by 90% in cells harboring moderate VLCAD deficiency. 

Phrase: "Bezafibrate also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "diminished"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205216:Diminished [Quantitative Concept]

Phrase: "the production of toxic long-chain acylcarnitines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0033268:production [Occupational Activity]

Phrase: "by 90%"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439083:>90 [Quantitative Concept]
  1000   C0439087:<90 [Quantitative Concept]

Phrase: "in cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "harboring"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0475311:Harbor [Manufactured Object]

Phrase: "moderate"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0205081:Moderate [Qualitative Concept]
  1000   C1881878:Moderate [Qualitative Concept]
   944 E C1553901:Mitigate [Idea or Concept]

Phrase: "VLCAD deficiency."
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.20: Finally, real-time PCR studies indicated that bezafibrate potentially stimulated gene expression of other enzymes in the -oxidation pathway. 

Phrase: "Finally,"

Phrase: "real-time PCR studies"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   923   C1709846:Real-Time PCR [Molecular Biology Research Technique]
   875   C0040227:Time Studies [Intellectual Product]
   812   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0677874:pCR [Finding]
   812   C0947630:studies [Laboratory Procedure]
   779 E C0557651:Study [Manufactured Object]
   779 E C2603343:Study [Research Activity]

Phrase: "indicated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1444656:Indicated [Finding]

Phrase: "that bezafibrate potentially stimulated gene expression of other enzymes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   764   C0017262:Gene Expression [Genetic Function]
   745   C1333402:Enzyme Gene [Gene or Genome]
   742   C0017337:Gene [Gene or Genome]
   742   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "in the -oxidation pathway."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1704259:Pathway [Molecular Function]
   861   C1705987:Pathway [Conceptual Entity]
Processing 00000000.tx.21: These data highlight the potential of fibrates in the correction of inborn FAO defects, as most mutations associated with these defects are compatible with the synthesis of a mutant protein with variable levels of residual enzyme activity.  

Phrase: "These data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "highlight"

Phrase: "the potential of fibrates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C3245505:Potential [Qualitative Concept]

Phrase: "in the correction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1705565:CORRECTION [Intellectual Product]
  1000   C1947976:Correction [Functional Concept]

Phrase: "of inborn FAO defects,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   937   C1829742:Fatty acid oxidation defects [Disease or Syndrome]
   804   C0243067:defects [Functional Concept]
   771 E C1457869:Defect [Functional Concept]
   771 E C1861101:DEFECT [Disease or Syndrome]
   717   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "as"

Phrase: "most mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "associated with these defects"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0243067:defects [Functional Concept]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1457869:Defect [Functional Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
   737 E C1861101:DEFECT [Disease or Syndrome]

Phrase: "are"

Phrase: "compatible with the synthesis of a mutant protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0332290:compatible [Idea or Concept]
   744   C1524057:Compatible [Qualitative Concept]

Phrase: "with variable levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "of residual enzyme activity."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   901   C0243102:enzyme activity [Molecular Function]
   827   C0014442:Enzyme [Enzyme,Organic Chemical]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]
   743 E C0014445:enzymes [Functional Concept]
Processing 00000000.tx.22: INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  Mitochondrial -oxidation of long-chain fatty acids is the main energy-producing pathway in many organs and tissues. 

Phrase: "INTRODUCTION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Mitochondrial -oxidation of long-chain fatty acids"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   800   C1158366:acids fatty oxidation [Molecular Function]
   748   C0030011:Oxidation [Molecular Function]

Phrase: "is"

Phrase: "the main energy-producing pathway in many organs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1704259:Pathway [Molecular Function]
   744   C1705987:Pathway [Conceptual Entity]

Phrase: "and"

Phrase: "tissues."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040300:Tissues [Tissue]
   966 E C1547928:Tissue [Intellectual Product]
Processing 00000000.tx.23: Therefore, inherited defects in enzymes of mitochondrial fatty acid oxidation (FAO) are associated with a spectrum of clinical manifestations varying in severity, tissue involvement and age of onset (1). 

Phrase: "Therefore,"

Phrase: "inherited defects in enzymes of mitochondrial fatty acid oxidation"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   810   C1829742:Fatty acid oxidation defects [Disease or Syndrome]
   742   C0243067:defects [Functional Concept]
   708 E C1457869:Defect [Functional Concept]
   708 E C1861101:DEFECT [Disease or Syndrome]

Phrase: "(FAO"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1158366:fatty acid oxidation [Molecular Function]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0030011:Oxidation [Molecular Function]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: ")"

Phrase: "are"

Phrase: "associated with a spectrum of clinical manifestations"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   778   C0332281:Associated with [Qualitative Concept]
           Associated
   757   C1280464:Manifestation of [Qualitative Concept]
           manifestations
   748   C0205210:Clinical [Qualitative Concept]
   748   C0205319:manifestations [Functional Concept]
   748   C1883073:Spectrum [Quantitative Concept]
   748   C2827424:Spectrum [Conceptual Entity]
   714 E C0750490:Associate [Idea or Concept]
   714 E C1706221:Associate [Professional or Occupational Group]

Phrase: "varying in severity,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0439793:Severity [Qualitative Concept]
   790   C2983285:Severity [Intellectual Product]
   718 E C0205082:Severe [Qualitative Concept]

Phrase: "tissue involvement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1314939:Involvement [Functional Concept]

Phrase: "and"

Phrase: "age of onset"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0206132:Age of Onset [Quantitative Concept]
           Onset Age
   790   C0001779:Age [Organism Attribute]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")."
Processing 00000000.tx.24: Very-long chain acyl-CoA dehydrogenase (VLCAD) is one of the four acyl-CoA dehydrogenases with various chain length specificities that catalyze the initial step of mitochondrial FAO. 

Phrase: "Very-long chain acyl-CoA dehydrogenase"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
  1000   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   947   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   901   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   861   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   861   C1980013:Very long chain [Qualitative Concept]
   799   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0205166:Long [Qualitative Concept]
   799   C0337112:Chain [Manufactured Object]
   799   C0442824:Very [Qualitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1706317:Long [Qualitative Concept]

Phrase: "(VLCAD"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
  1000   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   947   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   901   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   861   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   861   C1980013:Very long chain [Qualitative Concept]
   799   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0205166:Long [Qualitative Concept]
   799   C0337112:Chain [Manufactured Object]
   799   C0442824:Very [Qualitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1706317:Long [Qualitative Concept]

Phrase: ")"

Phrase: "is"

Phrase: "one of the four acyl-CoA dehydrogenases"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0205447:One [Quantitative Concept]

Phrase: "with various chain length specificities"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   779   C0037791:Specificity [Quantitative Concept]
   779   C1511884:Specificity [Quantitative Concept]
   729 E C0205369:Specific [Qualitative Concept]
   729 E C1552740:specific [Intellectual Product]

Phrase: "that"

Phrase: "catalyze"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0007382:catalyse [Natural Phenomenon or Process]

Phrase: "the initial step of mitochondrial FAO."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C1261552:Step [Conceptual Entity]
   744   C1704379:Step [Functional Concept]
   744   C1705117:Step [Quantitative Concept]
   744   C2825408:Step [Manufactured Object]
Processing 00000000.tx.25: In humans, VLCAD is the main isoform involved in the oxidation of long-chain fatty acids. 

Phrase: "In humans,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086418:Humans [Human]

Phrase: "VLCAD"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
  1000   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   947   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   901   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   861   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   861   C1980013:Very long chain [Qualitative Concept]
   799   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0205166:Long [Qualitative Concept]
   799   C0337112:Chain [Manufactured Object]
   799   C0442824:Very [Qualitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1706317:Long [Qualitative Concept]

Phrase: "is"

Phrase: "the main isoform"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0597298:Isoform [Amino Acid, Peptide, or Protein]

Phrase: "involved in the oxidation of long-chain fatty acids."
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   807   C0522095:Fatty acids.long chain [Biologically Active Substance,Lipid]
   781   C1158366:acids fatty oxidation [Molecular Function]
   764   C0015684:Fatty Acids [Lipid]
   742   C0001128:Acids [Chemical]
   742   C0030011:Oxidation [Molecular Function]
   742   C0205166:Long [Qualitative Concept]
   742   C0337112:Chain [Manufactured Object]
   742   C1314939:Involved [Functional Concept]
   742   C1524075:Chain [Idea or Concept]
   742   C1706317:Long [Qualitative Concept]
   708 E C0202406:Acid [Laboratory Procedure]
Processing 00000000.tx.26: In fact, patients presenting with palmitoyl-CoA dehydrogenase deficiency by enzyme assay were discovered to have disease-causing mutations in the VLCAD gene and not in the long-chain acyl-CoA dehydrogenase (LCAD) gene (1). 

Phrase: "In fact,"

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "presenting with palmitoyl-CoA dehydrogenase deficiency"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   833   C0050688:Palmitoyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0030239:Palmitoyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
   790   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   753   C0011155:Deficiency [Functional Concept]
   753   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   753   C0162429:Deficiency [Disease or Syndrome]
   753   C0449450:Presenting [Idea or Concept]
   753   C1623416:deficiency [Qualitative Concept]
   719 E C0150312:Present [Quantitative Concept]

Phrase: "by enzyme assay"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C2717977:Enzyme Assay [Laboratory Procedure]
   861   C0005507:Assay [Laboratory Procedure]
   861   C0014442:Enzyme [Enzyme,Organic Chemical]
   861   C0243073:assay [Qualitative Concept]
   861   C1510438:Assay [Laboratory Procedure]
   777 E C0014445:enzymes [Functional Concept]

Phrase: "were"

Phrase: "discovered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1880355:Discover [Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "have"

Phrase: "disease-causing mutations"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   988   C2985434:Disease-causing Mutation [Cell or Molecular Dysfunction]
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]
   717   C1314792:disease cause [Functional Concept]

Phrase: "in the VLCAD gene"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0017337:Gene [Gene or Genome]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and"

Phrase: "not in the long-chain acyl-CoA dehydrogenase (LCAD) gene"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   849   C0065170:Long-Chain-Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   849   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   818   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   790   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   742   C0017337:Gene [Gene or Genome]
   742   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   742   C0205166:Long [Qualitative Concept]
   742   C0337112:Chain [Manufactured Object]
   742   C1518422:Not [Functional Concept]
   742   C1524075:Chain [Idea or Concept]
   742   C1706317:Long [Qualitative Concept]

Phrase: "(1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")."
Processing 00000000.tx.27: Like many FAO enzymes, VLCAD is ubiquitously expressed at various levels in most tissues. 

Phrase: "Like many FAO enzymes,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0014442:Enzymes [Enzyme,Organic Chemical]
   812   C0014445:enzymes [Functional Concept]
   756   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "VLCAD"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
  1000   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   947   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   901   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   861   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   861   C1980013:Very long chain [Qualitative Concept]
   799   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0205166:Long [Qualitative Concept]
   799   C0337112:Chain [Manufactured Object]
   799   C0442824:Very [Qualitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1706317:Long [Qualitative Concept]

Phrase: "is"

Phrase: "ubiquitously"

Phrase: "expressed at various levels"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0440102:Various [Indicator, Reagent, or Diagnostic Aid]
   770   C0441889:Levels [Qualitative Concept]
   737 E C0456079:Level [Classification]
   737 E C1547707:Level [Geographic Area]
   737 E C2946261:Level [Pharmacologic Substance]

Phrase: "in most tissues."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040300:Tissues [Tissue]
   966 E C1547928:Tissue [Intellectual Product]
Processing 00000000.tx.28: Nonetheless, VLCAD deficiency can manifest in quite different phenotypes (2), consistent with the clinical, biochemical and genetic diversity of inborn FAO disorders. 

Phrase: "Nonetheless,"

Phrase: "VLCAD deficiency"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "can"

Phrase: "manifest in quite different phenotypes"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0031437:Phenotypes [Organism Attribute]
   760   C0205319:Manifest [Functional Concept]
   760   C1705242:Different [Qualitative Concept]
   726 E C1285572:Phenotype [Laboratory Procedure]

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")"

Phrase: ","

Phrase: "consistent with the clinical, biochemical"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0332290:Consistent with [Idea or Concept]
           Consistent

Phrase: "and"

Phrase: "genetic diversity of inborn FAO disorders."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   770   C0042333:Genetic Diversity [Natural Phenomenon or Process]
   767   C0019247:Genetic Disorders [Disease or Syndrome]
   767   C2924406:Genetic disorders [Laboratory Procedure]
   744   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   744   C0314603:Genetic [Functional Concept]
   744   C1880371:Diversity [Qualitative Concept]
   739 E C0242354:birth disorders [Congenital Abnormality,Disease or Syndrome]
   725 E C0178829:Genital Disorders [Disease or Syndrome]
Processing 00000000.tx.29: Furthermore, VLCAD deficiency is one among the more common FAO defects, with more than 100 reported patients (3). 

Phrase: "Furthermore,"

Phrase: "VLCAD deficiency"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "is"

Phrase: "one among the more common FAO defects,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0205447:One [Quantitative Concept]

Phrase: "with more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "than 100 reported patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")."
Processing 00000000.tx.30: Three distinct presentations of the disease have been described. 

Phrase: "Three distinct presentations of the disease"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C3274800:Disease Presentation [Clinical Attribute]
   753   C0449450:presentations [Idea or Concept]

Phrase: "have"

Phrase: "been"

Phrase: "described."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]
Processing 00000000.tx.31: In its most severe form, VLCAD deficiency presents with severe neonatal cardiomyopathy and liver failure, generally leading to death. 

Phrase: "In its most severe form,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0348078:Form [Qualitative Concept]
   827   C0376315:Form [Manufactured Object]
   827   C1522492:Form [Functional Concept]

Phrase: "VLCAD deficiency"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "presents with severe neonatal cardiomyopathy"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0150312:Present [Quantitative Concept]
   760   C0205082:Severe [Qualitative Concept]
   760   C0449450:Present [Idea or Concept]
   760   C0878544:Cardiomyopathy [Disease or Syndrome]
   760   C1552240:Neonatal [Professional or Occupational Group]
   760   C1552264:Neonatal [Professional or Occupational Group]
   760   C2939425:Neonatal [Temporal Concept]

Phrase: "and"

Phrase: "liver failure,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085605:Liver Failure [Disease or Syndrome]
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "generally"

Phrase: "leading to death."
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   790   C0011065:Death [Organism Function]
   790   C0332152:Leading [Temporal Concept]
   790   C1306577:Death, NOS [Finding]
   790   C1522538:Leading [Functional Concept]
   756 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   756 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   756 E C2348269:Lead [Element, Ion, or Isotope]
   756 E C3275067:LEAD [Therapeutic or Preventive Procedure]
Processing 00000000.tx.32: In the infantile onset form, delayed disease onset is encountered, characterized by hypoketotic hypoglycemia. 

Phrase: "In the infantile onset form,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0348078:Form [Qualitative Concept]
   827   C0376315:Form [Manufactured Object]
   827   C1522492:Form [Functional Concept]
   734   C1848924:Infantile onset [Finding]

Phrase: "delayed disease onset"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0277793:disease onset [Temporal Concept]
   827   C0332162:Onset [Qualitative Concept]

Phrase: "is"

Phrase: "encountered"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0545082:Encounter [Behavior]
   966   C1512346:encounter [Health Care Activity]
   966   C1947978:Encounter [Behavior]

Phrase: ","

Phrase: "characterized by hypoketotic hypoglycemia."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1856438:Hypoglycemia, hypoketotic [Finding]
   770   C0020615:Hypoglycaemia [Disease or Syndrome]
   770   C1880022:Characterized [Activity]
Processing 00000000.tx.33: Finally, a last group of VLCAD-deficient patients are asymptomatic early in life, but develop a purely myopathic form of the disease in adolescence or adulthood, with myalgia and exercise intolerance, usually with episodes of rhabdomyolysis triggered by metabolic stress conditions such as exercise, starvation, exposure to cold or fever; 

Phrase: "Finally,"

Phrase: "a last group"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "of VLCAD-deficient patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "are"

Phrase: "asymptomatic early in life,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C0376558:Life [Idea or Concept]
   812   C1279919:Early [Temporal Concept]
   729 E C0595998:lives [Finding]

Phrase: "but"

Phrase: "develop"

Phrase: "a purely myopathic form of the disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0348078:Form [Qualitative Concept]
   748   C0376315:Form [Manufactured Object]
   748   C1522492:Form [Functional Concept]

Phrase: "in adolescence"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0001578:Adolescence [Age Group]
   928 E C0205653:Adolescent [Age Group]

Phrase: "or"

Phrase: "adulthood,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700597:Adulthood [Temporal Concept]

Phrase: "with myalgia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231528:Myalgia [Sign or Symptom]

Phrase: "and"

Phrase: "exercise intolerance,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0241885:Exercise intolerance [Sign or Symptom]
   861   C0231199:Intolerance [Organism Function]
   861   C1744706:intolerance [Intellectual Product]
   861   C2355652:Intolerance [Organism Attribute]
   789 E C0231200:Intolerant [Functional Concept]

Phrase: "usually with episodes of rhabdomyolysis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0332189:Episode of [Temporal Concept]
           Episodes
   760   C0035410:Rhabdomyolysis [Pathologic Function]

Phrase: "triggered by metabolic stress"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   833   C1444748:Triggered by [Qualitative Concept]
           Trigger
   833   C2350024:Metabolic Stress [Organism Attribute]
   770   C0038435:Stress [Finding]
   770   C0311400:Metabolic [Functional Concept]
   770   C1524026:Metabolic [Cell Function]
   770   C2707259:Metabolic [Clinical Attribute]
   737   C0032930:Trigger [Clinical Attribute]

Phrase: "conditions such as exercise,"
Meta Candidates (Total=10; Excluded=5; Pruned=0; Remaining=5)
   770   C0012634:condition [Disease or Syndrome]
   770   C0015259:Exercise [Daily or Recreational Activity]
   770   C0348080:Condition [Qualitative Concept]
   770   C1522704:Exercise [Therapeutic or Preventive Procedure]
   770   C1705253:Condition [Conceptual Entity]
   715 E C0040607:Training [Educational Activity]
   715 E C0220931:Training [Educational Activity]
   715 E C0336809:Train [Manufactured Object]
   715 E C1552514:Train [Manufactured Object]
   715 E C2673163:training [Qualitative Concept]

Phrase: "starvation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038187:Starvation [Finding]

Phrase: "exposure to cold"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   882   C0332157:Exposure to [Clinical Attribute]
           Exposure
   858   C0231275:Cold exposure [Injury or Poisoning]
   790   C0274281:Exposure, NOS [Injury or Poisoning]

Phrase: "or"

Phrase: "fever"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015967:Fever [Finding]

Phrase: ";"
Processing 00000000.tx.34: this presentation represents the largest group among all the VLCAD-deficient patients (3). 

Phrase: "this presentation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449450:Presentation [Idea or Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "the largest group among all"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   790   C0679991:large group [Group Attribute]
   760   C0441833:Group [Idea or Concept]
   760   C0687744:group [Population Group]
   760   C1257890:Group [Population Group]
   760   C1552516:Group [Health Care Related Organization]
   760   C1705428:Group [Conceptual Entity]
   760   C1705429:Group [Population Group]

Phrase: "the VLCAD-deficient patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")."
Processing 00000000.tx.35: The molecular basis of VLCAD deficiency has been studied in a relatively large panel of patients. 

Phrase: "The molecular basis of VLCAD deficiency"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   756   C1853126:MOLECULAR BASIS [Idea or Concept]
   738   C1527178:Basis [Functional Concept]
   738   C1874451:Basis [Pharmacologic Substance]
   706   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]

Phrase: "has"

Phrase: "been"

Phrase: "studied in a relatively large panel of patients."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   750   C0681848:Panel Study [Research Activity]
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0441833:Panel [Idea or Concept]
   744   C0549177:Large [Quantitative Concept]
   744   C1999270:Panel [Intellectual Product]
   744   C3537156:Panel [Manufactured Object]
   711   C0557651:Study [Manufactured Object]
   711   C2603343:Study [Research Activity]
Processing 00000000.tx.36: At present, more than 80 different gene mutations have been characterized that span the entire gene. 

Phrase: "At present,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0150312:Present [Quantitative Concept]
  1000   C0449450:Present [Idea or Concept]

Phrase: "more than 80 different gene mutations"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   790   C0596611:gene mutations [Genetic Function]
   753   C0017337:Gene [Gene or Genome]
   753   C0026882:Mutations [Genetic Function]
   753   C0205172:More [Functional Concept]
   753   C1705242:Different [Qualitative Concept]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "have"

Phrase: "been"

Phrase: "characterized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1880022:Characterized [Activity]

Phrase: "that"

Phrase: "span"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1711300:Span [Conceptual Entity]
  1000   C2700613:Span [Quantitative Concept]

Phrase: "the entire gene."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017337:Gene [Gene or Genome]
Processing 00000000.tx.37: No prevalent mutation has been identified among symptomatic patients (3). 

Phrase: "No prevalent mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0026882:Mutation [Genetic Function]
   861   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "has"

Phrase: "been"

Phrase: "identified among symptomatic patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0205396:Identified [Qualitative Concept]
   770   C0231220:Symptomatic [Functional Concept]
   770   C1550043:Identified [Finding]
   770   C1551388:Identified [Functional Concept]

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")."
Processing 00000000.tx.38: Besides its usefulness in family studies and pre-natal diagnosis, mutation analysis defined clear genotypephenotype correlations (24) because individuals with the severe phenotype generally carry gene deletions, insertions or mutations leading to complete lack of mRNA and/or protein expression, so-called null mutations. 

Phrase: "Besides its usefulness"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   900   C0042153:use [Functional Concept]
   900   C0457083:Use [Functional Concept]
   900   C1947944:Use [Intellectual Product]

Phrase: "in family studies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0199236:family studies [Diagnostic Procedure]
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "pre-natal diagnosis,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0011900:Diagnosis [Finding]
   827   C1704338:diagnosis [Qualitative Concept]
   827   C1704656:DIAGNOSIS [Research Activity]

Phrase: "mutation analysis"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0796357:mutation analysis [Laboratory Procedure]
   861   C0002778:Analysis [Laboratory Procedure]
   861   C0936012:Analysis [Research Activity]
   861   C1524024:analysis [Functional Concept]

Phrase: "defined"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1704788:Defined [Conceptual Entity]
  1000   C3539106:Defined [Intellectual Product]

Phrase: "clear genotypephenotype correlations"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C1707520:Correlation [Qualitative Concept]

Phrase: "(24"

Phrase: ")"

Phrase: "because"

Phrase: "individuals with the severe phenotype generally"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C0027361:Individual [Population Group]
   719   C0237401:Individual [Human]

Phrase: "carry"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:Carry [Activity]
  1000   C0699809:carry [Finding]

Phrase: "gene deletions,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0017260:Gene Deletions [Genetic Function]
   966 E C1442161:Gene Deletion [Cell or Molecular Dysfunction]
       E   Deletion
   861   C0017337:Gene [Gene or Genome]
   861   C1880274:Deletions [Activity]
   827 E C1511760:Deletion [Genetic Function]

Phrase: "insertions"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0441587:insertions [Health Care Activity]
   966 E C0021107:Insertion [Therapeutic or Preventive Procedure]
   966 E C1512796:Insertion [Genetic Function]
   966 E C1883719:Insertion [Functional Concept]

Phrase: "or"

Phrase: "mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026882:Mutations [Genetic Function]
   966 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "leading"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0332152:Leading [Temporal Concept]
  1000   C1522538:Leading [Functional Concept]
   966 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   966 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   966 E C2348269:Lead [Element, Ion, or Isotope]
   966 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "complete"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Complete [Qualitative Concept]

Phrase: "lack of mRNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0332268:lack [Qualitative Concept]

Phrase: "and/or"

Phrase: "protein expression,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1171362:protein expression [Genetic Function]
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "so-called null mutations."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0026882:Mutations [Genetic Function]
   779 E C1705285:Mutation [Cell or Molecular Dysfunction]
Processing 00000000.tx.39: In contrast, the majority of VLCAD gene mutations found in the milder phenotypes are missense or small in-frame deletions or insertions compatible with mRNA production, translation and expression of some residual enzyme activity. 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "the majority of VLCAD gene mutations"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0680220:majority [Social Behavior]

Phrase: "found in the milder phenotypes"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   773   C1855585:Mild phenotype [Finding]
   760   C0031437:Phenotypes [Organism Attribute]
   760   C0150312:Found [Quantitative Concept]
   726 E C0243095:Find [Finding]
   726 E C1285572:Phenotype [Laboratory Procedure]
   726   C2945599:Mild [Qualitative Concept]

Phrase: "are"

Phrase: "missense"

Phrase: "or"

Phrase: "small in-frame deletions"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C1880274:Deletions [Activity]
   779 E C1442161:Deletion [Cell or Molecular Dysfunction]
   779 E C1511760:Deletion [Genetic Function]

Phrase: "or"

Phrase: "insertions"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0441587:insertions [Health Care Activity]
   966 E C0021107:Insertion [Therapeutic or Preventive Procedure]
   966 E C1512796:Insertion [Genetic Function]
   966 E C1883719:Insertion [Functional Concept]

Phrase: "compatible with mRNA production,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0332290:compatible [Idea or Concept]
   770   C1524057:Compatible [Qualitative Concept]

Phrase: "translation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0040712:Translation [Intellectual Product]
  1000   C0597295:translation [Molecular Function]
  1000   C1519614:Translation [Genetic Function]

Phrase: "and"

Phrase: "expression of some residual enzyme activity."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0185117:Expression [Therapeutic or Preventive Procedure]
Processing 00000000.tx.40: The correlation between disease phenotype and the extent of metabolic block has mainly been addressed by studies of acylcarnitines profile in blood or cultured cells of VLCAD-deficient patients (5,6). 

Phrase: "The correlation between disease phenotype"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1707520:Correlation [Qualitative Concept]

Phrase: "and"

Phrase: "the extent of metabolic block"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0439792:Extent [Spatial Concept]

Phrase: "has"

Phrase: "mainly"

Phrase: "been"

Phrase: "addressed by studies of acylcarnitines"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   760   C0368608:acylcarnitines [Organic Chemical]
   760   C0947630:studies [Laboratory Procedure]
   726   C0376649:Address [Intellectual Product]
   726 E C0557651:Study [Manufactured Object]
   726   C1442065:Address [Spatial Concept]
   726 E C2603343:Study [Research Activity]

Phrase: "profile in blood"
Meta Candidates (Total=10; Excluded=5; Pruned=0; Remaining=5)
   790   C0005767:Blood [Tissue]
   790   C0005768:blood [Body Substance]
   790   C0229664:Blood [Body Substance]
   790   C1979963:Profile [Laboratory Procedure]
   790   C2003903:Profile [Functional Concept]
   718 E C0333275:Bloody [Qualitative Concept]
   706 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   706 E C0392895:Bloods [Population Group]
   706 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   706 E C1511228:VESSEL, BLOOD [Tissue]

Phrase: "or"

Phrase: "cultured cells"
Meta Candidates (Total=13; Excluded=4; Pruned=0; Remaining=9)
  1000   C0007600:cultured cells [Cell]
  1000   C0007635:Cultured Cells [Cell]
  1000   C3282338:Cells, Cultured [Cell]
   966 E C0007585:culture cell [Laboratory Procedure]
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827   C0010453:Culture [Idea or Concept]
   827   C0220814:culture [Functional Concept]
   827   C0430400:Culture [Laboratory Procedure]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
   827   C2242979:Culture [Laboratory Procedure]

Phrase: "of VLCAD-deficient patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "(5,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: "6"

Phrase: ")."
Processing 00000000.tx.41: In fact, the development of electrospray ionization tandem mass spectrometry (ESI-MS-MS) has provided a powerful tool to characterize the patterns of acylcarnitine species that typically accumulate in various forms of the disease, secondary to impaired FAO. 

Phrase: "In fact,"

Phrase: "the development of electrospray ionization tandem mass spectrometry (ESI-MS-MS)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0243107:development [Physiologic Function]
   744   C0678723:Development [Organism Function]
   744   C1527148:Development [Functional Concept]

Phrase: "has"

Phrase: "provided"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provided [Activity]

Phrase: "a powerful tool to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   865   C0336794:Power tool [Manufactured Object]
   827   C0336791:Tool [Manufactured Object]
   827   C2827396:Tool [Manufactured Object]

Phrase: "characterize"

Phrase: "the patterns of acylcarnitine species"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   781   C2598335:Acylcarnitine pattern [Clinical Attribute]
   760   C0449774:Patterns [Spatial Concept]

Phrase: "that typically"

Phrase: "accumulate in various forms of the disease,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   748   C0012634:Disease [Disease or Syndrome]
   748   C0348078:forms [Qualitative Concept]
   748   C0376315:Forms [Manufactured Object]
   748   C0440102:Various [Indicator, Reagent, or Diagnostic Aid]
   714 E C1522492:Form [Functional Concept]

Phrase: "secondary to impaired FAO."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0175668:Secondary to [Temporal Concept]
           Secondary
   753   C0027627:secondary [Neoplastic Process]
   753   C0205436:Secondary [Quantitative Concept]
Processing 00000000.tx.42: Altogether, these studies point out that the most severe phenotypes are associated with a more marked accumulation of long-chain acylcarnitines when compared with milder forms (7), and support the notion that residual long-chain FAO flux is extremely low in cells harboring a severe VLCAD defect, whereas milder phenotypes exhibit less profound defects in FAO capacities. 

Phrase: "Altogether,"

Phrase: "these studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "point"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1552961:Point [Quantitative Concept]
  1000   C2347617:point [Quantitative Concept]

Phrase: "out"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439787:Out [Spatial Concept]
  1000   C0849355:Out [Qualitative Concept]

Phrase: "that"

Phrase: "the most severe phenotypes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   884   C1836408:Severe phenotype [Finding]
   827   C0031437:Phenotypes [Organism Attribute]
   793 E C1285572:Phenotype [Laboratory Procedure]

Phrase: "are"

Phrase: "associated with a more marked accumulation of long-chain acylcarnitines"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   760   C0332281:Associated with [Qualitative Concept]
           Associated
   739   C0205166:Long [Qualitative Concept]
   739   C0337112:Chain [Manufactured Object]
   739   C0368608:acylcarnitines [Organic Chemical]
   739   C0522501:Marked [Qualitative Concept]
   739   C1524075:Chain [Idea or Concept]
   739   C1706089:Marked [Qualitative Concept]
   739   C1706317:Long [Qualitative Concept]
   706 E C0750490:Associate [Idea or Concept]
   706 E C1706221:Associate [Professional or Occupational Group]

Phrase: "when"

Phrase: "compared with milder forms"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0348078:forms [Qualitative Concept]
   770   C0376315:Forms [Manufactured Object]
   770   C1707455:Compared [Activity]
   737 E C1522492:Form [Functional Concept]
   737   C2945599:Mild [Qualitative Concept]

Phrase: "(7"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "support"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0183683:Support [Medical Device]
  1000   C1521721:Support [Conceptual Entity]

Phrase: "the notion"

Phrase: "that residual long-chain FAO flux"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   795   C2348693:Flux [Natural Phenomenon or Process]
   710   C0522095:Long chain fatty acid [Biologically Active Substance,Lipid]

Phrase: "is"

Phrase: "extremely low in cells"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205251:low [Qualitative Concept]
   770   C1299352:Low [Qualitative Concept]
   770   C1550472:low [Idea or Concept]

Phrase: "harboring"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0475311:Harbor [Manufactured Object]

Phrase: "a severe VLCAD defect,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   793   C1457869:Defect [Functional Concept]
   793   C1861101:DEFECT [Disease or Syndrome]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "whereas"

Phrase: "milder phenotypes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   966   C1855585:Mild phenotype [Finding]
   861   C0031437:Phenotypes [Organism Attribute]
   827 E C1285572:Phenotype [Laboratory Procedure]

Phrase: "exhibit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015272:Exhibit [Intellectual Product]

Phrase: "less profound defects in FAO capacities."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   822   C1829742:Fatty acid oxidation defects [Disease or Syndrome]
   744   C0243067:defects [Functional Concept]
   711 E C1457869:Defect [Functional Concept]
   711 E C1861101:DEFECT [Disease or Syndrome]
Processing 00000000.tx.43: In several American and European centers, large-scale applications of ESI-MS-MS have allowed systematic population-based neonatal screening for VLCAD deficiency (8). 

Phrase: "In several American"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596070:American [Population Group]

Phrase: "and"

Phrase: "European centers,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205099:centers [Spatial Concept]

Phrase: "large-scale applications of ESI-MS-MS"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   742   C0185125:applications [Health Care Activity]
   708 E C1947919:Application [Intellectual Product]
   708 E C2347934:Application [Intellectual Product]
   708 E C3539080:APPLICATION [Quantitative Concept]

Phrase: "have"

Phrase: "allowed systematic population-based neonatal screening"
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
   827   C0027617:Neonatal Screening [Diagnostic Procedure]
   799   C0220908:Screening [Health Care Activity]
   799   C0220909:screening [Functional Concept]
   799   C1552240:Neonatal [Professional or Occupational Group]
   799   C1552264:Neonatal [Professional or Occupational Group]
   799   C1698960:screening [Intellectual Product]
   799   C1710031:Screening [Diagnostic Procedure]
   799   C1710477:SCREENING [Research Activity]
   799   C2939425:Neonatal [Temporal Concept]
   766 E C1305399:screen [Functional Concept]
   766 E C1705053:Screen [Medical Device]

Phrase: "for VLCAD deficiency"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "(8"

Phrase: ")."
Processing 00000000.tx.44: Combined with genetic analysis, this approach has greatly improved detection of this potentially severe FAO disorder. 

Phrase: "Combined with genetic analysis,"
Meta Candidates (Total=16; Excluded=8; Pruned=0; Remaining=8)
   833   C0679560:genetic analysis [Laboratory Procedure]
   833   C0796344:Genetic Analysis [Laboratory Procedure]
   770   C0002778:Analysis [Laboratory Procedure]
   770   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   770   C0205195:Combined [Qualitative Concept]
   770   C0314603:Genetic [Functional Concept]
   770   C0936012:Analysis [Research Activity]
   770   C1524024:analysis [Functional Concept]
   737 E C0336789:Combine [Manufactured Object]
   715 E C0005615:Birth [Organism Function]
   715 E C0035150:Reproduction [Organism Function]
   715 E C0079946:origin [Classification]
   715 E C0439659:Origin [Temporal Concept]
   715 E C1550512:origin [Intellectual Product]
   715 E C1550722:birth [Idea or Concept]
   715 E C3245487:birth [Intellectual Product]

Phrase: "this approach"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449445:Approach [Spatial Concept]

Phrase: "has"

Phrase: "greatly improved detection of this potentially severe FAO disorder."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C1511790:Detection [Therapeutic or Preventive Procedure]
Processing 00000000.tx.45: In particular, it is now possible to identify asymptomatic patients carrying disease-causing VLCAD gene mutations (9), long before the onset of clinical manifestations. 

Phrase: "In particular,"

Phrase: "it"

Phrase: "is"

Phrase: "now possible to"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0332149:Possible [Qualitative Concept]
   827   C1705910:Possible [Qualitative Concept]
   827   C1948052:Now [Temporal Concept]
   827   C2362652:Possible [Qualitative Concept]

Phrase: "identify"

Phrase: "asymptomatic patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "carrying"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0206243:Carrying [Activity]
   966 E C0699809:carry [Finding]

Phrase: "disease-causing VLCAD gene mutations"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   883   C2985434:Disease-causing Mutation [Cell or Molecular Dysfunction]
   852   C1416989:MAL gene [Gene or Genome]
   804   C0596611:gene mutations [Genetic Function]
   790   C0017337:Gene [Gene or Genome]
   790   C0026882:Mutations [Genetic Function]
   756 E C1705285:Mutation [Cell or Molecular Dysfunction]
   717   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]

Phrase: "(9"

Phrase: ")"

Phrase: ","

Phrase: "long before the onset of clinical manifestations."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0205166:Long [Qualitative Concept]
   748   C1706317:Long [Qualitative Concept]
Processing 00000000.tx.46: These rapid advances in the characterization of the disease over the last years are in marked contrast with the limited progress in therapy for VLCAD deficiency and FAO disorders. 

Phrase: "These rapid advances in the characterization of the disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   708   C0725066:Advance [Medical Device]

Phrase: "over the last years"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439234:years [Temporal Concept]
   827 E C0439508:/year [Temporal Concept]

Phrase: "are in marked contrast"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0522501:Marked [Qualitative Concept]
   770   C1551058:Are [Quantitative Concept]
   770   C1706089:Marked [Qualitative Concept]
   770   C1979874:Contrast [Qualitative Concept]

Phrase: "with the limited progress"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1272688:progress [Functional Concept]
   861   C1280477:Progress [Functional Concept]

Phrase: "in therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039798:therapy [Functional Concept]
  1000   C0087111:Therapy [Therapeutic or Preventive Procedure]
  1000   C1363945:Therapy [Finding]

Phrase: "for VLCAD deficiency"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and"

Phrase: "FAO disorders."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0012634:Disorders [Disease or Syndrome]
   756   C1158366:fatty acid oxidation [Molecular Function]
Processing 00000000.tx.47: Management of patients is still essentially supportive, based on preventing hypoglycemia and conditions associated with mobilization of fatty acids as energy substrates (10) by avoidance of fasting. 

Phrase: "Management of patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0001554:Management [Occupational Activity]
   790   C0376636:management [Health Care Activity]
   790   C1273870:Management [Occupational Activity]
   790   C3273539:Management [Occupation or Discipline]

Phrase: "is"

Phrase: "still essentially supportive,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1521721:Supportive [Conceptual Entity]

Phrase: "based on preventing hypoglycemia"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0020615:Hypoglycaemia [Disease or Syndrome]
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737   C0309872:PREVENT [Pharmacologic Substance]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "and"

Phrase: "conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   966   C0012634:condition [Disease or Syndrome]
   966   C0348080:Condition [Qualitative Concept]
   966   C1705253:Condition [Conceptual Entity]
   916 E C0009647:Conditioned [Mental Process]
   916 E C1701901:Conditional [Qualitative Concept]
   916 E C1963686:Conditional [Functional Concept]
   893 E C1519605:Conditionality [Conceptual Entity]

Phrase: "associated with mobilization of fatty acids"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   790   C0015684:Fatty Acids [Lipid]
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   753   C0001128:Acids [Chemical]
   753   C0185112:Mobilisation [Therapeutic or Preventive Procedure]
   753   C0300926:mobilization [Functional Concept]
   719 E C0202406:Acid [Laboratory Procedure]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]

Phrase: "as energy substrates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1710236:Substrate [Manufactured Object]

Phrase: "(10"

Phrase: ")"

Phrase: "by avoidance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0870186:Avoidance [Mental Process]

Phrase: "of fasting."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0015663:Fasting [Finding]
  1000   C1550565:fasting [Intellectual Product]
   966 E C0456962:Fast [Qualitative Concept]
Processing 00000000.tx.48: In the only therapeutic study (11), three patients with the severe form of VLCAD deficiency were apparently successfully treated by dietary supplementation with the seven-carbon medium-chain fatty acid, triheptanoin. 

Phrase: "In the only therapeutic study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0039796:Therapeutic [Therapeutic or Preventive Procedure]
   827   C0302350:Therapeutic [Functional Concept]
   827   C0557651:Study [Manufactured Object]
   827   C2603343:Study [Research Activity]

Phrase: "(11"

Phrase: ")"

Phrase: ","

Phrase: "three patients with the severe form"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0030705:Patients [Patient or Disabled Group]

Phrase: "of VLCAD deficiency"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "were"

Phrase: "apparently successfully"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0750541:apparently [Idea or Concept]

Phrase: "treated by dietary supplementation"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C0242297:Dietary Supplementation [Therapeutic or Preventive Procedure]
           Supplementation
   770   C0012155:Dietary [Food]
   770   C0332293:treated [Therapeutic or Preventive Procedure]
   770   C1522326:Treated [Functional Concept]
   770   C2699635:DIETARY [Functional Concept]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "with the seven-carbon medium-chain fatty acid,"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   901   C0522094:Medium chain fatty acid [Biologically Active Substance,Lipid]
   840   C0007027:Carbonic Acid [Inorganic Chemical]
   827   C0015684:Fatty acid [Lipid]
   799   C0001128:Acid [Chemical]
   799   C0009458:Medium [Intellectual Product]
   799   C0202406:Acid [Laboratory Procedure]
   799   C0337112:Chain [Manufactured Object]
   799   C0439536:Medium [Quantitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1705217:Medium [Substance]
   799   C3244283:medium [Intellectual Product]

Phrase: "triheptanoin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2604598:triheptanoin [Lipid]
Processing 00000000.tx.49: However, no treatment has been described for the more frequent myopathic form of the disease. 

Phrase: "However,"

Phrase: "no treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "has"

Phrase: "been"

Phrase: "described for the more frequent myopathic form of the disease."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   757   C0026848:Myopathic disease [Disease or Syndrome]
   739   C0012634:Disease [Disease or Syndrome]
   739   C0332183:Frequent [Temporal Concept]
   739   C0348078:Form [Qualitative Concept]
   739   C0376315:Form [Manufactured Object]
   739   C1522492:Form [Functional Concept]
   739   C1552738:described [Idea or Concept]
Processing 00000000.tx.50: Overall, clinical heterogeneity of this and other FAO defects suggests that many different pathogenic mechanisms might be activated in response to the deficiency of a single enzyme step, making the design of an appropriate therapeutic strategy complex. 

Phrase: "Overall,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282416:Overall [Intellectual Product]
  1000   C1561607:Overall [Qualitative Concept]

Phrase: "clinical heterogeneity of this"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1850620:Clinical heterogeneity [Finding]
   770   C0019409:Heterogeneity [Qualitative Concept]

Phrase: "and"

Phrase: "other FAO defects"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C1829742:Fatty acid oxidation defects [Disease or Syndrome]
   812   C0243067:defects [Functional Concept]
   779 E C1457869:Defect [Functional Concept]
   779 E C1861101:DEFECT [Disease or Syndrome]
   756   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "many different pathogenic mechanisms"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0441712:Mechanisms [Functional Concept]
   793 E C1706376:Mechanism [Manufactured Object]

Phrase: "might"

Phrase: "be"

Phrase: "activated in response"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   790   C0871261:Response [Organism Attribute]
   790   C1704632:Response [Finding]
   790   C1706817:Response [Intellectual Product]
   790   C1879547:Activated [Activity]
   790   C2911692:Response [Mental Process]
   756 E C1515877:Activate [Functional Concept]

Phrase: "to the deficiency"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0011155:Deficiency [Functional Concept]
  1000   C0162429:Deficiency [Disease or Syndrome]
  1000   C1623416:deficiency [Qualitative Concept]
   928 E C1636779:% deficient [Quantitative Concept]

Phrase: "of a single enzyme step,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1261552:Step [Conceptual Entity]
   827   C1704379:Step [Functional Concept]
   827   C1705117:Step [Quantitative Concept]
   827   C2825408:Step [Manufactured Object]

Phrase: "making"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1881534:Make [Functional Concept]

Phrase: "the design of an appropriate therapeutic strategy complex."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1707689:Design [Activity]
   744   C2983265:DESIGN [Intellectual Product]
Processing 00000000.tx.51: The clear genotypephenotype correlation suggests that the pattern of tissue involvement and associated clinical manifestations depend, at least partially, on the levels of residual long-chain FAO flux and VLCAD protein expression in various tissues. 

Phrase: "The clear genotypephenotype correlation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1707520:Correlation [Qualitative Concept]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the pattern of tissue involvement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0449774:Pattern [Spatial Concept]

Phrase: "and"

Phrase: "associated clinical manifestations"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205319:manifestations [Functional Concept]
   827   C1280464:manifestations [Qualitative Concept]

Phrase: "depend"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0725813:depend [Medical Device]

Phrase: ","

Phrase: "at least partially,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439092:less [Intellectual Product]
   827   C0547044:Less [Qualitative Concept]

Phrase: "on the levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0441889:Levels [Qualitative Concept]
   966 E C0456079:Level [Classification]
   966 E C1547707:Level [Geographic Area]
   966 E C2946261:Level [Pharmacologic Substance]

Phrase: "of residual long-chain FAO flux"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   795   C2348693:Flux [Natural Phenomenon or Process]
   710   C0522095:Long chain fatty acid [Biologically Active Substance,Lipid]

Phrase: "and"

Phrase: "VLCAD protein expression"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C1171362:protein expression [Genetic Function]
   793   C0185117:Expression [Therapeutic or Preventive Procedure]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "in various tissues."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0040300:Tissues [Tissue]
   827 E C1547928:Tissue [Intellectual Product]
Processing 00000000.tx.52: This latter could be determined not only by intrinsic factors such as the nature of the mutation and stability of the mutant protein (3), but also by regulatory factors that control cell and tissue-specific VLCAD gene expression. 

Phrase: "This latter"

Phrase: "could"

Phrase: "be"

Phrase: "determined"

Phrase: "not only by intrinsic factors"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   806   C0021918:intrinsic factors [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   760   C0205102:Intrinsic [Spatial Concept]
   760   C0205171:Only [Quantitative Concept]
   760   C0439674:Intrinsic [Functional Concept]
   760   C1518422:Not [Functional Concept]
   760   C1720467:Only [Intellectual Product]
   726   C1521761:Factor [Functional Concept]
   726   C2827422:Factor [Conceptual Entity]

Phrase: "such as the nature"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0349590:Nature [Idea or Concept]
  1000   C1262865:Nature [Functional Concept]
   928 E C0205296:Natural [Functional Concept]

Phrase: "of the mutation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0026882:Mutation [Genetic Function]
  1000   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "and"

Phrase: "stability of the mutant protein"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C2350440:Protein Stability [Qualitative Concept]
   760   C0205360:Stability [Qualitative Concept]
   760   C2347098:Stability [Qualitative Concept]

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: "also by regulatory factors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0220905:regulatory [Regulation or Law]
   770   C1704735:Regulatory [Conceptual Entity]
   737   C1521761:Factor [Functional Concept]
   737   C2827422:Factor [Conceptual Entity]

Phrase: "that control cell"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   861   C0007634:Cell [Cell]
   861   C0243148:control [Qualitative Concept]
   861   C1269647:Cell [Cell]
   861   C1550141:Control [Substance]
   861   C1704653:Cell [Medical Device]
   861   C1882979:Control [Conceptual Entity]
   861   C1948049:Cell [Spatial Concept]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "tissue-specific VLCAD gene expression."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   897   C1519516:Tissue-Specific Gene Expression [Genetic Function]
   804   C0017262:Gene Expression [Genetic Function]
   790   C0017337:Gene [Gene or Genome]
   790   C0185117:Expression [Therapeutic or Preventive Procedure]
   717   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
Processing 00000000.tx.53: Recent data highlight the importance of transcriptional regulation in the control of mitochondrial FAO (12). 

Phrase: "Recent data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "highlight"

Phrase: "the importance of transcriptional regulation"

Phrase: "in the control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "of mitochondrial FAO"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   923   C1158366:fatty acid oxidation [Molecular Function]
   861   C0015684:Fatty acid [Lipid]
   812   C0001128:Acid [Chemical]
   812   C0030011:Oxidation [Molecular Function]
   812   C0202406:Acid [Laboratory Procedure]

Phrase: "(12"

Phrase: ")."
Processing 00000000.tx.54: This regulatory network involves the nuclear hormone receptor family of peroxisomal proliferator-activated receptors (PPARs), which include the , / and isoforms. 

Phrase: "This regulatory network"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1513822:Network [Professional or Occupational Group]
   861   C1705739:Network [Manufactured Object]
   861   C1882071:Network [Conceptual Entity]

Phrase: "involves"

Phrase: "the nuclear hormone receptor family of peroxisomal proliferator-activated receptors"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   757   C0028574:Nuclear Family [Family Group]
   739   C0015576:Family [Family Group]
   739   C1704727:Family [Conceptual Entity]

Phrase: "(PPARs"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0166418:Peroxisome Proliferator-Activated Receptors [Amino Acid, Peptide, or Protein,Receptor]
   988 E C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: ")"

Phrase: ","

Phrase: "which"

Phrase: "include"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:include [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "the ,"

Phrase: "/"

Phrase: "and"

Phrase: "isoforms."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0597298:Isoforms [Amino Acid, Peptide, or Protein]
Processing 00000000.tx.55: PPAR is preferentially expressed in tissues with high fatty acid utilization like heart and muscle, the PPAR isoform is ubiquitously expressed and PPAR is found at high levels in adipocytes and other cell types involved in lipid synthesis and storage (12). 

Phrase: "PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "preferentially"

Phrase: "expressed in tissues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0040300:Tissues [Tissue]
   756 E C1547928:Tissue [Intellectual Product]

Phrase: "with high fatty acid utilization"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0042153:utilization [Functional Concept]

Phrase: "like heart"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018787:Heart [Body Part, Organ, or Organ Component]
  1000   C1281570:Heart [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "muscle,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0026845:Muscle [Tissue]
   928 E C0442025:Muscular [Spatial Concept]

Phrase: "the PPAR isoform"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0597298:Isoform [Amino Acid, Peptide, or Protein]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "is"

Phrase: "ubiquitously"

Phrase: "expressed"

Phrase: "and"

Phrase: "PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "is"

Phrase: "found at high levels"
Meta Candidates (Total=9; Excluded=4; Pruned=0; Remaining=5)
   770   C0150312:Found [Quantitative Concept]
   770   C0205250:High [Qualitative Concept]
   770   C0441889:Levels [Qualitative Concept]
   770   C1299351:High [Qualitative Concept]
   770   C2700149:HIGH [Intellectual Product]
   737 E C0243095:Find [Finding]
   737 E C0456079:Level [Classification]
   737 E C1547707:Level [Geographic Area]
   737 E C2946261:Level [Pharmacologic Substance]

Phrase: "in adipocytes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0206131:Adipocytes [Cell]

Phrase: "and"

Phrase: "other cell types"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0449475:Cell types [Intellectual Product]
   966 E C0007634:Cell Type [Cell]
           Cell
   861   C0332307:Types [Qualitative Concept]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]
   827 E C1547052:*Type [Quantitative Concept]

Phrase: "involved in lipid synthesis"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C1563744:lipid synthesis [Organism Function]
   770   C0023779:Lipid [Lipid]
   770   C0220781:synthesis [Biologic Function]
   770   C1314939:Involved [Functional Concept]
   770   C1883254:Synthesis [Activity]

Phrase: "and"

Phrase: "storage"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0337174:Storage [Spatial Concept]
  1000   C1698986:Storage [Functional Concept]
  1000   C1753314:storage [Cell Component]

Phrase: "(12"

Phrase: ")."
Processing 00000000.tx.56: These nuclear hormone receptors act by coordinately controlling gene transcription rates of various enzymes in specific metabolic pathways. 

Phrase: "These nuclear hormone receptors"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0887829:Nuclear Hormone Receptors [Amino Acid, Peptide, or Protein,Receptor]
   966 E C1753269:nuclear hormone receptor [Molecular Function]
   913   C0206588:Receptors, Nuclear [Amino Acid, Peptide, or Protein,Receptor]
   901   C0019929:hormone receptors [Amino Acid, Peptide, or Protein,Receptor]
   867 E C1367453:HORMONE RECEPTOR [Gene or Genome]
   827   C0019932:Hormone [Hormone]
   827   C0521447:Nuclear [Spatial Concept]
   827   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   755 E C0458083:Hormonal [Qualitative Concept]

Phrase: "act by coordinately"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "controlling"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0332298:controlling [Functional Concept]
  1000   C2587213:Controlling [Functional Concept]
   966 E C0243148:control [Qualitative Concept]
   966 E C1550141:Control [Substance]
   966 E C1882979:Control [Conceptual Entity]
   966 E C3274648:Control [Qualitative Concept]

Phrase: "gene transcription rates of various enzymes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C0871208:Rate [Activity]
   719   C1521828:Rate [Quantitative Concept]

Phrase: "in specific metabolic pathways."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C1291081:Metabolic Pathways [Functional Concept]
   827   C0311400:Metabolic [Functional Concept]
   827   C1524026:Metabolic [Cell Function]
   827   C1704259:Pathways [Molecular Function]
   827   C1705987:Pathways [Conceptual Entity]
   827   C2707259:Metabolic [Clinical Attribute]
Processing 00000000.tx.57: Thus, PPAR controls basal levels of FAO enzyme gene expression, can drive FAO gene adaptations to normal or pathological challenges and, therefore, plays a crucial role in energy homeostasis (13). 

Phrase: "Thus,"

Phrase: "PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
  1000   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "basal levels of FAO enzyme gene expression,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   767   C1281901:Fatty acid level [Laboratory Procedure]
   762   C0014440:enzyme levels [Laboratory Procedure]
   762   C1287349:enzyme levels [Laboratory or Test Result]
   745   C3244092:expression level [Idea or Concept]
   742   C0441889:Levels [Qualitative Concept]
   708 E C0456079:Level [Classification]
   708 E C1547707:Level [Geographic Area]
   708 E C2946261:Level [Pharmacologic Substance]

Phrase: "can"

Phrase: "drive"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013126:Drive [Mental Process]

Phrase: "FAO gene adaptations to normal"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0000934:adaptations [Organism Function]
   748   C0392673:ADAPTATIONS [Biologic Function]

Phrase: "or"

Phrase: "pathological challenges"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0805586:challenges [Health Care Activity]
   827 E C0798503:Challenge [Clinical Attribute]
   827 E C3274764:Challenge [Conceptual Entity]

Phrase: "and"

Phrase: ","

Phrase: "therefore,"

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "a crucial role in energy homeostasis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "(13"

Phrase: ")."
Processing 00000000.tx.58: PPARs have attracted attention in terms of therapeutic potential because many ligands or activators of these receptors have been identified, including common drugs like fibrates (13). 

Phrase: "PPARs"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0166418:Peroxisome Proliferator-Activated Receptors [Amino Acid, Peptide, or Protein,Receptor]
   988 E C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "have"

Phrase: "attracted attention in terms of therapeutic potential"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0004268:Attention [Mental Process]

Phrase: "because"

Phrase: "many ligands"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023688:Ligands [Chemical]

Phrase: "or"

Phrase: "activators of these receptors"

Phrase: "have"

Phrase: "been"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: ","

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "common drugs like fibrates"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C0013227:Drugs [Pharmacologic Substance]
   737 E C1254351:Drug [Pharmacologic Substance]

Phrase: "(13"

Phrase: ")."
Processing 00000000.tx.59: In fact, fibrates and other newly developed PPAR agonists are potent pharmaceutical tools to stimulate FAO in a wide variety of cells, tissues or animal models, as abundantly documented in the literature (12,13). 

Phrase: "In fact,"

Phrase: "fibrates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1449704:Fibrates [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "other newly developed PPAR agonists"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   795   C0243192:agonists [Pharmacologic Substance]
   795   C2987634:agonists [Pharmacologic Substance]
   710   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   710   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "are"

Phrase: "potent pharmaceutical tools to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   779   C0336791:Tool [Manufactured Object]
   779   C2827396:Tool [Manufactured Object]

Phrase: "stimulate"

Phrase: "FAO in a wide variety of cells,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C1158366:fatty acid oxidation [Molecular Function]
   764   C0015684:Fatty acid [Lipid]
   742   C0001128:Acid [Chemical]
   742   C0030011:Oxidation [Molecular Function]
   742   C0202406:Acid [Laboratory Procedure]

Phrase: "tissues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040300:Tissues [Tissue]
   966 E C1547928:Tissue [Intellectual Product]

Phrase: "or"

Phrase: "animal models,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0599779:Models, Animal [Animal]
   861   C0003062:Animal [Animal]
   861   C3161035:Models [Intellectual Product]

Phrase: "as"

Phrase: "abundantly"

Phrase: "documented in the literature"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   770   C0023866:Literature [Intellectual Product]
   770   C0034036:LITERATURE [Intellectual Product,Manufactured Object]
   770   C1301725:Documented [Health Care Activity]
   770   C1609436:documented [Idea or Concept]
   737 E C1301746:document [Intellectual Product]
   737 E C1547673:Document [Intellectual Product]

Phrase: "(12,"

Phrase: "13"

Phrase: ")."
Processing 00000000.tx.60: FAO control by PPARs has stimulated active research in many different fields of medicine, including treatment of diabetes and obesity (14,15), but, surprisingly, has received no recognition for possible therapy of inborn FAO errors. 

Phrase: "FAO control by PPARs"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   742   C0243148:control [Qualitative Concept]
   742   C1550141:Control [Substance]
   742   C1882979:Control [Conceptual Entity]
   742   C2587213:Control [Functional Concept]
   742   C3274648:Control [Qualitative Concept]

Phrase: "has"

Phrase: "stimulated active research in many different fields of medicine,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   745   C0683945:field research [Research Activity]
   742   C0035168:research [Research Activity]
   742   C0242481:Research [Research Activity]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "treatment of diabetes"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]

Phrase: "and"

Phrase: "obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "(14,"

Phrase: "15"

Phrase: ")"

Phrase: ","

Phrase: "but"

Phrase: ","

Phrase: "surprisingly,"

Phrase: "has"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "no recognition for possible therapy of inborn FAO errors."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0524637:Recognition [Mental Process]
Processing 00000000.tx.61: In the present study, we, therefore, investigated the effects of bezafibrate, a common hypolipidemic drug acting as a PPAR agonist, on FAO capacities of VLCAD-deficient patients and provide data in support of a possible complete correction of this inborn FAO defect in response to treatment by this drug.  

Phrase: "In the present study,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "we,"

Phrase: "therefore,"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "the effects of bezafibrate,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1280500:effects [Qualitative Concept]
   737 E C2348382:Effect [Qualitative Concept]

Phrase: "a common hypolipidemic drug"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   859   C0086440:Hypolipidemic Drugs [Pharmacologic Substance]
   827   C0013227:Drug [Pharmacologic Substance]
   827   C1254351:Drug [Pharmacologic Substance]
   771 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   771 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   734 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "acting as a PPAR agonist,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   833   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   833   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   770   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   744   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   744   C0752063:Peroxysome [Cell Component]
   744   C1879547:Activated [Activity]
   744   C2984308:Peroxisome [Functional Concept]
   744   C2987634:Agonist [Pharmacologic Substance]
   711   C0079613:ACT [Therapeutic or Preventive Procedure]
   711 E C1515877:Activate [Functional Concept]

Phrase: "on FAO capacities"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   779   C1516240:Capacity [Quantitative Concept]
   756   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "of VLCAD-deficient patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "and"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "data in support of a possible complete correction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1511726:Data [Idea or Concept]
   744   C3245479:data [Medical Device]

Phrase: "of this inborn FAO defect"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C1457869:Defect [Functional Concept]
   804   C1861101:DEFECT [Disease or Syndrome]
   717   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "in response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "to treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "by this drug."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0013227:Drug [Pharmacologic Substance]
  1000   C1254351:Drug [Pharmacologic Substance]
   944 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   944 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   907 E C0456386:Medicament [Pharmacologic Substance]
Processing 00000000.tx.62: RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  Bezafibrate increases palmitate oxidation in fibroblast cultures from VLCAD-deficient patients Fibroblasts cultured from VLCAD-deficient patients were used to determine the effects of fenofibric acid and bezafibrate, two widely used hypolipidemic drugs, on 3H-palmitate oxidation. 

Phrase: "RESULTS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "palmitate oxidation in fibroblast cultures"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030011:Oxidation [Molecular Function]

Phrase: "from VLCAD-deficient patients Fibroblasts"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   791   C0016030:Fibroblasts [Cell]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "cultured from VLCAD-deficient patients"
Meta Candidates (Total=23; Excluded=0; Pruned=0; Remaining=23)
   862   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   862   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   833   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   806   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   782   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   782   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   782   C1980013:Very long chain [Qualitative Concept]
   739   C0011155:Deficient [Functional Concept]
   739   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   739   C0030705:Patients [Patient or Disabled Group]
   739   C0205166:Long [Qualitative Concept]
   739   C0337112:Chain [Manufactured Object]
   739   C0442824:Very [Qualitative Concept]
   739   C1524075:Chain [Idea or Concept]
   739   C1636779:% deficient [Quantitative Concept]
   739   C1706317:Long [Qualitative Concept]
   706   C0010453:Culture [Idea or Concept]
   706   C0220814:culture [Functional Concept]
   706   C0430400:Culture [Laboratory Procedure]
   706   C2242979:Culture [Laboratory Procedure]

Phrase: "were"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "determine"

Phrase: "the effects of fenofibric acid"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "bezafibrate,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "two widely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205448:Two [Quantitative Concept]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "hypolipidemic drugs,"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0086440:Hypolipidemic Drugs [Pharmacologic Substance]
   861   C0013227:Drugs [Pharmacologic Substance]
   827 E C1254351:Drug [Pharmacologic Substance]
   789 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   789 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   761 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "on 3H-palmitate oxidation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030011:Oxidation [Molecular Function]
Processing 00000000.tx.63: Three patients (patients 13) carried missense mutations (see Materials and Methods) compatible with the milder, later-onset, myopathic form of the disease with episodic muscle weakness, myalgia and myoglobinuria (3). 

Phrase: "Three patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(patients 13"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: ")"

Phrase: "carried missense mutations"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   901   C0599155:Mutations, Missense [Genetic Function]
   827   C0026882:Mutations [Genetic Function]
   793 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "("

Phrase: "see"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0042789:see [Organism Function]
  1000   C1947903:See [Activity]

Phrase: "Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: ")"

Phrase: "compatible with the milder, later-onset,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0332290:compatible [Idea or Concept]
   753   C1524057:Compatible [Qualitative Concept]

Phrase: "myopathic form of the disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0348078:Form [Qualitative Concept]
   760   C0376315:Form [Manufactured Object]
   760   C1522492:Form [Functional Concept]

Phrase: "with episodic muscle weakness,"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   901   C0030552:muscle weakness [Sign or Symptom]
   901   C0151786:Muscle Weakness [Sign or Symptom]
   827   C0004093:Weakness [Sign or Symptom]
   827   C0026845:Muscle [Tissue]
   755 E C0442025:Muscular [Spatial Concept]
   755 E C1762617:Weak [Qualitative Concept]

Phrase: "myalgia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231528:Myalgia [Sign or Symptom]

Phrase: "and"

Phrase: "myoglobinuria"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0027080:Myoglobinuria [Finding]

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")."
Processing 00000000.tx.64: Patient 4 suffered from the severe form of the disease and had died suddenly in infancy. 

Phrase: "Patient 4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "suffered from the severe form of the disease"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   744   C0012634:Disease [Disease or Syndrome]
   744   C0205082:Severe [Qualitative Concept]
   744   C0348078:Form [Qualitative Concept]
   744   C0376315:Form [Manufactured Object]
   744   C0683278:suffered [Mental or Behavioral Dysfunction]
   744   C1522492:Form [Functional Concept]

Phrase: "and"

Phrase: "had"

Phrase: "died"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
  1000   C0011065:Died [Organism Function]
  1000   C1546956:Died [Finding]
   928 E C0231800:Expired [Organ or Tissue Function]
   928 E C1704631:Expire [Idea or Concept]
   907 E C0184532:dying [Organism Function]
   907 E C1553404:terminated [Idea or Concept]
   907 E C2348570:Terminated [Functional Concept]

Phrase: "suddenly in infancy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0231330:Infancy [Temporal Concept]
Processing 00000000.tx.65: These phenotypes are in agreement with the residual palmitate oxidation measured in the patients' fibroblasts (Fig.1). 

Phrase: "These phenotypes"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0031437:Phenotypes [Organism Attribute]
   966 E C1285572:Phenotype [Laboratory Procedure]

Phrase: "are in agreement"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0680240:Agreement [Social Behavior]
   790   C1551058:Are [Quantitative Concept]

Phrase: "with the residual palmitate oxidation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030011:Oxidation [Molecular Function]

Phrase: "measured in the patients' fibroblasts"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   760   C0016030:Fibroblasts [Cell]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0444706:Measured [Qualitative Concept]
   760   C3541902:MEASURED [Diagnostic Procedure]
   726 E C0079809:Measure [Quantitative Concept]
   726 E C0242485:Measure [Functional Concept]

Phrase: "(Fig.1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.66: That is, patients 13 exhibited 3348% of control palmitate oxidation values, but patient 4 had <10%. 

Phrase: "That"

Phrase: "is"

Phrase: ","

Phrase: "patients 13"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "exhibited"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0015272:Exhibit [Intellectual Product]

Phrase: "3348% of control palmitate oxidation values,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   753   C0030011:Oxidation [Molecular Function]
   753   C0030233:palmitate [Lipid]
   753   C0042295:Values [Qualitative Concept]
   753   C0243148:control [Qualitative Concept]
   753   C1550141:Control [Substance]
   753   C1882979:Control [Conceptual Entity]
   753   C2587213:Control [Functional Concept]
   753   C3274648:Control [Qualitative Concept]
   753   C3503116:palmitate [Biomedical or Dental Material,Lipid]
   719 E C1522609:Value [Quantitative Concept]

Phrase: "but"

Phrase: "patient 4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "had <"

Phrase: "10%."
Processing 00000000.tx.67: Similar results were obtained when the assay was run using 3H-oleate (data not shown). 

Phrase: "Similar results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "were"

Phrase: "obtained"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C1301820:Obtained [Functional Concept]
   966 E C1706701:Obtain [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "when"

Phrase: "the assay"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0005507:Assay [Laboratory Procedure]
  1000   C0243073:assay [Qualitative Concept]
  1000   C1510438:Assay [Laboratory Procedure]

Phrase: "was"

Phrase: "run"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0035953:run [Daily or Recreational Activity]
  1000   C0600140:run [Finding]
  1000   C1704688:Run [Functional Concept]
  1000   C2346414:Run [Finding]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "3H-oleate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0133788:oleate [Lipid]
   861   C0220884:Oleate [Biologically Active Substance,Lipid,Pharmacologic Substance]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.68: View larger version (24K): [in this window] [in a new window]  Figure1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(24K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure1."
Processing 00000000.tx.69: (A) Increases in palmitate oxidation in fibroblasts derived from normal or VLCAD-deficient individuals treated with fibrates. 

Phrase: "(A)"

Phrase: "Increases in palmitate oxidation"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0030011:Oxidation [Molecular Function]
   770   C0030233:palmitate [Lipid]
   770   C0442805:Increase [Functional Concept]
   770   C3503116:palmitate [Biomedical or Dental Material,Lipid]
   715 E C1517378:Gain [Quantitative Concept]

Phrase: "in fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016030:Fibroblasts [Cell]

Phrase: "derived from normal"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0205307:Normal [Qualitative Concept]
   790   C0439166:% normal [Quantitative Concept]
   790   C1441547:Derived [Qualitative Concept]
   790   C2347086:% Normal [Quantitative Concept]
   790   C3245521:derived [Idea or Concept]

Phrase: "or"

Phrase: "VLCAD-deficient individuals"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0027361:Individual [Population Group]
   760   C0237401:Individual [Human]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "treated with fibrates."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C1449704:Fibrates [Organic Chemical,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]
Processing 00000000.tx.70: Cells were incubated for 48h with 100M fenofibric acid, 500M bezafibrate or vehicle (DMSO). 

Phrase: "Cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "incubated for 48h"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1439852:Incubated [Laboratory Procedure]
   790   C1442464:48H [Temporal Concept]

Phrase: "with 100M fenofibric acid,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0060179:fenofibric acid [Organic Chemical,Pharmacologic Substance]
   827   C0001128:Acid [Chemical]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: "500M bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "or"

Phrase: "vehicle"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0042444:Vehicle [Biomedical or Dental Material]
  1000   C0348005:Vehicle [Manufactured Object]
   928 E C0445373:Vehicular [Functional Concept]

Phrase: "(DMSO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.71: The assays were performed in triplicate, and the results are expressed as meanSD. 

Phrase: "The assays"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005507:Assay [Laboratory Procedure]
   966   C0243073:assay [Qualitative Concept]
   966   C1510438:Assay [Laboratory Procedure]

Phrase: "were"

Phrase: "performed in triplicate,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0205174:Triplicate [Quantitative Concept]
   790   C0884358:Performed [Functional Concept]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "and"

Phrase: "the results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "expressed as meanSD."
Processing 00000000.tx.72: ***P<0.001 when compared with the DMSO-treated fibroblasts of a given subject. 

Phrase: "*"

Phrase: "*"

Phrase: "*P<0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "when"

Phrase: "compared with the DMSO-treated fibroblasts of a given subject."
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   757   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   739   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]
   739   C0016030:Fibroblasts [Cell]
   739   C0681850:Subject [Group]
   739   C1522326:Treated [Functional Concept]
   739   C1550501:{Subject} [Idea or Concept]
   739   C1706203:Subject [Idea or Concept]
   739   C1707455:Compared [Activity]
   739   C2349001:Subject [Human]
   739   C2697811:Subject [Functional Concept]
   706 E C1292734:TREAT [Functional Concept]
Processing 00000000.tx.73: Doseresponse studies of fenofibric acid (B) or bezafibrate (C) effects on tritiated palmitate oxidation rates, in control or patient 2 cells.  

Phrase: "Doseresponse"

Phrase: "studies of fenofibric acid"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0060179:fenofibric acid [Organic Chemical,Pharmacologic Substance]
   770   C0001128:Acid [Chemical]
   770   C0202406:Acid [Laboratory Procedure]
   770   C0557651:Study [Manufactured Object]
   770   C0947630:studies [Laboratory Procedure]
   770   C2603343:Study [Research Activity]

Phrase: "(B)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "or"

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "(C) effects on tritiated palmitate oxidation rates,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C1280500:effects [Qualitative Concept]
   714 E C2348382:Effect [Qualitative Concept]

Phrase: "in control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "or"

Phrase: "patient 2 cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.74: Fibroblasts were treated with 100M fenofibric acid or 500M bezafibrate for 48h. 

Phrase: "Fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016030:Fibroblasts [Cell]

Phrase: "were"

Phrase: "treated with 100M fenofibric acid"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   806   C0060179:fenofibric acid [Organic Chemical,Pharmacologic Substance]
   806   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   760   C0001128:Acid [Chemical]
   760   C0202406:Acid [Laboratory Procedure]
   760   C1522326:Treated [Functional Concept]
   726 E C1292734:TREAT [Functional Concept]

Phrase: "or"

Phrase: "500M bezafibrate for 48h."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.75: The optimal concentrations of fenofibric acid and bezafibrate were established by a doseresponse experiment ranging from 50 to 500M (Fig.1B and C). 

Phrase: "The optimal concentrations of fenofibric acid"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0086045:Concentrations [Mental Process]
   719 E C1446561:Concentration [Quantitative Concept]

Phrase: "and"

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "were"

Phrase: "established by a doseresponse experiment ranging"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0443211:Established [Qualitative Concept]
   753   C0681814:Experiment [Research Activity]
   753   C1272684:Established [Qualitative Concept]
   753   C1706386:Experiment [Conceptual Entity]
   719   C1514721:Range [Quantitative Concept]
   719   C2348147:Range [Quantitative Concept]
   719   C3542016:Range [Intellectual Product]

Phrase: "from 50"

Phrase: "to 500M"

Phrase: "(Fig.1B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450345:1B [Intellectual Product]

Phrase: "and"

Phrase: "C)."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]
Processing 00000000.tx.76: Exposure to fenofibric acid induced no significant changes in FAO in control and patient 4 fibroblasts. 

Phrase: "Exposure to fenofibric acid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C0332157:Exposure to [Clinical Attribute]
           Exposure
   770   C0274281:Exposure, NOS [Injury or Poisoning]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "no significant changes in FAO"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   757   C0152254:Fatty change [Pathologic Function]
   757   C0442739:No change [Finding]
   757   C1548568:No change [Intellectual Product]
   748   C0392747:changes [Functional Concept]
   748   C0443172:changes [Quantitative Concept]
   714 E C1705241:Change [Quantitative Concept]

Phrase: "in control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "patient 4 fibroblasts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0016030:Fibroblasts [Cell]
Processing 00000000.tx.77: However, palmitate oxidation of fibroblasts from patients 13 treated with fenofibric acid was 1.8-, 2- and 1.5-fold greater than that in vehicle-treated cells. 

Phrase: "However,"

Phrase: "palmitate oxidation of fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030011:Oxidation [Molecular Function]

Phrase: "from patients 13"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "treated with fenofibric acid"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C0060179:fenofibric acid [Organic Chemical,Pharmacologic Substance]
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0001128:Acid [Chemical]
   770   C0202406:Acid [Laboratory Procedure]
   770   C1522326:Treated [Functional Concept]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "was"

Phrase: "1.8-,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C2827734:1+ [Quantitative Concept]
   861   C2981698:1+ [Classification]

Phrase: "2-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "and"

Phrase: "1.5-fold"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0332462:Fold [Spatial Concept]
   827   C1880834:FOLD [Phenomenon or Process]
   734   C0450316:1/5 [Quantitative Concept]

Phrase: "greater than that in vehicle-treated cells."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   778   C0439093:Greater Than [Quantitative Concept]
   748   C0443228:greater [Quantitative Concept]
   748   C1704243:Greater [Quantitative Concept]
   714 E C0549177:Great [Quantitative Concept]
Processing 00000000.tx.78: In contrast to fenofibric acid, bezafibrate resulted in an increase of FAO in control fibroblasts (+51%, P<0.001). 

Phrase: "In contrast to fenofibric acid,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0060179:fenofibric acid [Organic Chemical,Pharmacologic Substance]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "resulted in an increase of FAO"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   800   C1158366:fatty acid oxidation [Molecular Function]
   770   C0015684:Fatty acid [Lipid]
   744   C0001128:Acid [Chemical]
   744   C0030011:Oxidation [Molecular Function]
   744   C0202406:Acid [Laboratory Procedure]
   744   C0442805:Increase [Functional Concept]
   711   C1274040:Result [Functional Concept]
   711   C1546471:Result [Idea or Concept]
   711   C2825142:Result [Finding]

Phrase: "in control fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0016030:Fibroblasts [Cell]

Phrase: "(+51%,"

Phrase: "P<0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.79: Response of patient 4 fibroblasts to bezafibrate was similar to fenofibric acid, with no significant change in FAO. 

Phrase: "Response of patient 4 fibroblasts"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]

Phrase: "to bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "was"

Phrase: "similar to fenofibric acid,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C2348205:Similar [Qualitative Concept]

Phrase: "with no significant change"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0392747:Change [Functional Concept]
   861   C0443172:change [Quantitative Concept]
   861   C1705241:Change [Quantitative Concept]

Phrase: "in FAO."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1158366:fatty acid oxidation [Molecular Function]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0030011:Oxidation [Molecular Function]
   827   C0202406:Acid [Laboratory Procedure]
Processing 00000000.tx.80: However, in fibroblasts from patients 13, bezafibrate induced a 2.83.2-fold stimulation of palmitate oxidation rates, resulting in the restoration of normal palmitate oxidation. 

Phrase: "However,"

Phrase: "in fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016030:Fibroblasts [Cell]

Phrase: "from patients 13,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "a 2.83.2-fold stimulation of palmitate oxidation rates,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   739   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "resulting in the restoration of normal palmitate oxidation."
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   770   C0332294:Resulting in [Functional Concept]
   750   C0459422:Normal result [Finding]
   744   C0030011:Oxidation [Molecular Function]
   744   C0030233:palmitate [Lipid]
   744   C0205307:Normal [Qualitative Concept]
   744   C0439166:% normal [Quantitative Concept]
   744   C0449982:Restoration [Intellectual Product]
   744   C0678226:resulting [Functional Concept]
   744   C2347086:% Normal [Quantitative Concept]
   744   C3503116:palmitate [Biomedical or Dental Material,Lipid]
   711 E C1274040:Result [Functional Concept]
   711 E C1546471:Result [Idea or Concept]
   711 E C2825142:Result [Finding]
Processing 00000000.tx.81: Bezafibrate corrects acylcarnitine accumulation in VLCAD-deficient fibroblasts As mentioned earlier, detection of abnormal concentrations of various acylcarnitines in body fluids (8) or cultured human cells (7) has become a common tool for biochemical diagnosis of inborn errors of FAO. 

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "corrects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349182:Correct [Qualitative Concept]

Phrase: "acylcarnitine accumulation"

Phrase: "in VLCAD-deficient fibroblasts"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0016030:Fibroblasts [Cell]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "As"

Phrase: "mentioned"

Phrase: "earlier,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1279919:Early [Temporal Concept]

Phrase: "detection of abnormal concentrations of various acylcarnitines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "in body fluids"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
  1000   C0005889:Body Fluids [Body Substance]
           Fluids
   861   C0242821:body [Human]
   861   C0302908:fluids [Substance]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   861   C1521806:Fluids [Tissue]
   827 E C0444611:Fluid [Qualitative Concept]
   827 E C1704353:Fluid [Substance]
   777 E C1995017:Bodies [Cell Component]

Phrase: "(8"

Phrase: ")"

Phrase: "or"

Phrase: "cultured human cells"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   913   C0007600:cultured cells [Cell]
   913   C0007635:Cultured Cells [Cell]
   913   C3282338:Cells, Cultured [Cell]
   901   C0427861:Human cells [Laboratory or Test Result]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "(7"

Phrase: ")"

Phrase: "has"

Phrase: "become"

Phrase: "a common tool for biochemical diagnosis of inborn errors"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0336791:Tool [Manufactured Object]
   742   C2827396:Tool [Manufactured Object]

Phrase: "of FAO."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1158366:fatty acid oxidation [Molecular Function]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0030011:Oxidation [Molecular Function]
   827   C0202406:Acid [Laboratory Procedure]
Processing 00000000.tx.82: The acylcarnitine profiles produced are characteristic and helpful in defining the specific enzyme defect in the FAO pathway. 

Phrase: "The acylcarnitine profiles"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1979963:Profile [Laboratory Procedure]
   827   C2003903:Profile [Functional Concept]

Phrase: "produced"

Phrase: "are"

Phrase: "characteristic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1521970:Characteristic [Qualitative Concept]

Phrase: "and"

Phrase: "helpful in defining"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   718   C0018896:Help [Social Behavior]
   718   C1552861:help [Idea or Concept]

Phrase: "the specific enzyme defect in the FAO pathway."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C1457869:Defect [Functional Concept]
   739   C1861101:DEFECT [Disease or Syndrome]
Processing 00000000.tx.83: Fibroblasts from controls and VLCAD-deficient patients were incubated for 72h with palmitate and L-carnitine (Fig.2). 

Phrase: "Fibroblasts from controls"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0016030:Fibroblasts [Cell]

Phrase: "and"

Phrase: "VLCAD-deficient patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "were"

Phrase: "incubated for 72h"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1292423:72H [Temporal Concept]
   790   C1439852:Incubated [Laboratory Procedure]

Phrase: "with palmitate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0030233:palmitate [Lipid]
  1000   C3503116:palmitate [Biomedical or Dental Material,Lipid]

Phrase: "and"

Phrase: "L-carnitine"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0007258:L-Carnitine [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
           Carnitine
  1000   C0087163:L-Carnitine [Organic Chemical,Pharmacologic Substance,Vitamin]
           Carnitine
   861   C0439394:l's [Quantitative Concept]
   861   C1706495:L- [Intellectual Product]
   861   C3642217:/L [Quantitative Concept]

Phrase: "(Fig.2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.84: Acylcarnitine intermediates detected by tandem mass spectrometry in VLCAD-deficient cells correspond to palmitoyl-(C16)-, myristoyl-(C14)-, dodecanoyl-(C12)-, decanoyl-(C10)- and octanoyl-(C8)- carnitines. 

Phrase: "Acylcarnitine intermediates"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205103:Intermediate [Spatial Concept]
   827   C1550465:intermediate [Idea or Concept]
   827   C2827755:INTERMEDIATE [Laboratory or Test Result]

Phrase: "detected by tandem mass spectrometry"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   862   C0599748:Tandem Mass Spectrometry [Molecular Biology Research Technique]
   806   C0037813:Mass Spectrometry [Laboratory Procedure]
   760   C0075804:TANDEM [Organic Chemical,Pharmacologic Substance]
   760   C0436196:Spectrometry [Laboratory Procedure]
   760   C0442726:Detected [Finding]
   760   C0577559:Mass [Finding]
   760   C1306372:*Mass [Quantitative Concept]
   760   C1511790:Detected [Therapeutic or Preventive Procedure]
   760   C3152252:Mass [Quantitative Concept]

Phrase: "in VLCAD-deficient cells"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   793   C0007634:Cells [Cell]
   793   C3282337:Cells [Cell]
   760 E C1269647:Cell [Cell]
   760 E C1704653:Cell [Medical Device]
   760 E C1948049:Cell [Spatial Concept]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "correspond to palmitoyl-"

Phrase: "(C16"

Phrase: ")-"

Phrase: ","

Phrase: "myristoyl-"

Phrase: "(C14"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0302945:C-14 [Element, Ion, or Isotope,Indicator, Reagent, or Diagnostic Aid]

Phrase: ")-"

Phrase: ","

Phrase: "dodecanoyl-"

Phrase: "(C12"

Phrase: ")-"

Phrase: ","

Phrase: "decanoyl-"

Phrase: "(C10"

Phrase: ")"

Phrase: "-"

Phrase: "and"

Phrase: "octanoyl-"

Phrase: "(C8"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1305854:C8 [Body Location or Region]

Phrase: ")-"

Phrase: "carnitines."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0682742:carnitines [Organic Chemical,Vitamin]
   966 E C0007258:Carnitine [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   966 E C0087163:Carnitine [Organic Chemical,Pharmacologic Substance,Vitamin]
Processing 00000000.tx.85: The acylcarnitine profile from normal fibroblasts showed small peaks of C10 and C16 species (Fig.2A). 

Phrase: "The acylcarnitine profile from normal fibroblasts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1979963:Profile [Laboratory Procedure]
   753   C2003903:Profile [Functional Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "small peaks of C10"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   816   C0442820:Small peak [Finding]
   770   C0444505:peaks [Quantitative Concept]

Phrase: "and"

Phrase: "C16 species"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1705920:Species [Conceptual Entity]

Phrase: "(Fig.2A"

Phrase: ")."
Processing 00000000.tx.86: View larger version (23K): [in this window] [in a new window]  Figure2. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(23K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure2."
Processing 00000000.tx.87: Acylcarnitines profiles generated during incubation of human fibroblasts with L-carnitine and palmitate for 72h. 

Phrase: "Acylcarnitines profiles"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1979963:Profile [Laboratory Procedure]
   827   C2003903:Profile [Functional Concept]

Phrase: "generated during incubation of human fibroblasts"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0016030:Fibroblasts [Cell]
   753   C0086418:Human [Human]
   753   C3146294:Generated [Activity]

Phrase: "with L-carnitine"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0007258:L-Carnitine [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
           Carnitine
  1000   C0087163:L-Carnitine [Organic Chemical,Pharmacologic Substance,Vitamin]
           Carnitine
   861   C0439394:l's [Quantitative Concept]
   861   C1706495:L- [Intellectual Product]
   861   C3642217:/L [Quantitative Concept]

Phrase: "and"

Phrase: "palmitate for 72h."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030233:palmitate [Lipid]
   790   C3503116:palmitate [Biomedical or Dental Material,Lipid]
Processing 00000000.tx.88: The signals represent molecular ions of acylcarnitine detected by tandem mass spectrometry from control cells (A and B), cells isolated from VLCAD-deficient patient with the mild muscle phenotype(C and D) or cells from the VLCAD-deficient patients with cardiomyopathy (E and F). 

Phrase: "The signals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1710082:Signal [Phenomenon or Process]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "molecular ions of acylcarnitine"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0022023:Ions [Element, Ion, or Isotope]
   770   C1521991:Molecular [Qualitative Concept]
   737 E C1700702:ION [Functional Concept]

Phrase: "detected by tandem mass spectrometry"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   862   C0599748:Tandem Mass Spectrometry [Molecular Biology Research Technique]
   806   C0037813:Mass Spectrometry [Laboratory Procedure]
   760   C0075804:TANDEM [Organic Chemical,Pharmacologic Substance]
   760   C0436196:Spectrometry [Laboratory Procedure]
   760   C0442726:Detected [Finding]
   760   C0577559:Mass [Finding]
   760   C1306372:*Mass [Quantitative Concept]
   760   C1511790:Detected [Therapeutic or Preventive Procedure]
   760   C3152252:Mass [Quantitative Concept]

Phrase: "from control cells"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   861   C0007634:Cells [Cell]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "(A"

Phrase: "and"

Phrase: "B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "isolated from VLCAD-deficient patient"
Meta Candidates (Total=23; Excluded=2; Pruned=0; Remaining=21)
   862   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   862   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   833   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   806   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   782   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   782   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   782   C1980013:Very long chain [Qualitative Concept]
   739   C0011155:Deficient [Functional Concept]
   739   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   739   C0030705:*^patient [Patient or Disabled Group]
   739   C0205166:Long [Qualitative Concept]
   739   C0205409:Isolated [Functional Concept]
   739   C0337112:Chain [Manufactured Object]
   739   C0442824:Very [Qualitative Concept]
   739   C1524075:Chain [Idea or Concept]
   739   C1548221:Isolated [Idea or Concept]
   739   C1636779:% deficient [Quantitative Concept]
   739   C1706317:Long [Qualitative Concept]
   706 E C0370215:Isolate [Substance]
   706 E C1875400:ISOLATE [Pharmacologic Substance]

Phrase: "with the mild muscle phenotype"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C1855585:Mild phenotype [Finding]
   827   C0031437:Phenotype [Organism Attribute]
   827   C1285572:Phenotype [Laboratory Procedure]

Phrase: "(C"

Phrase: "and"

Phrase: "D)"

Phrase: "or"

Phrase: "cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "from the VLCAD-deficient patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "with cardiomyopathy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0878544:Cardiomyopathy [Disease or Syndrome]

Phrase: "(E"

Phrase: "and"

Phrase: "F)."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.89: Internal standards (IS): (2H3)-octanoylcarnitine (m/z=292), (2H3)-myristoylcarnitine (m/z=382), (2H3)-palmitoylcarnitine (m/z=404). 

Phrase: "Internal standards (IS)"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   861   C0038137:standards [Intellectual Product]
   861   C0175675:Standards [Qualitative Concept]
   861   C0205102:Internal [Spatial Concept]
   861   C1553872:Internal [Intellectual Product]
   861   C1619620:Internal [Intellectual Product]
   827 E C1442989:Standard [Qualitative Concept]
   827 E C2828392:Standard [Intellectual Product]

Phrase: ":"

Phrase: "(2H3"

Phrase: ")-"

Phrase: "octanoylcarnitine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0069344:octanoylcarnitine [Organic Chemical]

Phrase: "("

Phrase: "m/"

Phrase: "z=292"

Phrase: ")"

Phrase: ","

Phrase: "(2H3"

Phrase: ")-"

Phrase: "myristoylcarnitine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2714090:myristoylcarnitine [Lipid]

Phrase: "("

Phrase: "m/"

Phrase: "z=382"

Phrase: ")"

Phrase: ","

Phrase: "(2H3"

Phrase: ")-"

Phrase: "palmitoylcarnitine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030242:Palmitoylcarnitine [Amino Acid, Peptide, or Protein,Vitamin]

Phrase: "("

Phrase: "m/"

Phrase: "z=404"

Phrase: ")."
Processing 00000000.tx.90: (G) Quantification of C16 acylcarnitine. 

Phrase: "(G) Quantification of C16 acylcarnitine."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1709793:Quantification [Quantitative Concept]
Processing 00000000.tx.91: Determinations were performed in triplicate. 

Phrase: "Determinations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0680730:determinations [Governmental or Regulatory Activity]
   966 E C1148554:determination [Laboratory Procedure]

Phrase: "were"

Phrase: "performed in triplicate."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0205174:Triplicate [Quantitative Concept]
   790   C0884358:Performed [Functional Concept]
   756 E C2947996:Perform [Pharmacologic Substance]
Processing 00000000.tx.92: Results are expressed as meanSD. 

Phrase: "Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "expressed as meanSD."
Processing 00000000.tx.93: ***P<0.001 when compared with the control. 

Phrase: "*"

Phrase: "*"

Phrase: "*P<0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "when"

Phrase: "compared with the control."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0243148:control [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1707455:Compared [Activity]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.94: m/z, mass/charge.  

Phrase: "m/"

Phrase: "z,"

Phrase: "mass/charge."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0007961:Charge [Quantitative Concept]
   861   C1706211:Charge [Organism Attribute]
Processing 00000000.tx.95: In our VLCAD-deficient patients, and as reported by others (16,17), we demonstrated a more pronounced accumulation of C12-, C14- and C16-acylcarnitines in the severe phenotype (Fig.2E) when compared with the milder form (Fig.2C). 

Phrase: "In our VLCAD-deficient patients,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "and"

Phrase: "as"

Phrase: "reported by others"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   882   C1709908:Reported By [Group]
   790   C0684224:Reported [Intellectual Product]
   790   C0700287:Reported [Health Care Activity]
   790   C1955473:Others [Finding]
   790   C3496591:Reported [Clinical Attribute]
   756 E C3273238:Report [Intellectual Product]

Phrase: "(16,"

Phrase: "17"

Phrase: ")"

Phrase: ","

Phrase: "we"

Phrase: "demonstrated"

Phrase: "a more pronounced accumulation of C12-,"

Phrase: "C14-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0302945:C-14 [Element, Ion, or Isotope,Indicator, Reagent, or Diagnostic Aid]

Phrase: "and"

Phrase: "C16-acylcarnitines in the severe phenotype"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0368608:acylcarnitines [Organic Chemical]

Phrase: "(Fig.2E"

Phrase: ")"

Phrase: "when"

Phrase: "compared with the milder form"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0348078:Form [Qualitative Concept]
   760   C0376315:Form [Manufactured Object]
   760   C1522492:Form [Functional Concept]
   760   C1707455:Compared [Activity]
   726   C2945599:Mild [Qualitative Concept]

Phrase: "(Fig.2C"

Phrase: ")."
Processing 00000000.tx.96: Cells of patients 2 and 3 exhibited the same acylcarnitine profiles as patient 1 (data not shown). 

Phrase: "Cells of patients 2"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0007634:Cells [Cell]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "and"

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "exhibited"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0015272:Exhibit [Intellectual Product]

Phrase: "the same acylcarnitine profiles as patient 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   757   C0747306:patient profile [Health Care Activity]
   714   C1979963:Profile [Laboratory Procedure]
   714   C2003903:Profile [Functional Concept]

Phrase: "(data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.97: The quantification of palmitoyl-(C16)-acylcarnitine (Fig.2G) revealed that the concentration in cells from the severely VLCAD-deficient neonate was 1.53.5-fold higher than that in cells from the mild VLCAD-deficient individuals (patients 13), in agreement with data from others (16). 

Phrase: "The quantification of palmitoyl-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1709793:Quantification [Quantitative Concept]

Phrase: "(C16"

Phrase: ")-"

Phrase: "acylcarnitine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0368608:Acyl carnitine [Organic Chemical]

Phrase: "(Fig.2G"

Phrase: ")"

Phrase: "revealed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:Revealed [Qualitative Concept]

Phrase: "that"

Phrase: "the concentration in cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0086045:Concentration [Mental Process]
   770   C1446561:Concentration [Quantitative Concept]

Phrase: "from the severely VLCAD-deficient neonate"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   791   C0021289:Neonate [Age Group]
   791   C2239178:Neonate [Finding]
   791   C2939425:Neonate, NOS [Temporal Concept]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "was"

Phrase: "1.53.5-fold"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0332462:Fold [Spatial Concept]
   812   C1880834:FOLD [Phenomenon or Process]
   708   C0450316:1/5 [Quantitative Concept]

Phrase: "higher than that"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   756   C0205250:High [Qualitative Concept]
   756   C1299351:High [Qualitative Concept]
   756   C2700149:HIGH [Intellectual Product]
   706 E C0489786:Height [Organism Attribute]

Phrase: "in cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "from the mild VLCAD-deficient individuals"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   758   C0027361:Individual [Population Group]
   758   C0237401:Individual [Human]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "(patients 13"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: ")"

Phrase: ","

Phrase: "in agreement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0680240:Agreement [Social Behavior]

Phrase: "with data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "from others"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1955473:Others [Finding]
   966 E C0205394:Other [Qualitative Concept]

Phrase: "(16"

Phrase: ")."
Processing 00000000.tx.98: In all cases, the production of C16-acylcarnitine in patient cells was 516-fold higher than that in control cells. 

Phrase: "In all cases,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "the production of C16-acylcarnitine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0033268:production [Occupational Activity]

Phrase: "in patient cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "was"

Phrase: "516-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332462:Fold [Spatial Concept]
   861   C1880834:FOLD [Phenomenon or Process]

Phrase: "higher than that"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   756   C0205250:High [Qualitative Concept]
   756   C1299351:High [Qualitative Concept]
   756   C2700149:HIGH [Intellectual Product]
   706 E C0489786:Height [Organism Attribute]

Phrase: "in control cells."
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   861   C0007634:Cells [Cell]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.99: Concerning the other acylcarnitine species, C14- and C12-acylcarnitines were found to be, on average, 6.5- and 8.8-fold higher or 2.3 and 3.8-fold higher in the mild or severe VLCAD-deficient fibroblasts, compared with control. 

Phrase: "Concerning"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2699424:Concern [Idea or Concept]

Phrase: "the other acylcarnitine species,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1705920:Species [Conceptual Entity]

Phrase: "C14-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0302945:C-14 [Element, Ion, or Isotope,Indicator, Reagent, or Diagnostic Aid]

Phrase: "and"

Phrase: "C12-acylcarnitines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0368608:acylcarnitines [Organic Chemical]

Phrase: "were"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: ","

Phrase: "on average,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1510992:Average [Quantitative Concept]
  1000   C2825518:AVERAGE [Quantitative Concept]

Phrase: "6.5-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442749:6/5 [Finding]

Phrase: "and"

Phrase: "8.8-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0332462:Fold [Spatial Concept]
   827   C1880834:FOLD [Phenomenon or Process]

Phrase: "higher"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   966   C0205250:High [Qualitative Concept]
   966   C1299351:High [Qualitative Concept]
   966   C2700149:HIGH [Intellectual Product]
   916 E C0489786:Height [Organism Attribute]

Phrase: "or"

Phrase: "2.3"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1519042:2-3 [Research Activity]
   861   C0740116:+2 [Quantitative Concept]
   861   C2827735:2+ [Quantitative Concept]
   861   C2981700:2+ [Classification]

Phrase: "and"

Phrase: "3.8-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0332462:Fold [Spatial Concept]
   827   C1880834:FOLD [Phenomenon or Process]

Phrase: "higher in the mild"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   737   C0205250:High [Qualitative Concept]
   737   C1299351:High [Qualitative Concept]
   737   C2700149:HIGH [Intellectual Product]

Phrase: "or"

Phrase: "severe VLCAD-deficient fibroblasts,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   791   C0016030:Fibroblasts [Cell]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "compared with control."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0243148:control [Qualitative Concept]
   790   C1550141:Control [Substance]
   790   C1707455:Compared [Activity]
   790   C1882979:Control [Conceptual Entity]
   790   C2587213:Control [Functional Concept]
   790   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.100: Because bezafibrate appeared to be more potent in stimulating FAO oxidation than fenofibric acid, we investigated the effect of bezafibrate on C16-acylcarnitine intermediates in control and VLCAD-deficient fibroblasts. 

Phrase: "Because"

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "appeared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "more potent in stimulating FAO oxidation"

Phrase: "than fenofibric acid,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0060179:fenofibric acid [Organic Chemical,Pharmacologic Substance]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "we"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "the effect of bezafibrate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1280500:Effect [Qualitative Concept]
   770   C2348382:Effect [Qualitative Concept]

Phrase: "on C16-acylcarnitine intermediates"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C0205103:Intermediate [Spatial Concept]
   793   C1550465:intermediate [Idea or Concept]
   793   C2827755:INTERMEDIATE [Laboratory or Test Result]

Phrase: "in control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "VLCAD-deficient fibroblasts."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0016030:Fibroblasts [Cell]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
Processing 00000000.tx.101: The results indicate that a 3 day treatment of mild VLCAD-deficient fibroblasts (patients 13) with bezafibrate normalized the C16-acylcarnitine production in mutant cells to control levels, but no beneficial effect was observed in severe VLCAD-deficient cells (patient 4). 

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "indicate"

Phrase: "that"

Phrase: "a 3 day treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0039798:treatment [Functional Concept]
   827   C0087111:Treatment [Therapeutic or Preventive Procedure]
   827   C1522326:Treatment [Functional Concept]
   827   C1533734:Treatment [Therapeutic or Preventive Procedure]
   827   C1705169:Treatment [Conceptual Entity]
   827   C3538994:TREATMENT [Research Activity]

Phrase: "of mild VLCAD-deficient fibroblasts"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   791   C0016030:Fibroblasts [Cell]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "(patients 13"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: ")"

Phrase: "with bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "normalized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882115:Normalized [Research Activity]

Phrase: "the C16-acylcarnitine production in mutant cells to control levels,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0033268:production [Occupational Activity]

Phrase: "but"

Phrase: "no beneficial effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]

Phrase: "was"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: "in severe VLCAD-deficient cells"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   791   C0007634:Cells [Cell]
   791   C3282337:Cells [Cell]
   758 E C1269647:Cell [Cell]
   758 E C1704653:Cell [Medical Device]
   758 E C1948049:Cell [Spatial Concept]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "(patient 4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: ")."
Processing 00000000.tx.102: Bezafibrate also diminished the production of C14- and C12-acylcarnitines in both control and patient cells. 

Phrase: "Bezafibrate also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "diminished"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205216:Diminished [Quantitative Concept]

Phrase: "the production of C14-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0033268:production [Occupational Activity]

Phrase: "and"

Phrase: "C12-acylcarnitines in both control"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0368608:acylcarnitines [Organic Chemical]

Phrase: "and"

Phrase: "patient cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.103: Thus, the C14-acylcarnitines were decreased by 40% in control and moderately deficient fibroblasts, and by 53% in severely deficient cells. 

Phrase: "Thus,"

Phrase: "the C14-acylcarnitines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0368608:acylcarnitines [Organic Chemical]

Phrase: "were"

Phrase: "decreased by 40%"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0205216:Decreased [Quantitative Concept]
   790   C0392756:Decreased [Qualitative Concept]
   790   C0439509:/40 [Temporal Concept]
   790   C0442797:decreased [Qualitative Concept]
   756 E C0547047:Decrease [Quantitative Concept]

Phrase: "in control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "moderately deficient fibroblasts,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0016030:Fibroblasts [Cell]

Phrase: "and by 53%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1515981:And [Idea or Concept]

Phrase: "in severely deficient cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.104: Concerning the C12-acylcarnitines, the decreases were more pronounced in all patient cells (80%) than in control fibroblasts. 

Phrase: "Concerning"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2699424:Concern [Idea or Concept]

Phrase: "the C12-acylcarnitines,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0368608:acylcarnitines [Organic Chemical]

Phrase: "the decreases"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0547047:decreases [Quantitative Concept]
   966 E C0392756:Decrease [Qualitative Concept]

Phrase: "were"

Phrase: "more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "pronounced in all patient cells"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   760   C0007634:Cells [Cell]
   760   C0030705:*^patient [Patient or Disabled Group]
   760   C3282337:Cells [Cell]
   726 E C1269647:Cell [Cell]
   726 E C1704653:Cell [Medical Device]
   726 E C1948049:Cell [Spatial Concept]

Phrase: "(80%"

Phrase: ")"

Phrase: "than"

Phrase: "in control fibroblasts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0016030:Fibroblasts [Cell]
Processing 00000000.tx.105: Interestingly, although there was no abnormal accumulation of C8- or C10-acylcarnitine in the patient cells, bezafibrate decreased the amount of these acylcarnitines by 75%. 

Phrase: "Interestingly,"

Phrase: "although"

Phrase: "there"

Phrase: "was"

Phrase: "no abnormal accumulation of C8-"

Phrase: "or"

Phrase: "C10-acylcarnitine in the patient cells,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0368608:Acyl carnitine [Organic Chemical]

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "decreased"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0205216:Decreased [Quantitative Concept]
  1000   C0392756:Decreased [Qualitative Concept]
  1000   C0442797:decreased [Qualitative Concept]
   966 E C0547047:Decrease [Quantitative Concept]

Phrase: "the amount of these acylcarnitines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1265611:Amount [Quantitative Concept]

Phrase: "by 75%."
Processing 00000000.tx.106: Bezafibrate increases VLCAD enzyme activity Fibroblasts from controls and VLCAD-deficient patients were treated with 500M bezafibrate for 48h. 

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "VLCAD enzyme activity Fibroblasts from controls"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0016030:Fibroblasts [Cell]

Phrase: "and"

Phrase: "VLCAD-deficient patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "were"

Phrase: "treated with 500M bezafibrate"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
   770   C1522326:Treated [Functional Concept]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "for 48h."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1442464:48H [Temporal Concept]
Processing 00000000.tx.107: In control cells, VLCAD enzyme activity was increased 2.2-fold, from 2.60.2 to 5.80.1, in response to bezafibrate (Fig.3). 

Phrase: "In control cells,"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   861   C0007634:Cells [Cell]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "VLCAD enzyme activity"
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   953   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   920   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   920   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   812   C0243102:enzyme activity [Molecular Function]
   793   C0014442:Enzyme [Enzyme,Organic Chemical]
   793   C0205177:Activity [Functional Concept]
   793   C0439167:% activity [Quantitative Concept]
   793   C0441655:Activity [Activity]
   793   C1561536:*Activity [Idea or Concept]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710 E C0014445:enzymes [Functional Concept]

Phrase: "was"

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "2.2-fold,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0332462:Fold [Spatial Concept]
   827   C1880834:FOLD [Phenomenon or Process]

Phrase: "from 2.60.2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0740116:+2 [Quantitative Concept]
   827   C2827735:2+ [Quantitative Concept]
   827   C2981700:2+ [Classification]

Phrase: "to 5.80.1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: "in response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "to bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "(Fig.3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.108: The residual enzyme activity measured in mild-type VLCAD-deficient patient' fibroblasts represented 1520% of control values. 

Phrase: "The residual enzyme activity"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   901   C0243102:enzyme activity [Molecular Function]
   827   C0014442:Enzyme [Enzyme,Organic Chemical]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]
   743 E C0014445:enzymes [Functional Concept]

Phrase: "measured"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "in mild-type VLCAD-deficient patient' fibroblasts"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   788   C0016030:Fibroblasts [Cell]
   704   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   704   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]

Phrase: "represented"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1882932:Represent [Activity]

Phrase: "1520% of control values."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   770   C0042295:Values [Qualitative Concept]
   770   C0243148:control [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]
   737 E C1522609:Value [Quantitative Concept]
Processing 00000000.tx.109: Exposure of these cells to bezafibrate resulted in a highly significant rise in enzyme activity, ranging from +80 to +775% compared with vehicle-treated cells. 

Phrase: "Exposure of these cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0274281:Exposure, NOS [Injury or Poisoning]
   770   C0332157:Exposure [Clinical Attribute]

Phrase: "to bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "resulted in a highly significant rise"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C1299395:Highly significant [Qualitative Concept]
   753   C0205250:Highly [Qualitative Concept]
   753   C0237881:significant [Quantitative Concept]
   753   C0750502:Significant [Idea or Concept]
   753   C1546944:Significant [Qualitative Concept]
   719   C1274040:Result [Functional Concept]
   719   C1546471:Result [Idea or Concept]
   719   C2825142:Result [Finding]

Phrase: "in enzyme activity,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
  1000   C0243102:enzyme activity [Molecular Function]
   861   C0014442:Enzyme [Enzyme,Organic Chemical]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]
   777 E C0014445:enzymes [Functional Concept]

Phrase: "ranging from +80 to +775%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C1514721:Range [Quantitative Concept]
   726   C2348147:Range [Quantitative Concept]
   726   C3542016:Range [Intellectual Product]

Phrase: "compared with vehicle-treated cells."
Meta Candidates (Total=12; Excluded=4; Pruned=0; Remaining=8)
   797   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   760   C0007634:Cells [Cell]
   760   C0042444:Vehicle [Biomedical or Dental Material]
   760   C0348005:Vehicle [Manufactured Object]
   760   C1522326:Treated [Functional Concept]
   760   C1707455:Compared [Activity]
   760   C3282337:Cells [Cell]
   726 E C1269647:Cell [Cell]
   726 E C1292734:TREAT [Functional Concept]
   726 E C1704653:Cell [Medical Device]
   726 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.110: In patients 2 and 3, bezafibrate actually restored enzyme activity to almost normal levels, whereas the value reached in patient 1 represented only 35% of control values. 

Phrase: "In patients 2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "bezafibrate actually restored enzyme activity to almost normal levels,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   764   C0243102:enzyme activity [Molecular Function]
   762   C0014440:enzyme levels [Laboratory Procedure]
   762   C0683317:activity levels [Finding]
   762   C1287349:enzyme levels [Laboratory or Test Result]
   742   C0014442:Enzyme [Enzyme,Organic Chemical]
   742   C0205177:Activity [Functional Concept]
   742   C0439167:% activity [Quantitative Concept]
   742   C0441655:Activity [Activity]
   742   C1561536:*Activity [Idea or Concept]

Phrase: "whereas"

Phrase: "the value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522609:Value [Quantitative Concept]

Phrase: "reached in patient 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0030705:*^patient [Patient or Disabled Group]
   737   C2584321:Reach [Organism Function]

Phrase: "represented"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1882932:Represent [Activity]

Phrase: "only 35% of control values."
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   760   C0042295:Values [Qualitative Concept]
   760   C0205171:Only [Quantitative Concept]
   760   C0243148:control [Qualitative Concept]
   760   C1550141:Control [Substance]
   760   C1720467:Only [Intellectual Product]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C3274648:Control [Qualitative Concept]
   726 E C1522609:Value [Quantitative Concept]
Processing 00000000.tx.111: Bezafibrate failed to increase VLCAD activity in cells from patient 4. 

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "VLCAD activity in cells"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   919   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   882   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   882   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   742   C0205177:Activity [Functional Concept]
   742   C0439167:% activity [Quantitative Concept]
   742   C0441655:Activity [Activity]
   742   C1561536:*Activity [Idea or Concept]
   716   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   716   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]

Phrase: "from patient 4."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]
Processing 00000000.tx.112: View larger version (37K): [in this window] [in a new window]  Figure3. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(37K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure3."
Processing 00000000.tx.113: Effect of bezafibrate on VLCAD enzyme activity. 

Phrase: "Effect of bezafibrate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "on VLCAD enzyme activity."
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   953   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   920   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   920   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   812   C0243102:enzyme activity [Molecular Function]
   793   C0014442:Enzyme [Enzyme,Organic Chemical]
   793   C0205177:Activity [Functional Concept]
   793   C0439167:% activity [Quantitative Concept]
   793   C0441655:Activity [Activity]
   793   C1561536:*Activity [Idea or Concept]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710 E C0014445:enzymes [Functional Concept]
Processing 00000000.tx.114: Control and VLCAD-deficient fibroblasts were incubated for 48h with bezafibrate (500M) and then harvested for VLCAD enzyme activity. 

Phrase: "Control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "VLCAD-deficient fibroblasts"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0016030:Fibroblasts [Cell]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "were"

Phrase: "incubated for 48h"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1439852:Incubated [Laboratory Procedure]
   790   C1442464:48H [Temporal Concept]

Phrase: "with bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "(500M"

Phrase: ")"

Phrase: "and"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "harvested for VLCAD enzyme activity."
Meta Candidates (Total=28; Excluded=0; Pruned=0; Remaining=28)
   880   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   862   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   862   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   851   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   851   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   833   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   806   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   782   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   782   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   782   C1980013:Very long chain [Qualitative Concept]
   760   C0243102:enzyme activity [Molecular Function]
   739   C0014442:Enzyme [Enzyme,Organic Chemical]
   739   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   739   C0205166:Long [Qualitative Concept]
   739   C0205177:Activity [Functional Concept]
   739   C0337112:Chain [Manufactured Object]
   739   C0439167:% activity [Quantitative Concept]
   739   C0441655:Activity [Activity]
   739   C0442824:Very [Qualitative Concept]
   739   C1524075:Chain [Idea or Concept]
   739   C1561536:*Activity [Idea or Concept]
   739   C1706317:Long [Qualitative Concept]
   706   C1512335:Harvest [Health Care Activity]
Processing 00000000.tx.115: Control values are shown as meanSD of three different individuals. 

Phrase: "Control values"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   861   C0042295:Values [Qualitative Concept]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   827 E C1522609:Value [Quantitative Concept]

Phrase: "are"

Phrase: "shown as meanSD of three different individuals."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0205449:Three [Quantitative Concept]
   748   C1705242:Different [Qualitative Concept]
   721   C0021228:Individual Difference [Mental Process]
   714   C0027361:Individual [Population Group]
   714   C0237401:Individual [Human]
   714   C1547282:Show [Intellectual Product]
Processing 00000000.tx.116: For patients, the determinations were performed in duplicate. 

Phrase: "For patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "the determinations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0680730:determinations [Governmental or Regulatory Activity]
   966 E C1148554:determination [Laboratory Procedure]

Phrase: "were"

Phrase: "performed in duplicate."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0205173:Duplicate [Functional Concept]
   790   C0884358:Performed [Functional Concept]
   790   C3539942:Duplicate [Intellectual Product]
   756 E C2947996:Perform [Pharmacologic Substance]
Processing 00000000.tx.117: ***P<0.001 versus vehicle (DMSO).  

Phrase: "*"

Phrase: "*"

Phrase: "*P<0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "versus"

Phrase: "vehicle"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0042444:Vehicle [Biomedical or Dental Material]
  1000   C0348005:Vehicle [Manufactured Object]
   928 E C0445373:Vehicular [Functional Concept]

Phrase: "(DMSO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0012403:DMSO [Organic Chemical,Pharmacologic Substance]

Phrase: ")."
Processing 00000000.tx.118: Bezafibrate increases VLCAD protein levels Fibroblasts from VLCAD-deficient patients and controls were cultured in the presence or absence of bezafibrate (500M) for 48h and were then analyzed by western blot with a VLCAD antibody and with a -actin antibody as a protein loading control. 

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "VLCAD protein levels Fibroblasts"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   791   C0016030:Fibroblasts [Cell]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "from VLCAD-deficient patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "and"

Phrase: "controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0243148:control [Qualitative Concept]
   966   C1550141:Control [Substance]
   966   C1882979:Control [Conceptual Entity]
   966   C2587213:Control [Functional Concept]
   966   C3274648:Control [Qualitative Concept]

Phrase: "were"

Phrase: "cultured in the presence"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0392148:Presence [Therapeutic or Preventive Procedure]
   737   C0010453:Culture [Idea or Concept]
   737   C0220814:culture [Functional Concept]
   737   C0430400:Culture [Laboratory Procedure]
   737   C2242979:Culture [Laboratory Procedure]

Phrase: "or"

Phrase: "absence of bezafibrate"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0332197:absence [Quantitative Concept]
   790   C1689985:Absence [Anatomical Abnormality]
   718 E C2699517:ABSENT [Finding]

Phrase: "(500M"

Phrase: ")"

Phrase: "for 48h"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1442464:48H [Temporal Concept]

Phrase: "and"

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "analyzed by western blot"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   833   C0949466:Western Blot [Laboratory Procedure]
   770   C0936012:Analyzed [Research Activity]
   770   C1705493:Western [Spatial Concept]

Phrase: "with a VLCAD antibody"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   829   C2360861:Co^a Antibody [Immunologic Factor]
   795   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   795   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and with a -actin antibody"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C1718641:Actin Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0001271:Actin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   760   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   760   C1515981:And [Idea or Concept]

Phrase: "as a protein loading control."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   827   C0243148:control [Qualitative Concept]
   827   C1550141:Control [Substance]
   827   C1882979:Control [Conceptual Entity]
   827   C2587213:Control [Functional Concept]
   827   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.119: In Figure4A and B, representative western blots of control and VLCAD patients are shown with a histogram (Fig.4C) displaying mean levels of VLCAD protein relative to -actin. 

Phrase: "In Figure4A"

Phrase: "and"

Phrase: "B,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "representative western blots of control"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   806   C0949466:Western Blots [Laboratory Procedure]
   773 E C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   760   C1705493:Western [Spatial Concept]

Phrase: "and"

Phrase: "VLCAD patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0030705:Patients [Patient or Disabled Group]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "are"

Phrase: "shown with a histogram"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C2348974:Histogram [Manufactured Object]
   737   C1547282:Show [Intellectual Product]

Phrase: "(Fig.4C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450376:4c [Intellectual Product]

Phrase: ")"

Phrase: "displaying mean levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "of VLCAD protein relative to -actin."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0001271:Actin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   718 E C0439681:Actinic [Qualitative Concept]
   717   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
Processing 00000000.tx.120: The amounts of immunoreactive VLCAD protein were significantly reduced in all analyzed patient fibroblasts compared with control cells. 

Phrase: "The amounts of immunoreactive VLCAD protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C1265611:amounts [Quantitative Concept]

Phrase: "were"

Phrase: "significantly"

Phrase: "reduced in all analyzed patient fibroblasts"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0016030:Fibroblasts [Cell]
   753   C0030705:*^patient [Patient or Disabled Group]
   753   C0392756:Reduced [Qualitative Concept]
   753   C0936012:Analyzed [Research Activity]

Phrase: "compared with control cells."
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   770   C0007634:Cells [Cell]
   770   C0243148:control [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1707455:Compared [Activity]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.121: VLCAD protein levels ranged from 50% of control cells in patients 2 and 3 to 35% of control cells in patients 1 and 4. 

Phrase: "VLCAD protein levels"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   793   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   793   C0441889:Levels [Qualitative Concept]
   779   C0428479:Protein level [Laboratory or Test Result]
   760 E C0456079:Level [Classification]
   760 E C1547707:Level [Geographic Area]
   760 E C2946261:Level [Pharmacologic Substance]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "ranged from 50% of control cells"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   753   C0007634:Cells [Cell]
   753   C0243148:control [Qualitative Concept]
   753   C1550141:Control [Substance]
   753   C1882979:Control [Conceptual Entity]
   753   C2587213:Control [Functional Concept]
   753   C3274648:Control [Qualitative Concept]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719   C1514721:Range [Quantitative Concept]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]
   719   C2348147:Range [Quantitative Concept]
   719   C3542016:Range [Intellectual Product]

Phrase: "in patients 2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "3 to 35% of control cells"
Meta Candidates (Total=13; Excluded=3; Pruned=0; Remaining=10)
   753   C0007634:Cells [Cell]
   753   C0243148:control [Qualitative Concept]
   753   C0439086:<3 [Quantitative Concept]
   753   C1550141:Control [Substance]
   753   C1882979:Control [Conceptual Entity]
   753   C2587213:Control [Functional Concept]
   753   C2827736:3+ [Quantitative Concept]
   753   C2981702:3+ [Classification]
   753   C3274648:Control [Qualitative Concept]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]

Phrase: "in patients 1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "4."
Processing 00000000.tx.122: View larger version (24K): [in this window] [in a new window]  Figure4. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(24K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure4."
Processing 00000000.tx.123: Effect of bezafibrate on VLCAD protein expression in fibroblasts from normal (A) and VLCAD-deficient individuals (B). 

Phrase: "Effect of bezafibrate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "on VLCAD protein expression"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C1171362:protein expression [Genetic Function]
   793   C0185117:Expression [Therapeutic or Preventive Procedure]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "in fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016030:Fibroblasts [Cell]

Phrase: "from normal"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205307:Normal [Qualitative Concept]
  1000   C0439166:% normal [Quantitative Concept]
  1000   C2347086:% Normal [Quantitative Concept]

Phrase: "(A)"

Phrase: "and"

Phrase: "VLCAD-deficient individuals"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0027361:Individual [Population Group]
   760   C0237401:Individual [Human]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "(B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.124: Western blots of protein extracts from control and VLCAD-deficient cells were incubated with anti-VLCAD antibody and then re-probed with anti--actin antibody. 

Phrase: "Western blots of protein"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   833   C0949466:Western Blots [Laboratory Procedure]
   799 E C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   770   C1705493:Western [Spatial Concept]

Phrase: "extracts from control"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0243148:control [Qualitative Concept]
   790   C1550141:Control [Substance]
   790   C1882979:Control [Conceptual Entity]
   790   C2587213:Control [Functional Concept]
   790   C2828366:Extract [Substance]
   790   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "VLCAD-deficient cells"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   793   C0007634:Cells [Cell]
   793   C3282337:Cells [Cell]
   760 E C1269647:Cell [Cell]
   760 E C1704653:Cell [Medical Device]
   760 E C1948049:Cell [Spatial Concept]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "were"

Phrase: "incubated with anti-VLCAD antibody"
Meta Candidates (Total=21; Excluded=0; Pruned=0; Remaining=21)
   862   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   862   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   833   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   806   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   782   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   782   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   782   C1980013:Very long chain [Qualitative Concept]
   757   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757   C2360861:Co^a Antibody [Immunologic Factor]
   739   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   739   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   739   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   739   C0205166:Long [Qualitative Concept]
   739   C0337112:Chain [Manufactured Object]
   739   C0442824:Very [Qualitative Concept]
   739   C1439852:Incubated [Laboratory Procedure]
   739   C1524075:Chain [Idea or Concept]
   739   C1706317:Long [Qualitative Concept]

Phrase: "and"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "re-"

Phrase: "probed with anti--actin antibody."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   862   C0369998:Anti-actin antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   806   C1718641:Actin Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   797   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0001271:Actin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   760   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   726   C0182400:Probe [Medical Device]
   726   C1704681:Probe [Gene or Genome]
   726   C2347609:Probe [Chemical Viewed Functionally]
   726   C3536729:Probe [Manufactured Object]
Processing 00000000.tx.125: (C) Histogram of VLCAD protein amount relative to -actin. 

Phrase: "(C) Histogram"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2348974:Histogram [Manufactured Object]

Phrase: "of VLCAD protein"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "amount"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1265611:Amount [Quantitative Concept]

Phrase: "relative to -actin."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0001271:Actin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   755 E C0439681:Actinic [Qualitative Concept]
Processing 00000000.tx.126: Values are depicted as meanSD of two independent experiments. 

Phrase: "Values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0042295:Values [Qualitative Concept]
   966 E C1522609:Value [Quantitative Concept]

Phrase: "are"

Phrase: "depicted as meanSD of two independent experiments."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   774   C0332291:Independent of [Functional Concept]
   748   C0085862:Independent [Idea or Concept]
   748   C0205448:Two [Quantitative Concept]
   748   C0681814:Experiments [Research Activity]
   748   C1299583:Independent [Finding]
   714 E C1706386:Experiment [Conceptual Entity]
Processing 00000000.tx.127: **P<0.01, ***P<0.001 when compared with the vehicle-treated fibroblasts of a given subject.  

Phrase: "*"

Phrase: "*P<0.01,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "*"

Phrase: "*"

Phrase: "*P<0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "when"

Phrase: "compared with the vehicle-treated fibroblasts of a given subject."
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   757   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   739   C0016030:Fibroblasts [Cell]
   739   C0042444:Vehicle [Biomedical or Dental Material]
   739   C0348005:Vehicle [Manufactured Object]
   739   C0681850:Subject [Group]
   739   C1522326:Treated [Functional Concept]
   739   C1550501:{Subject} [Idea or Concept]
   739   C1706203:Subject [Idea or Concept]
   739   C1707455:Compared [Activity]
   739   C2349001:Subject [Human]
   739   C2697811:Subject [Functional Concept]
   706 E C1292734:TREAT [Functional Concept]
Processing 00000000.tx.128: In cells from control and patients 13, a significant increase of VLCAD protein was observed after bezafibrate treatment, ranging between 1.5- and 2-fold when compared with untreated cells. 

Phrase: "In cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "from control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "patients 13,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "a significant increase of VLCAD protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0442805:Increase [Functional Concept]

Phrase: "was"

Phrase: "observed after bezafibrate treatment,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1441672:Observed [Functional Concept]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "ranging between 1.5-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   737   C1514721:Range [Quantitative Concept]
   737   C2348147:Range [Quantitative Concept]
   737   C3542016:Range [Intellectual Product]

Phrase: "and"

Phrase: "2-fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332462:Fold [Spatial Concept]
   861   C1880834:FOLD [Phenomenon or Process]

Phrase: "when"

Phrase: "compared with untreated cells."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0007634:Cells [Cell]
   770   C0332155:untreated [Finding]
   770   C1707455:Compared [Activity]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.129: Bezafibrate failed to increase the amount of VLCAD immunoreactive protein in patient 4. 

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "increase"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "the amount of VLCAD immunoreactive protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C1265611:Amount [Quantitative Concept]

Phrase: "in patient 4."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]
Processing 00000000.tx.130: Bezafibrate increases VLCAD mRNA and other FAO enzyme mRNA Quantitative RT-PCR analysis was performed to determine whether bezafibrate increased VLCAD gene expression. 

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "increases"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]
   944 E C1517378:Gain [Quantitative Concept]
   916 E C0205217:Increased [Quantitative Concept]
   916 E C0439661:Acquired [Temporal Concept]
   916 E C0442808:Increasing [Functional Concept]
   916 E C1301820:Obtain [Functional Concept]
   916 E C1706701:Acquire [Activity]
   916 E C3245488:acquired [Intellectual Product]

Phrase: "VLCAD mRNA"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and"

Phrase: "other FAO enzyme mRNA Quantitative RT-PCR analysis"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   834   C2733022:Quantitative PCR analysis [Laboratory Procedure]
   807   C0200931:PCR analysis [Laboratory Procedure]
   791   C0002778:Analysis [Laboratory Procedure]
   791   C0936012:Analysis [Research Activity]
   791   C1524024:analysis [Functional Concept]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "determine"

Phrase: "whether"

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "VLCAD gene expression."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   812   C0017262:Gene Expression [Genetic Function]
   793   C0017337:Gene [Gene or Genome]
   793   C0185117:Expression [Therapeutic or Preventive Procedure]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
Processing 00000000.tx.131: Treatment with 500M bezafibrate for 48h (Table 1) resulted in stimulation (+44 to +150%; P<0.001) of VLCAD gene expression in control and patient cells compared with untreated cells. 

Phrase: "Treatment with 500M bezafibrate"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]

Phrase: "for 48h"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1442464:48H [Temporal Concept]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")"

Phrase: "resulted in stimulation"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   790   C1948023:Stimulation [Natural Phenomenon or Process]
   756   C1274040:Result [Functional Concept]
   756   C1546471:Result [Idea or Concept]
   756   C2825142:Result [Finding]

Phrase: "(+44 to +150%"

Phrase: "; P<0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "of VLCAD gene expression"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   812   C0017262:Gene Expression [Genetic Function]
   793   C0017337:Gene [Gene or Genome]
   793   C0185117:Expression [Therapeutic or Preventive Procedure]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "in control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0243148:control [Qualitative Concept]
  1000   C1550141:Control [Substance]
  1000   C1882979:Control [Conceptual Entity]
  1000   C2587213:Control [Functional Concept]
  1000   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "patient cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "compared with untreated cells."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0007634:Cells [Cell]
   770   C0332155:untreated [Finding]
   770   C1707455:Compared [Activity]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.132: Interestingly, bezafibrate also increased VLCAD mRNA in patient 4 cells. 

Phrase: "Interestingly,"

Phrase: "bezafibrate also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "VLCAD mRNA"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "in patient 4 cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.133: View this table: [in this window] [in a new window]  Table1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table1."
Processing 00000000.tx.134: Effects of bezafibrate on VLCAD gene expression  Finally, we investigated the effect of bezafibrate on the mRNA levels of several other FAO pathway genes in control cells (Fig.5). 

Phrase: "Effects of bezafibrate"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C1280500:effects [Qualitative Concept]
   756 E C2348382:Effect [Qualitative Concept]

Phrase: "on VLCAD gene expression  Finally,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   807   C0017262:Gene Expression [Genetic Function]
   791   C0017337:Gene [Gene or Genome]
   791   C0185117:Expression [Therapeutic or Preventive Procedure]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "we"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "the effect of bezafibrate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1280500:Effect [Qualitative Concept]
   770   C2348382:Effect [Qualitative Concept]

Phrase: "on the mRNA levels"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "of several"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439064:Several [Quantitative Concept]
  1000   C0443302:Several [Quantitative Concept]

Phrase: "other FAO pathway genes in control cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0017337:Genes [Gene or Genome]
   728   C1861886:CELL Gene [Gene or Genome]

Phrase: "(Fig.5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.135: Mutations in each of these genes that cause FAO disorders have been described. 

Phrase: "Mutations in each of these genes"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   767   C0596611:gene mutations [Genetic Function]
   753   C0026882:Mutations [Genetic Function]
   719 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "that"

Phrase: "cause"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015127:cause [Functional Concept]
  1000   C1524003:Cause [Conceptual Entity]

Phrase: "FAO disorders"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0012634:Disorders [Disease or Syndrome]
   756   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "have"

Phrase: "been"

Phrase: "described."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]
Processing 00000000.tx.136: In control cells, bezafibrate induced a significant increase (P<0.001) in gene expression of each enzyme analyzed, ranging from +40% for ETF-A to +158% for CPT1-A. 

Phrase: "In control cells,"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   861   C0007634:Cells [Cell]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "induced"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205263:Induced [Functional Concept]

Phrase: "a significant increase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0442805:Increase [Functional Concept]

Phrase: "(P<0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "in gene expression"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0017262:Gene Expression [Genetic Function]
   861   C0017337:Gene [Gene or Genome]
   861   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "of each enzyme"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0014442:Enzyme [Enzyme,Organic Chemical]
   916 E C0014445:enzymes [Functional Concept]

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: ","

Phrase: "ranging from +40%"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0439509:/40 [Temporal Concept]
   756   C1514721:Range [Quantitative Concept]
   756   C2348147:Range [Quantitative Concept]
   756   C3542016:Range [Intellectual Product]

Phrase: "for ETF-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420680:ETF [Gene or Genome]

Phrase: "A to +158% for CPT1-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C1413688:CPT1 [Gene or Genome]
   760   C1425131:CPT1 [Gene or Genome]
   760   C3539603:CPT1 [Gene or Genome]

Phrase: "A."
Processing 00000000.tx.137: View larger version (38K): [in this window] [in a new window]  Figure5. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(38K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure5."
Processing 00000000.tx.138: Upregulation of different FAO enzyme mRNAs in fibroblasts derived from normal individuals after treatment with bezafibrate (500M) for 48h. 

Phrase: "Upregulation of different FAO enzyme mRNAs"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   848   C1158371:up-regulation of fatty acid oxidation [Cell Function]
   744   C0041904:Up-Regulation [Cell Function,Molecular Function]
   744   C0162493:Up-Regulation [Genetic Function]

Phrase: "in fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016030:Fibroblasts [Cell]

Phrase: "derived from normal individuals"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   770   C0205307:Normal [Qualitative Concept]
   770   C0439166:% normal [Quantitative Concept]
   770   C1441547:Derived [Qualitative Concept]
   770   C2347086:% Normal [Quantitative Concept]
   770   C3245521:derived [Idea or Concept]
   737   C0027361:Individual [Population Group]
   737   C0237401:Individual [Human]

Phrase: "after treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "with bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "(500M"

Phrase: ")"

Phrase: "for 48h."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1442464:48H [Temporal Concept]
Processing 00000000.tx.139: The results are expressed as the fold increase in mRNA levels in cells treated with bezafibrate relative to vehicle-treated cells. 

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "expressed as the fold increase"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0332462:Fold [Spatial Concept]
   760   C0442805:Increase [Functional Concept]
   760   C1880834:FOLD [Phenomenon or Process]

Phrase: "in mRNA levels"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "in cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "treated with bezafibrate"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "relative to vehicle-treated cells."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0080103:Relative [Family Group]
   760   C0205345:Relative [Qualitative Concept]
   760   C1547039:*Relative [Quantitative Concept]
Processing 00000000.tx.140: The results are shown as meanSE of three independent experiments. 

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "shown as meanSE of three independent experiments."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   774   C0332291:Independent of [Functional Concept]
   748   C0085862:Independent [Idea or Concept]
   748   C0205449:Three [Quantitative Concept]
   748   C0681814:Experiments [Research Activity]
   748   C1299583:Independent [Finding]
   714   C1547282:Show [Intellectual Product]
   714 E C1706386:Experiment [Conceptual Entity]
Processing 00000000.tx.141: In each experiment, samples were run in duplicate. 

Phrase: "In each experiment,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0681814:Experiment [Research Activity]
  1000   C1706386:Experiment [Conceptual Entity]
   928 E C1517586:Experimental [Qualitative Concept]

Phrase: "samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0370003:Sample [Substance]
   966   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "run in duplicate."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205173:Duplicate [Functional Concept]
   827   C3539942:Duplicate [Intellectual Product]
   734   C3274438:RUN-IN [Temporal Concept]
Processing 00000000.tx.142: ***P<0.001 when compared with the vehicle-treated fibroblasts.   

Phrase: "*"

Phrase: "*"

Phrase: "*P<0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "when"

Phrase: "compared with the vehicle-treated fibroblasts."
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   783   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   753   C0016030:Fibroblasts [Cell]
   753   C0042444:Vehicle [Biomedical or Dental Material]
   753   C0348005:Vehicle [Manufactured Object]
   753   C1522326:Treated [Functional Concept]
   753   C1707455:Compared [Activity]
   719 E C1292734:TREAT [Functional Concept]
Processing 00000000.tx.143: DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  The data presented in this paper provide the foundation for possible therapeutic intervention and pharmacological correction of VLCAD deficiency because three of four deficient cell lines harboring missense mutations of VLCAD gene were fully responsive to bezafibrate therapy. 

Phrase: "DISCUSSION TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "presented in this paper"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0030351:Paper [Manufactured Object]
   770   C0449450:Presented [Idea or Concept]
   770   C1547566:Paper [Idea or Concept]
   737 E C0150312:Present [Quantitative Concept]

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "the foundation for possible therapeutic intervention"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0016617:Foundation [Organization]

Phrase: "and"

Phrase: "pharmacological correction of VLCAD deficiency"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   739   C1705565:CORRECTION [Intellectual Product]
   739   C1947976:Correction [Functional Concept]
   726   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]

Phrase: "because"

Phrase: "three of four deficient cell lines"
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   790   C0007600:Cell lines [Cell]
   753   C0007634:Cell [Cell]
   753   C0011155:Deficient [Functional Concept]
   753   C0205132:lines [Spatial Concept]
   753   C0205449:Three [Quantitative Concept]
   753   C0205450:Four [Quantitative Concept]
   753   C1269647:Cell [Cell]
   753   C1636779:% deficient [Quantitative Concept]
   753   C1704653:Cell [Medical Device]
   753   C1948049:Cell [Spatial Concept]
   719 E C1550648:Line [Substance]
   719 E C1552960:Line [Quantitative Concept]

Phrase: "harboring"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0475311:Harbor [Manufactured Object]

Phrase: "missense mutations of VLCAD gene"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   760   C0599155:Mutations, Missense [Genetic Function]
   757   C0596611:gene mutations [Genetic Function]
   739   C0026882:Mutations [Genetic Function]
   706 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "were"

Phrase: "fully responsive to bezafibrate therapy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0039798:therapy [Functional Concept]
   804   C0087111:Therapy [Therapeutic or Preventive Procedure]
   804   C1363945:Therapy [Finding]
Processing 00000000.tx.144: All patient's fibroblasts initially exhibited reduced levels of 3H-palmitate oxidation, varying from 30 to 50% of control values in individuals with a relatively mild deficiency of VLCAD (patients 13) to <10% in patient 4 with a severe VLCAD deficiency. 

Phrase: "All patient's fibroblasts initially"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0016030:Fibroblasts [Cell]

Phrase: "exhibited"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0015272:Exhibit [Intellectual Product]

Phrase: "reduced levels of 3H-palmitate oxidation,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]

Phrase: "varying from 30"

Phrase: "to 50%"

Phrase: "of control values"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   861   C0042295:Values [Qualitative Concept]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
   827 E C1522609:Value [Quantitative Concept]

Phrase: "in individuals"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0027361:Individual [Population Group]
   966   C0237401:Individual [Human]

Phrase: "with a relatively mild deficiency"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   827   C0011155:Deficiency [Functional Concept]
   827   C0162429:Deficiency [Disease or Syndrome]
   827   C1623416:deficiency [Qualitative Concept]
   755 E C1636779:% deficient [Quantitative Concept]

Phrase: "of VLCAD"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
  1000   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   947   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   901   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   861   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   861   C1980013:Very long chain [Qualitative Concept]
   799   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0205166:Long [Qualitative Concept]
   799   C0337112:Chain [Manufactured Object]
   799   C0442824:Very [Qualitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1706317:Long [Qualitative Concept]

Phrase: "(patients 13"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: ")"

Phrase: "to <10% in patient 4"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0030705:*^patient [Patient or Disabled Group]
   760   C1883351:To [Qualitative Concept]

Phrase: "with a severe VLCAD deficiency."
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
   960   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   923   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   861   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   812   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   793   C0011155:Deficiency [Functional Concept]
   793   C0162429:Deficiency [Disease or Syndrome]
   793   C1623416:deficiency [Qualitative Concept]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   721 E C1636779:% deficient [Quantitative Concept]
Processing 00000000.tx.145: This functional impairment, together with the accumulation of long-chain acylcarnitines in the culture medium, is the hallmark of the metabolic block associated with VLCAD deficiency. 

Phrase: "This functional impairment,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0684336:Impairment [Pathologic Function]

Phrase: "together with the accumulation"

Phrase: "of long-chain acylcarnitines"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0368608:acylcarnitines [Organic Chemical]

Phrase: "in the culture medium,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0010454:Culture medium [Indicator, Reagent, or Diagnostic Aid]
   861   C0009458:Medium [Intellectual Product]
   861   C0010453:Culture [Idea or Concept]
   861   C0220814:culture [Functional Concept]
   861   C0430400:Culture [Laboratory Procedure]
   861   C0439536:Medium [Quantitative Concept]
   861   C1705217:Medium [Substance]
   861   C2242979:Culture [Laboratory Procedure]
   861   C3244283:medium [Intellectual Product]

Phrase: "is"

Phrase: "the hallmark of the metabolic block"

Phrase: "associated with VLCAD deficiency."
Meta Candidates (Total=27; Excluded=2; Pruned=0; Remaining=25)
   919   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   882   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   882   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   882   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   849   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   818   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   818   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   790   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   790   C1980013:Very long chain [Qualitative Concept]
   764   C0332281:Associated with [Qualitative Concept]
           Associated
   764   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   742   C0011155:Deficiency [Functional Concept]
   742   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   742   C0162429:Deficiency [Disease or Syndrome]
   742   C0205166:Long [Qualitative Concept]
   742   C0337112:Chain [Manufactured Object]
   742   C0442824:Very [Qualitative Concept]
   742   C1524075:Chain [Idea or Concept]
   742   C1623416:deficiency [Qualitative Concept]
   742   C1706317:Long [Qualitative Concept]
   708 E C0750490:Associate [Idea or Concept]
   708 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.146: Following 48h of treatment with bezafibrate, both 3H-palmitate and acylcarnitine indexes were restored to normal in fibroblasts from patients 13, evidence for a strong stimulatory effect of the drug on FAO flux in these deficient cells. 

Phrase: "Following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "48h of treatment"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1442464:48H [Temporal Concept]

Phrase: "with bezafibrate,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "both 3H-palmitate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0030233:palmitate [Lipid]
   861   C3503116:palmitate [Biomedical or Dental Material,Lipid]

Phrase: "and"

Phrase: "acylcarnitine indexes"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0600653:Indexes [Intellectual Product]
   861   C0918012:indexes [Intellectual Product]
   827 E C1552854:index [Idea or Concept]
   827 E C1637833:% index [Quantitative Concept]

Phrase: "were"

Phrase: "restored to normal"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0205307:Normal [Qualitative Concept]
   790   C0439166:% normal [Quantitative Concept]
   790   C2347086:% Normal [Quantitative Concept]

Phrase: "in fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016030:Fibroblasts [Cell]

Phrase: "from patients 13,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "evidence for a strong stimulatory effect of the drug"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   762   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "on FAO flux"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C2348693:Flux [Natural Phenomenon or Process]
   756   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "in these deficient cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.147: In contrast, fibroblasts from patient 4 failed to respond to bezafibrate treatment, based on the same criteria. 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "fibroblasts from patient 4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0016030:Fibroblasts [Cell]

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "respond"

Phrase: "to bezafibrate treatment,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0039798:treatment [Functional Concept]
   827   C0087111:Treatment [Therapeutic or Preventive Procedure]
   827   C1522326:Treatment [Functional Concept]
   827   C1533734:Treatment [Therapeutic or Preventive Procedure]
   827   C1705169:Treatment [Conceptual Entity]
   827   C3538994:TREATMENT [Research Activity]

Phrase: "based on the same criteria."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   760   C0243161:criteria [Intellectual Product]
   760   C0445247:Same [Qualitative Concept]
   760   C1527178:Based [Functional Concept]
   760   C1705938:Based [Idea or Concept]
   726 E C0002055:base [Inorganic Chemical]
   726 E C0178499:Base [Chemical Viewed Functionally]
   726 E C1880279:Base [Biomedical or Dental Material]
Processing 00000000.tx.148: These differences in the response to bezafibrate did not correlate with the basal residual enzyme activities, because we initially found equivalently low levels of VLCAD enzyme activity in the four untreated patient cell lines. 

Phrase: "These differences in the response"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C1705241:*Difference [Quantitative Concept]
   726   C1705242:Difference [Qualitative Concept]

Phrase: "to bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "correlate with the basal residual enzyme activities,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   748   C0014442:Enzyme [Enzyme,Organic Chemical]
   748   C0205112:Basal [Spatial Concept]
   748   C0441655:Activities [Activity]
   748   C1609982:Residual [Qualitative Concept]
   745   C0243102:enzyme activity [Molecular Function]
   714 E C0205177:Activity [Functional Concept]
   714 E C0439167:% activity [Quantitative Concept]
   714 E C1561536:*Activity [Idea or Concept]

Phrase: "because"

Phrase: "we initially"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205265:Initially [Temporal Concept]

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "equivalently low levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "of VLCAD enzyme activity"
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   953   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   920   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   920   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   812   C0243102:enzyme activity [Molecular Function]
   793   C0014442:Enzyme [Enzyme,Organic Chemical]
   793   C0205177:Activity [Functional Concept]
   793   C0439167:% activity [Quantitative Concept]
   793   C0441655:Activity [Activity]
   793   C1561536:*Activity [Idea or Concept]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710 E C0014445:enzymes [Functional Concept]

Phrase: "in the four untreated patient cell lines."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   840   C0007600:Cell lines [Cell]
   804   C0007634:Cell [Cell]
   804   C0205132:lines [Spatial Concept]
   804   C1269647:Cell [Cell]
   804   C1704653:Cell [Medical Device]
   804   C1948049:Cell [Spatial Concept]
   771 E C1550648:Line [Substance]
   771 E C1552960:Line [Quantitative Concept]
Processing 00000000.tx.149: Previous studies already suggested that residual VLCAD enzyme levels do not discriminate among the various disease phenotypes and that the low VLCAD enzyme activity is clearly related to a decreased amount of immunoreactive protein (2,5). 

Phrase: "Previous studies already"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that residual VLCAD enzyme levels"
Meta Candidates (Total=12; Excluded=4; Pruned=0; Remaining=8)
   807   C0014440:enzyme levels [Laboratory Procedure]
   807   C1287349:enzyme levels [Laboratory or Test Result]
   791   C0014442:Enzyme [Enzyme,Organic Chemical]
   791   C0441889:Levels [Qualitative Concept]
   758 E C0456079:Level [Classification]
   758 E C1547707:Level [Geographic Area]
   758 E C2946261:Level [Pharmacologic Substance]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   708 E C0014445:enzymes [Functional Concept]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "do"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "discriminate among the various disease phenotypes"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   753   C0012634:Disease [Disease or Syndrome]
   753   C0031437:Phenotypes [Organism Attribute]
   753   C0205235:Discriminate [Qualitative Concept]
   753   C0440102:Various [Indicator, Reagent, or Diagnostic Aid]
   719 E C1285572:Phenotype [Laboratory Procedure]

Phrase: "and"

Phrase: "that"

Phrase: "the low VLCAD enzyme activity"
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   927   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   899   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   899   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   807   C0243102:enzyme activity [Molecular Function]
   791   C0014442:Enzyme [Enzyme,Organic Chemical]
   791   C0205177:Activity [Functional Concept]
   791   C0439167:% activity [Quantitative Concept]
   791   C0441655:Activity [Activity]
   791   C1561536:*Activity [Idea or Concept]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   708 E C0014445:enzymes [Functional Concept]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "is"

Phrase: "clearly"

Phrase: "related to a decreased amount of immunoreactive protein"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   767   C0038164:Protein A [Amino Acid, Peptide, or Protein,Immunologic Factor,Indicator, Reagent, or Diagnostic Aid]
   744   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   744   C0205216:Decreased [Quantitative Concept]
   744   C0392756:Decreased [Qualitative Concept]
   744   C0439849:Related [Qualitative Concept]
   744   C0442797:decreased [Qualitative Concept]
   744   C0445223:Related [Finding]
   744   C1265611:Amount [Quantitative Concept]
   711 E C0163712:Relate [Organic Chemical]
   711 E C0547047:Decrease [Quantitative Concept]

Phrase: "(2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.150: In patients 2 and 3, bezafibrate raised VLCAD enzyme activity to the values normally found in control fibroblasts. 

Phrase: "In patients 2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "raised"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442818:Raised [Quantitative Concept]

Phrase: "VLCAD enzyme activity"
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   953   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   920   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   920   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   812   C0243102:enzyme activity [Molecular Function]
   793   C0014442:Enzyme [Enzyme,Organic Chemical]
   793   C0205177:Activity [Functional Concept]
   793   C0439167:% activity [Quantitative Concept]
   793   C0441655:Activity [Activity]
   793   C1561536:*Activity [Idea or Concept]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710 E C0014445:enzymes [Functional Concept]

Phrase: "to the values normally"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0042295:Values [Qualitative Concept]
   827 E C1522609:Value [Quantitative Concept]

Phrase: "found in control fibroblasts."
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   770   C0016030:Fibroblasts [Cell]
   770   C0150312:Found [Quantitative Concept]
   770   C0243148:control [Qualitative Concept]
   770   C1550141:Control [Substance]
   770   C1882979:Control [Conceptual Entity]
   770   C2587213:Control [Functional Concept]
   770   C3274648:Control [Qualitative Concept]
   737 E C0243095:Find [Finding]
Processing 00000000.tx.151: Although stimulation of residual enzyme activity was more modest in patient 1, it was sufficient to restore normal FAO flux. 

Phrase: "Although"

Phrase: "stimulation of residual enzyme activity"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   891   C2248396:stimulation of enzyme activity [Organism Function]
   760   C1292856:Stimulation [Therapeutic or Preventive Procedure]
   760   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "was"

Phrase: "more modest in patient 1,"

Phrase: "it"

Phrase: "was"

Phrase: "sufficient to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205410:Sufficient [Qualitative Concept]

Phrase: "restore"

Phrase: "normal FAO flux."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C2348693:Flux [Natural Phenomenon or Process]
   717   C1158366:fatty acid oxidation [Molecular Function]
Processing 00000000.tx.152: Western blot studies showed that these changes in enzyme activity could be explained by increased levels of immunoreactive VLCAD protein in response to bezafibrate. 

Phrase: "Western blot studies"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]
   734   C0005863:Western Blot [Laboratory Procedure,Molecular Biology Research Technique]
   734   C0949466:Western Blot [Laboratory Procedure]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "these changes in enzyme activity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0392747:changes [Functional Concept]
   760   C0443172:changes [Quantitative Concept]
   726 E C1705241:Change [Quantitative Concept]

Phrase: "could"

Phrase: "be"

Phrase: "explained by increased levels"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   770   C0205217:Increased [Quantitative Concept]
   770   C0441889:Levels [Qualitative Concept]
   770   C0442805:Increased [Functional Concept]
   737 E C0456079:Level [Classification]
   737 E C1547707:Level [Geographic Area]
   737 E C2946261:Level [Pharmacologic Substance]

Phrase: "of immunoreactive VLCAD protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "in response"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0871261:Response [Organism Attribute]
  1000   C1704632:Response [Finding]
  1000   C1706817:Response [Intellectual Product]
  1000   C2911692:Response [Mental Process]

Phrase: "to bezafibrate."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.153: Therefore, the main beneficial effects of bezafibrate is an augmentation of steady-state levels of the variant VLCAD proteins, leading to enhanced residual VLCAD enzyme activity in the deficient cells. 

Phrase: "Therefore,"

Phrase: "the main beneficial effects of bezafibrate"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "is"

Phrase: "an augmentation of steady-state levels"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1293122:Augmentation [Therapeutic or Preventive Procedure]

Phrase: "of the variant VLCAD proteins,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "leading"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0332152:Leading [Temporal Concept]
  1000   C1522538:Leading [Functional Concept]
   966 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   966 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   966 E C2348269:Lead [Element, Ion, or Isotope]
   966 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "to enhanced residual VLCAD enzyme activity"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   907   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   891   C1707919:Enhanced Activity [Quantitative Concept]
   884   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   884   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   804   C0243102:enzyme activity [Molecular Function]
   790   C0014442:Enzyme [Enzyme,Organic Chemical]
   790   C0205177:Activity [Functional Concept]
   790   C0439167:% activity [Quantitative Concept]
   790   C0441655:Activity [Activity]
   790   C1561536:*Activity [Idea or Concept]
   717   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   706 E C0014445:enzymes [Functional Concept]

Phrase: "in the deficient cells."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.154: The relations between VLCAD mutant protein levels and residual enzyme activity have been previously analyzed by over-expression experiments (2). 

Phrase: "The relations"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0869014:Relations [Social Behavior]
   966 E C0080103:Relation [Family Group]
   916 E C0439849:Related [Qualitative Concept]
   916 E C0445223:Related [Finding]

Phrase: "between VLCAD mutant protein levels"
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   807   C1564139:Mutant Protein [Amino Acid, Peptide, or Protein]
   791   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   791   C0441889:Levels [Qualitative Concept]
   774   C0428479:Protein level [Laboratory or Test Result]
   758 E C0456079:Level [Classification]
   758 E C1547707:Level [Geographic Area]
   758 E C2946261:Level [Pharmacologic Substance]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "and"

Phrase: "residual enzyme activity"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   901   C0243102:enzyme activity [Molecular Function]
   827   C0014442:Enzyme [Enzyme,Organic Chemical]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]
   743 E C0014445:enzymes [Functional Concept]

Phrase: "have"

Phrase: "been"

Phrase: "previously"

Phrase: "analyzed by over-expression experiments"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C1707966:Expression Experiment [Conceptual Entity]
   760   C0185117:Expression [Therapeutic or Preventive Procedure]
   760   C0681814:Experiments [Research Activity]
   760   C0936012:Analyzed [Research Activity]
   726 E C1706386:Experiment [Conceptual Entity]

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")."
Processing 00000000.tx.155: Interestingly, these studies focused on the effects of the V243A mutation, carried by patients 2 and 3 in our study. 

Phrase: "Interestingly,"

Phrase: "these studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "focused on the effects of the V243A mutation,"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   744   C0026882:Mutation [Genetic Function]
   744   C0205234:Focused [Spatial Concept]
   744   C1280500:effects [Qualitative Concept]
   744   C1285542:focused [Functional Concept]
   744   C1705285:Mutation [Cell or Molecular Dysfunction]
   711 E C2348382:Effect [Qualitative Concept]

Phrase: "carried by patients 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0206243:carried [Activity]
   770   C0699809:carried [Finding]

Phrase: "and"

Phrase: "3 in our study."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0439086:<3 [Quantitative Concept]
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]
   770   C2827736:3+ [Quantitative Concept]
   770   C2981702:3+ [Classification]
Processing 00000000.tx.156: By transfection of the V243A mutant cDNA into COS-7 cells, it was shown that, in transfected cells, the levels of enzyme activity were proportional to the expression level of mutant VLCAD protein (2), and conclusions drawn from our study appear quite consistent with this notion. 

Phrase: "By transfection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040669:Transfection [Genetic Function,Molecular Biology Research Technique]

Phrase: "of the V243A mutant cDNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0006556:cDNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "into COS-7 cells,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
  1000   C1257858:COS-7 Cells [Cell]
   913   C0376702:COS Cells [Cell]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "it"

Phrase: "was"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that,"

Phrase: "in transfected cells,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "the levels of enzyme activity"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   797   C0014440:enzyme levels [Laboratory Procedure]
   797   C0683317:activity levels [Finding]
   797   C1287349:enzyme levels [Laboratory or Test Result]
   760   C0441889:Levels [Qualitative Concept]
   726 E C0456079:Level [Classification]
   726 E C1547707:Level [Geographic Area]
   726 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "proportional to the expression level"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0205351:Proportional [Qualitative Concept]

Phrase: "of mutant VLCAD protein"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   892   C1564139:Mutant Protein [Amino Acid, Peptide, or Protein]
   793   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "conclusions"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusions [Idea or Concept]

Phrase: "drawn from our study"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]
   737   C0013113:Draw [Intellectual Product]

Phrase: "appear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "quite consistent with this notion."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   806   C0332290:Consistent with [Idea or Concept]
           Consistent
Processing 00000000.tx.157: Overall, our data clearly indicate that pharmacological correction of FAO capacities was related to parallel increases in VLCAD mRNA, immunoreactive protein and enzyme activity, triggered by drug treatment. 

Phrase: "Overall,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0282416:Overall [Intellectual Product]
  1000   C1561607:Overall [Qualitative Concept]

Phrase: "our data clearly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "indicate"

Phrase: "that pharmacological correction of FAO capacities"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1705565:CORRECTION [Intellectual Product]
   744   C1947976:Correction [Functional Concept]

Phrase: "was"

Phrase: "related"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0439849:Related [Qualitative Concept]
  1000   C0445223:Related [Finding]
   966 E C0163712:Relate [Organic Chemical]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "parallel"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2348042:Parallel [Qualitative Concept]
  1000   C2826345:PARALLEL [Research Activity]

Phrase: "increases in VLCAD mRNA,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0442805:increases [Functional Concept]
   716   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   716   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]

Phrase: "immunoreactive protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "enzyme activity,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
  1000   C0243102:enzyme activity [Molecular Function]
   861   C0014442:Enzyme [Enzyme,Organic Chemical]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]
   777 E C0014445:enzymes [Functional Concept]

Phrase: "triggered by drug treatment."
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   833   C1444748:Triggered by [Qualitative Concept]
           Trigger
   770   C0013227:Drug [Pharmacologic Substance]
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1254351:Drug [Pharmacologic Substance]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]
   737   C0032930:Trigger [Clinical Attribute]
   715 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   715 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
Processing 00000000.tx.158: It can be noted that in cells with severe enzyme deficiency (patient 4), bezafibrate increased VLCAD mRNA levels to the same extent as in cells of patients 13. 

Phrase: "It"

Phrase: "can"

Phrase: "be"

Phrase: "noted"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1316572:Note [Clinical Attribute]
   966   C1317574:Note [Intellectual Product]
   966   C1369612:Note [Clinical Attribute]

Phrase: "that in cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C0007634:Cells [Cell]
   790   C3282337:Cells [Cell]
   756 E C1269647:Cell [Cell]
   756 E C1704653:Cell [Medical Device]
   756 E C1948049:Cell [Spatial Concept]

Phrase: "with severe enzyme deficiency"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   901   C0149676:Enzyme Deficiency [Disease or Syndrome]
   827   C0011155:Deficiency [Functional Concept]
   827   C0014442:Enzyme [Enzyme,Organic Chemical]
   827   C0162429:Deficiency [Disease or Syndrome]
   827   C1623416:deficiency [Qualitative Concept]
   755 E C1636779:% deficient [Quantitative Concept]
   743 E C0014445:enzymes [Functional Concept]

Phrase: "(patient 4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: ")"

Phrase: ","

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "VLCAD mRNA levels"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   793   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   793   C0441889:Levels [Qualitative Concept]
   760 E C0456079:Level [Classification]
   760 E C1547707:Level [Geographic Area]
   760 E C2946261:Level [Pharmacologic Substance]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "to the same extent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439792:Extent [Spatial Concept]

Phrase: "as in cells of patients 13."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   753   C0007634:Cells [Cell]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C3282337:Cells [Cell]
   719 E C1269647:Cell [Cell]
   719 E C1704653:Cell [Medical Device]
   719 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.159: Normal transcription of VLCAD gene is not the rule in patients with the severe presentation of the disease, who usually carry large deletions, premature stop codons or other null mutations leading to mRNA degradation (4). 

Phrase: "Normal transcription of VLCAD gene"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C0040649:Gene Transcription [Genetic Function]
           Transcription

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "the rule in patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0805874:Rule [Idea or Concept]
   770   C0870077:Rule [Intellectual Product]
   770   C1446409:rule [Qualitative Concept]

Phrase: "with the severe presentation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0449450:Presentation [Idea or Concept]

Phrase: "of the disease,"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]

Phrase: "who usually"

Phrase: "carry"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:Carry [Activity]
  1000   C0699809:carry [Finding]

Phrase: "large deletions,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C1880274:Deletions [Activity]
   827 E C1442161:Deletion [Cell or Molecular Dysfunction]
   827 E C1511760:Deletion [Genetic Function]

Phrase: "premature stop codons"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0242612:Premature Stop Codon [Nucleotide Sequence]
   901   C0242611:Stop Codon [Nucleotide Sequence]
   827   C0009221:Codon [Nucleotide Sequence]
   827   C1095825:Codon [Plant]

Phrase: "or"

Phrase: "other null mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0026882:Mutations [Genetic Function]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "leading to mRNA degradation"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   833   C1257759:mRNA Degradation [Genetic Function]
   770   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   770   C0243125:degradation [Functional Concept]
   770   C0332152:Leading [Temporal Concept]
   770   C0699900:Degradation [Organism Function]
   770   C1522538:Leading [Functional Concept]
   737 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   737 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   737 E C2348269:Lead [Element, Ion, or Isotope]
   737 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "(4"

Phrase: ")."
Processing 00000000.tx.160: In our case, the molecular defects underlying VLCAD deficiency in different patients did not alter the transcriptional response to bezafibrate, but likely had variable consequences on the production of VLCAD protein under stimulation by this drug. 

Phrase: "In our case,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0868928:Case [Functional Concept]
  1000   C1706255:CASE [Medical Device]
  1000   C1706256:Case [Conceptual Entity]

Phrase: "the molecular defects"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0243067:defects [Functional Concept]
   827 E C1457869:Defect [Functional Concept]
   827 E C1861101:DEFECT [Disease or Syndrome]

Phrase: "underlying"

Phrase: "VLCAD deficiency in different patients"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   893   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   862   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   806   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   760   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   739   C0011155:Deficiency [Functional Concept]
   739   C0162429:Deficiency [Disease or Syndrome]
   739   C1623416:deficiency [Qualitative Concept]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "the transcriptional response to bezafibrate,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0871261:Response [Organism Attribute]
   760   C1704632:Response [Finding]
   760   C1706817:Response [Intellectual Product]
   760   C2911692:Response [Mental Process]

Phrase: "but"

Phrase: "likely"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332148:Likely [Qualitative Concept]
  1000   C0750492:Likely [Idea or Concept]

Phrase: "had"

Phrase: "variable consequences on the production"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0686907:consequences [Functional Concept]

Phrase: "of VLCAD protein"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "under stimulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1292856:Stimulation [Therapeutic or Preventive Procedure]
  1000   C1948023:Stimulation [Natural Phenomenon or Process]

Phrase: "by this drug."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0013227:Drug [Pharmacologic Substance]
  1000   C1254351:Drug [Pharmacologic Substance]
   944 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   944 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   907 E C0456386:Medicament [Pharmacologic Substance]
Processing 00000000.tx.161: It can be proposed that point mutations carried by patients 13 lead to accelerated degradation of the enzyme under basal conditions, accounting for the low residual VLCAD enzyme activity. 

Phrase: "It"

Phrase: "can"

Phrase: "be"

Phrase: "proposed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1441414:PROPOSED [Idea or Concept]
  1000   C1553874:Proposed [Qualitative Concept]
  1000   C1578820:Proposed [Idea or Concept]

Phrase: "that point mutations"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0162735:Point Mutations [Cell or Molecular Dysfunction]
   861   C0026882:Mutations [Genetic Function]
   861   C1552961:Point [Quantitative Concept]
   861   C2347617:point [Quantitative Concept]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "carried by patients 13 lead"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0206243:carried [Activity]
   760   C0699809:carried [Finding]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "to accelerated degradation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0243125:degradation [Functional Concept]
   861   C0699900:Degradation [Organism Function]

Phrase: "of the enzyme"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0014442:Enzyme [Enzyme,Organic Chemical]
   916 E C0014445:enzymes [Functional Concept]

Phrase: "under basal conditions,"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]

Phrase: "accounting"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0000938:Accounting [Occupational Activity]
   966 E C1551359:account [Idea or Concept]
   966 E C2741673:Account # [Clinical Attribute]
   966 E C2981730:Account [Classification]

Phrase: "for the low residual VLCAD enzyme activity."
Meta Candidates (Total=14; Excluded=1; Pruned=0; Remaining=13)
   907   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   884   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   884   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   804   C0243102:enzyme activity [Molecular Function]
   790   C0014442:Enzyme [Enzyme,Organic Chemical]
   790   C0205177:Activity [Functional Concept]
   790   C0439167:% activity [Quantitative Concept]
   790   C0441655:Activity [Activity]
   790   C1561536:*Activity [Idea or Concept]
   717   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   717   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   706 E C0014445:enzymes [Functional Concept]
Processing 00000000.tx.162: However, increasing the rate of enzyme synthesis by pharmacological treatment probably compensate for this degradation in patient 13 cells, leading to increased residual VLCAD activity. 

Phrase: "However,"

Phrase: "increasing"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C0442808:Increasing [Functional Concept]
   966 E C0442805:Increase [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "the rate of enzyme synthesis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0871208:Rate [Activity]
   760   C1521828:Rate [Quantitative Concept]

Phrase: "by pharmacological treatment probably"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   901   C0013216:Pharmacological Treatment [Therapeutic or Preventive Procedure]
   827   C0039798:treatment [Functional Concept]
   827   C0087111:Treatment [Therapeutic or Preventive Procedure]
   827   C1522326:Treatment [Functional Concept]
   827   C1533734:Treatment [Therapeutic or Preventive Procedure]
   827   C1705169:Treatment [Conceptual Entity]
   827   C3538994:TREATMENT [Research Activity]

Phrase: "compensate for this degradation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205432:compensate [Qualitative Concept]
   770   C0243125:degradation [Functional Concept]
   770   C0699900:Degradation [Organism Function]

Phrase: "in patient 13 cells,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]

Phrase: "leading"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0332152:Leading [Temporal Concept]
  1000   C1522538:Leading [Functional Concept]
   966 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   966 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   966 E C2348269:Lead [Element, Ion, or Isotope]
   966 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "to increased residual VLCAD activity."
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   931   C1151750:very-long-chain-acyl-CoA dehydrogenase activity [Molecular Function]
   901   C1151743:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
           acyl-CoA dehydrogenase activity
           acyl dehydrogenase activity
   901   C1151748:long-chain acyl-CoA dehydrogenase activity [Molecular Function]
   891   C0474395:increased activity [Finding]
   791   C0205177:Activity [Functional Concept]
   791   C0439167:% activity [Quantitative Concept]
   791   C0441655:Activity [Activity]
   791   C1561536:*Activity [Idea or Concept]
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
Processing 00000000.tx.163: In patient 4, in contrast, the amino acid substitution in VLCAD might dramatically affect folding, assembly and/or cellular handling of the enzyme, so that degradation cannot be compensated by increased enzyme synthesis. 

Phrase: "In patient 4,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "in contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "the amino acid substitution in VLCAD"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   775   C0525038:Amino Acid Substitution [Genetic Function,Molecular Biology Research Technique]
   738   C1555721:Substitution [Idea or Concept]
   738   C1706204:Substitution [Activity]

Phrase: "might"

Phrase: "dramatically"

Phrase: "affect"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "folding,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0185026:Folding [Therapeutic or Preventive Procedure]

Phrase: "assembly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1706853:Assembly [Activity]
  1000   C1879748:Assembly [Manufactured Object]

Phrase: "and/or"

Phrase: "cellular handling of the enzyme,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0018578:Handling [Behavior]
   760   C1832073:Handling [Finding]

Phrase: "so"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0037640:SO [Geographic Area]

Phrase: "that degradation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0243125:degradation [Functional Concept]
  1000   C0699900:Degradation [Organism Function]

Phrase: "cannot"

Phrase: "be"

Phrase: "compensated by increased enzyme synthesis."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   762   C0597548:synthetic enzyme [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0014442:Enzyme [Enzyme,Organic Chemical]
   760   C0205217:Increased [Quantitative Concept]
   760   C0205432:Compensated [Qualitative Concept]
   760   C0220781:synthesis [Biologic Function]
   760   C0442805:Increased [Functional Concept]
   760   C1883254:Synthesis [Activity]
Processing 00000000.tx.164: Correction of VLCAD deficiency in patient fibroblasts very likely results from an activation of PPAR signaling pathway by bezafibrate. 

Phrase: "Correction of VLCAD deficiency"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   752   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   742   C1705565:CORRECTION [Intellectual Product]
   742   C1947976:Correction [Functional Concept]
   716   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   716   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   716   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]

Phrase: "in patient fibroblasts very likely"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   812   C0016030:Fibroblasts [Cell]
   812   C0030705:*^patient [Patient or Disabled Group]
   812   C0332148:Likely [Qualitative Concept]
   812   C0442824:Very [Qualitative Concept]
   812   C0750492:Likely [Idea or Concept]

Phrase: "results from an activation of PPAR signaling pathway"
Meta Candidates (Total=23; Excluded=3; Pruned=0; Remaining=20)
   846   C2752275:Peroxisome Proliferator-Activated Receptor Signaling Pathway [Molecular Function]
   797   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   797   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   756   C0037083:signaling pathway [Cell Function]
           Signaling
   756   C0086982:Signaling Pathway [Molecular Function]
   756   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   756   C1514762:Receptor Signaling [Molecular Function]
   754 E C0037080:pathway signaling [Molecular Function]
   754   C1514758:Receptor Activation [Cell Function]
   738   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   738   C0752063:Peroxysome [Cell Component]
   738   C1274040:Result [Functional Concept]
   738   C1546471:Result [Idea or Concept]
   738   C1704259:Pathway [Molecular Function]
   738   C1705987:Pathway [Conceptual Entity]
   738   C1879547:Activated [Activity]
           Activation
   738   C2825142:Result [Finding]
   738   C2984308:Peroxisome [Functional Concept]
   738   C3537152:signaling [Biologic Function]
   704 E C1515877:Activate [Functional Concept]
   704 E C1710082:Signal [Phenomenon or Process]

Phrase: "by bezafibrate."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.165: Indeed, although some reports initially suggested short-term inhibitory effects of bezafibrate on FAO (18), it is now firmly established that bezafibrate, acting as a PPAR agonist, has marked stimulatory effects on mitochondrial -oxidation in many cell types of different species (13). 

Phrase: "Indeed,"

Phrase: "although"

Phrase: "some"

Phrase: "reports"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0684224:Report [Intellectual Product]
  1000   C0700287:Report [Health Care Activity]
  1000   C3273238:Report [Intellectual Product]

Phrase: "initially"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205265:Initially [Temporal Concept]

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "short-term inhibitory effects of bezafibrate"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "on FAO"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1158366:fatty acid oxidation [Molecular Function]
   901   C0015684:Fatty acid [Lipid]
   827   C0001128:Acid [Chemical]
   827   C0030011:Oxidation [Molecular Function]
   827   C0202406:Acid [Laboratory Procedure]

Phrase: "(18"

Phrase: ")"

Phrase: ","

Phrase: "it"

Phrase: "is"

Phrase: "now firmly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1880776:Firmly [Qualitative Concept]
   861   C1948052:Now [Temporal Concept]

Phrase: "established"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0443211:Established [Qualitative Concept]
  1000   C1272684:Established [Qualitative Concept]

Phrase: "that bezafibrate,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "acting as a PPAR agonist,"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   833   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   833   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   770   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   744   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   744   C0752063:Peroxysome [Cell Component]
   744   C1879547:Activated [Activity]
   744   C2984308:Peroxisome [Functional Concept]
   744   C2987634:Agonist [Pharmacologic Substance]
   711   C0079613:ACT [Therapeutic or Preventive Procedure]
   711 E C1515877:Activate [Functional Concept]

Phrase: "has"

Phrase: "marked stimulatory effects on mitochondrial -oxidation"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "in many cell types"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
  1000   C0449475:Cell types [Intellectual Product]
   966 E C0007634:Cell Type [Cell]
           Cell
   861   C0332307:Types [Qualitative Concept]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]
   827 E C1547052:*Type [Quantitative Concept]

Phrase: "of different species"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1705920:Species [Conceptual Entity]

Phrase: "(13"

Phrase: ")."
Processing 00000000.tx.166: Studies of PPAR gene knockout mice identified VLCAD as a target gene of this nuclear receptor. 

Phrase: "Studies of PPAR gene knockout mice"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   762   C1273305:Gene studies [Laboratory Procedure]
   742   C0947630:studies [Laboratory Procedure]
   708 E C0557651:Study [Manufactured Object]
   708 E C2603343:Study [Research Activity]

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "VLCAD as a target gene"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   862   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   862   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   833   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   806   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   782   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   782   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   782   C1980013:Very long chain [Qualitative Concept]
   739   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   739   C0205166:Long [Qualitative Concept]
   739   C0337112:Chain [Manufactured Object]
   739   C0442824:Very [Qualitative Concept]
   739   C1524075:Chain [Idea or Concept]
   739   C1706317:Long [Qualitative Concept]

Phrase: "of this nuclear receptor."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0206588:Nuclear Receptor [Amino Acid, Peptide, or Protein,Receptor]
   861   C0521447:Nuclear [Spatial Concept]
   861   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
Processing 00000000.tx.167: Thus, the basal level of VLCAD mRNA was reduced in several tissues or organs of PPAR / mice (19), and the induction of VLCAD by PPAR agonist or fibrates was also abolished in these knockout animal (19,20). 

Phrase: "Thus,"

Phrase: "the basal level of VLCAD mRNA"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   738   C0441889:Level [Qualitative Concept]
   738   C0456079:Level [Classification]
   738   C1547707:Level [Geographic Area]
   738   C2946261:Level [Pharmacologic Substance]

Phrase: "was"

Phrase: "reduced in several tissues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0040300:Tissues [Tissue]
   770   C0392756:Reduced [Qualitative Concept]
   737 E C1547928:Tissue [Intellectual Product]

Phrase: "or"

Phrase: "organs of PPAR / mice"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   774   C0034837:organs receptor [Cell Component]
   748   C0178784:organs [Body Part, Organ, or Organ Component]

Phrase: "(19"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "the induction of VLCAD"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0205263:Induction [Functional Concept]
   742   C0857127:induction [Therapeutic or Preventive Procedure]
   716   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   716   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]

Phrase: "by PPAR agonist"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C2987634:Agonist [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "or"

Phrase: "fibrates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1449704:Fibrates [Organic Chemical,Pharmacologic Substance]

Phrase: "was"

Phrase: "also"

Phrase: "abolished in these knockout animal"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1171353:knockout animal [Animal]
   760   C0003062:Animal [Animal]
   760   C0560617:knock out [Injury or Poisoning]
   760   C1522225:Knock-out [Experimental Model of Disease]

Phrase: "(19,"

Phrase: "20"

Phrase: ")."
Processing 00000000.tx.168: Available data on the regulation of the human VLCAD gene failed to identify a nuclear hormone response element in the 5' flanking regulatory regions of this gene (21). 

Phrase: "Available data on the regulation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1511726:Data [Idea or Concept]
   760   C3245479:data [Medical Device]

Phrase: "of the human VLCAD gene"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   892   C0314604:Human gene [Gene or Genome]
   793   C0017337:Gene [Gene or Genome]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "failed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231175:Failed [Functional Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "identify"

Phrase: "a nuclear hormone response element in the 5'"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   800   C0598509:hormone response element [Nucleotide Sequence]
   770   C0600508:Response Element [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   744   C0013879:Element [Element, Ion, or Isotope]
   744   C0871261:Response [Organism Attribute]
   744   C1704632:Response [Finding]
   744   C1705248:Element [Conceptual Entity]
   744   C1706817:Response [Intellectual Product]
   744   C2911692:Response [Mental Process]

Phrase: "flanking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0230171:flanking [Body Location or Region]

Phrase: "regulatory regions of this gene"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0034987:Regulatory Regions [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   797   C0017362:Regulatory Gene [Gene or Genome]
   760   C0220905:regulatory [Regulation or Law]
   760   C1704735:Regulatory [Conceptual Entity]
   726   C0017446:Region [Geographic Area]
   726   C0205147:Region [Spatial Concept]

Phrase: "(21"

Phrase: ")."
Processing 00000000.tx.169: In addition to VLCAD, our results indicate that bezafibrate also stimulated the expression of several other FAO genes in human fibroblasts, including the carnitine palmitoyl-transferases (CPT1-A and CPT2), two acyl-CoA dehydrogenases (VLCAD and MCAD), the LCHAD which catalyzes the third step of long-chain FAO, the FAO electron transfer proteins (ETFa and ETFb) and the ETF dehydrogenase (ETF-QO) that is associated with the mitochondrial respiratory chain. 

Phrase: "In addition to VLCAD,"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
  1000   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   947   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   901   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   861   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   861   C1980013:Very long chain [Qualitative Concept]
   799   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0205166:Long [Qualitative Concept]
   799   C0337112:Chain [Manufactured Object]
   799   C0442824:Very [Qualitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1706317:Long [Qualitative Concept]

Phrase: "our results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "indicate"

Phrase: "that bezafibrate also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "stimulated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1948023:Stimulated [Natural Phenomenon or Process]

Phrase: "the expression of several"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "other FAO genes in human fibroblasts,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0314604:genes human [Gene or Genome]
   744   C0017337:Genes [Gene or Genome]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "the carnitine palmitoyl-transferases"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0007258:Carnitine [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
   827   C0040676:Transferases [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0087163:Carnitine [Organic Chemical,Pharmacologic Substance,Vitamin]

Phrase: "(CPT1-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1413688:CPT1 [Gene or Genome]
  1000   C1425131:CPT1 [Gene or Genome]
  1000   C3539603:CPT1 [Gene or Genome]

Phrase: "A"

Phrase: "and"

Phrase: "CPT2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1413690:CPT2 [Gene or Genome]

Phrase: ")"

Phrase: ","

Phrase: "two acyl-CoA dehydrogenases"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   923   C0085744:Acyl CoA Dehydrogenases [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   906 E C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   812   C0030016:Dehydrogenases [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(VLCAD"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
  1000   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   947   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   901   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   861   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   861   C1980013:Very long chain [Qualitative Concept]
   799   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0205166:Long [Qualitative Concept]
   799   C0337112:Chain [Manufactured Object]
   799   C0442824:Very [Qualitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1706317:Long [Qualitative Concept]

Phrase: "and"

Phrase: "MCAD"

Phrase: ")"

Phrase: ","

Phrase: "the LCHAD"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1151182:LCHAD [Molecular Function]
  1000   C1415460:LCHAD [Gene or Genome]

Phrase: "which"

Phrase: "catalyzes"

Phrase: "the third step of long-chain FAO,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C1261552:Step [Conceptual Entity]
   742   C1704379:Step [Functional Concept]
   742   C1705117:Step [Quantitative Concept]
   742   C2825408:Step [Manufactured Object]

Phrase: "the FAO electron transfer proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(ETFa"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1414471:ETFA [Gene or Genome]

Phrase: "and"

Phrase: "ETFb"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1414472:ETFB [Gene or Genome]

Phrase: ")"

Phrase: "and"

Phrase: "the ETF dehydrogenase"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0059018:ETF dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(ETF-QO"

Phrase: ")"

Phrase: "that"

Phrase: "is"

Phrase: "associated with the mitochondrial respiratory chain."
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   833   C1325653:mitochondrial respiratory chain [Cell Component]
           respiratory chain
   790   C0162362:Respiratory Chain [Molecular Function]
   790   C0332281:Associated with [Qualitative Concept]
           Associated
   753   C0026237:Mitochondrial [Cell Component]
   753   C0337112:Chain [Manufactured Object]
   753   C0521346:respiratory [Functional Concept]
   753   C0521451:Mitochondrial [Functional Concept]
   753   C1524075:Chain [Idea or Concept]
   753   C1546767:Respiratory [Intellectual Product]
   719 E C0750490:Associate [Idea or Concept]
   719 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.170: Inborn errors of the FAO pathway affecting each of these enzymes have been described. 

Phrase: "Inborn errors of the FAO pathway"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C0743559:errors [Qualitative Concept]
   711 E C1608199:Error [Functional Concept]

Phrase: "affecting"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0392760:Affecting [Functional Concept]
  1000   C1314939:Affecting [Functional Concept]
   966 E C0001721:Affect [Mental Process]

Phrase: "each of these enzymes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0014442:Enzymes [Enzyme,Organic Chemical]
   770   C0014445:enzymes [Functional Concept]
   770   C1457900:Each [Quantitative Concept]

Phrase: "have"

Phrase: "been"

Phrase: "described."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]
Processing 00000000.tx.171: We speculate that bezafibrate could also be efficacious in correcting some of these other FAO disorders. 

Phrase: "We"

Phrase: "speculate"

Phrase: "that bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "could"

Phrase: "also"

Phrase: "be"

Phrase: "efficacious in correcting"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   718   C1280519:Efficacy [Qualitative Concept]
   718   C1707887:EFFICACY [Research Activity]

Phrase: "some of these"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0205392:Some [Quantitative Concept]
   790   C3540770:Some [Intellectual Product]

Phrase: "other FAO disorders."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0012634:Disorders [Disease or Syndrome]
   756   C1158366:fatty acid oxidation [Molecular Function]
Processing 00000000.tx.172: In vitro studies in patient fibroblasts, such as those presented here, can easily be adapted to assess the effects of bezafibrate in other FAO enzyme defects. 

Phrase: "In vitro studies in patient fibroblasts,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   816   C0681828:in vitro study [Research Activity]
           studies vitro
   753   C0947630:studies [Laboratory Procedure]
   719 E C0557651:Study [Manufactured Object]
   719 E C2603343:Study [Research Activity]

Phrase: "such as those presented here,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0449450:Presented [Idea or Concept]
   827 E C0150312:Present [Quantitative Concept]

Phrase: "can"

Phrase: "easily"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332219:Easily [Qualitative Concept]

Phrase: "be"

Phrase: "adapted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2937289:adapted [Organic Chemical]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "assess"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assess [Activity]

Phrase: "the effects of bezafibrate"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1280500:effects [Qualitative Concept]
   737 E C2348382:Effect [Qualitative Concept]

Phrase: "in other FAO enzyme defects."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   933   C1829742:Fatty acid oxidation defects [Disease or Syndrome]
   804   C0243067:defects [Functional Concept]
   771 E C1457869:Defect [Functional Concept]
   771 E C1861101:DEFECT [Disease or Syndrome]
   717   C1158366:fatty acid oxidation [Molecular Function]
Processing 00000000.tx.173: In fact, measurements of enzyme activity and FAO capacities, combined with studies of acylcarnitine profiles in treated cells should allow to determine whether bezafibrate can stimulate residual enzyme levels, and whether this has beneficial effects on -oxidation flux in the deficient cells. 

Phrase: "In fact,"

Phrase: "measurements of enzyme activity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   802   C0014440:Enzyme measurement [Laboratory Procedure]
   770   C0242485:measurements [Functional Concept]

Phrase: "and"

Phrase: "FAO capacities,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   779   C1516240:Capacity [Quantitative Concept]
   756   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "combined with studies of acylcarnitine profiles in treated cells"
Meta Candidates (Total=17; Excluded=7; Pruned=0; Remaining=10)
   762   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   742   C0007634:Cells [Cell]
   742   C0205195:Combined [Qualitative Concept]
   742   C0368608:Acyl carnitine [Organic Chemical]
   742   C0947630:studies [Laboratory Procedure]
   742   C1522326:Treated [Functional Concept]
   742   C3282337:Cells [Cell]
   708 E C0336789:Combine [Manufactured Object]
   708 E C0557651:Study [Manufactured Object]
   708 E C1269647:Cell [Cell]
   708 E C1292734:TREAT [Functional Concept]
   708 E C1704653:Cell [Medical Device]
   708 E C1948049:Cell [Spatial Concept]
   708   C1979963:Profile [Laboratory Procedure]
   708   C2003903:Profile [Functional Concept]
   708 E C2603343:Study [Research Activity]

Phrase: "should"

Phrase: "allow"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0683607:allow [Social Behavior]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "determine"

Phrase: "whether"

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "can"

Phrase: "stimulate"

Phrase: "residual enzyme levels,"
Meta Candidates (Total=8; Excluded=4; Pruned=0; Remaining=4)
   901   C0014440:enzyme levels [Laboratory Procedure]
   901   C1287349:enzyme levels [Laboratory or Test Result]
   827   C0014442:Enzyme [Enzyme,Organic Chemical]
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]
   743 E C0014445:enzymes [Functional Concept]

Phrase: "and"

Phrase: "whether"

Phrase: "this"

Phrase: "has"

Phrase: "beneficial effects on -oxidation flux in the deficient cells."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C2348693:Flux [Natural Phenomenon or Process]
Processing 00000000.tx.174: Our recent studies prove that bezafibrate can successfully correct the mitochondrial FAO defect in cells from patients presenting the mild forms of VLCAD or CPT2 deficiency (22), which both result in adolescent or adult-onset myopathy, and for which no therapeutic approach has been described. 

Phrase: "Our recent studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "prove"

Phrase: "that bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "can"

Phrase: "successfully correct"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2349182:Correct [Qualitative Concept]

Phrase: "the mitochondrial FAO defect in cells"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C1457869:Defect [Functional Concept]
   744   C1861101:DEFECT [Disease or Syndrome]

Phrase: "from patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "presenting"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0449450:Presenting [Idea or Concept]
   966 E C0150312:Present [Quantitative Concept]

Phrase: "the mild forms of VLCAD"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   739   C0348078:forms [Qualitative Concept]
   739   C0376315:Forms [Manufactured Object]
   706 E C1522492:Form [Functional Concept]

Phrase: "or"

Phrase: "CPT2 deficiency"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0011155:Deficiency [Functional Concept]
   861   C0162429:Deficiency [Disease or Syndrome]
   861   C1623416:deficiency [Qualitative Concept]
   789 E C1636779:% deficient [Quantitative Concept]

Phrase: "(22"

Phrase: ")"

Phrase: ","

Phrase: "which"

Phrase: "both result in adolescent"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1274040:Result [Functional Concept]
   770   C1546471:Result [Idea or Concept]
   770   C2825142:Result [Finding]

Phrase: "or"

Phrase: "adult-onset myopathy,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0026848:Myopathy [Disease or Syndrome]
   734   C1836537:Adult onset [Finding]

Phrase: "and for which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1515981:And [Idea or Concept]

Phrase: "no therapeutic approach"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0449445:Approach [Spatial Concept]

Phrase: "has"

Phrase: "been"

Phrase: "described."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]
Processing 00000000.tx.175: This represents a large group within the family of FAO disorders, with more than 200 affected patients described to date. 

Phrase: "This"

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a large group within the family of FAO disorders,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   756   C0679991:large group [Group Attribute]
   754   C0015576:Family Group [Family Group]
   754   C0441835:Group A [Classification]
   738   C0441833:Group [Idea or Concept]
   738   C0687744:group [Population Group]
   738   C1257890:Group [Population Group]
   738   C1552516:Group [Health Care Related Organization]
   738   C1705428:Group [Conceptual Entity]
   738   C1705429:Group [Population Group]

Phrase: "with more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205172:More [Functional Concept]

Phrase: "than 200 affected patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0522476:affected patients [Qualitative Concept]
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "described to date."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0011008:Date [Temporal Concept]
   790   C1552738:described [Idea or Concept]
   790   C2348077:Date [Food]
Processing 00000000.tx.176: In conclusion, the potential for bezafibrate to correct inborn FAO disorders is highlighted in this study, and our results provide strong grounds for the design of clinical trials assessing the efficiency of this drug in CPT2 or VLCAD-deficient patients. 

Phrase: "In conclusion,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707478:Conclusion [Idea or Concept]

Phrase: "the potential for bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C3245505:Potential [Qualitative Concept]

Phrase: "to correct inborn FAO disorders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0012634:Disorders [Disease or Syndrome]

Phrase: "is"

Phrase: "highlighted in this study,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]

Phrase: "and"

Phrase: "our results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "strong grounds for the design of clinical trials"

Phrase: "assessing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1516048:Assess [Activity]

Phrase: "the efficiency of this drug"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0013682:Efficiency [Quantitative Concept]

Phrase: "in CPT2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1413690:CPT2 [Gene or Genome]

Phrase: "or"

Phrase: "VLCAD-deficient patients."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0030705:Patients [Patient or Disabled Group]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
Processing 00000000.tx.177: Furthermore, our approach offers a valuable mean to select patients by in vitro studies before considering a clinical trial of bezafibrate. 

Phrase: "Furthermore,"

Phrase: "our approach"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449445:Approach [Spatial Concept]

Phrase: "offers"

Phrase: "a valuable mean to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0444504:Mean [Quantitative Concept]
   827   C2347634:Mean [Quantitative Concept]
   827   C2348143:Mean [Quantitative Concept]

Phrase: "select"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707391:Select [Activity]

Phrase: "patients by in vitro studies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030705:Patients [Patient or Disabled Group]

Phrase: "before considering"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considering [Idea or Concept]

Phrase: "a clinical trial of bezafibrate."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C0008976:Clinical Trial [Research Activity]
           Trial
   806   C1096775:Clinical Trial [Intellectual Product]
   760   C0205210:Clinical [Qualitative Concept]
Processing 00000000.tx.178: This pharmacological therapy opens new avenues for the treatment of FAO defects, based on a strategy that primarily targets the enzyme defect, rather than treatments directed at downstream consequences of the enzyme defect. 

Phrase: "This pharmacological therapy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   950   C0013217:pharmacologic therapy [Functional Concept]
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]

Phrase: "opens"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0175566:Open [Spatial Concept]

Phrase: "new avenues for the treatment of FAO defects,"

Phrase: "based on a strategy"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   770   C0679199:strategy [Mental Process]
   770   C1527178:Based [Functional Concept]
   770   C1705938:Based [Idea or Concept]
   737 E C0002055:base [Inorganic Chemical]
   737 E C0178499:Base [Chemical Viewed Functionally]
   737 E C1880279:Base [Biomedical or Dental Material]

Phrase: "that primarily"

Phrase: "targets"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1521840:Target [Functional Concept]
  1000   C2986546:TARGET [Diagnostic Procedure]

Phrase: "the enzyme defect,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1457869:Defect [Functional Concept]
   861   C1861101:DEFECT [Disease or Syndrome]

Phrase: "rather than"

Phrase: "treatments"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0087111:Treatments [Therapeutic or Preventive Procedure]
   966 E C0039798:treatment [Functional Concept]
   966 E C1522326:Treatment [Functional Concept]
   966 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   966 E C1705169:Treatment [Conceptual Entity]
   966 E C3538994:TREATMENT [Research Activity]

Phrase: "directed at downstream consequences of the enzyme defect."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   754   C0686907:Consequence of [Functional Concept]
           consequences
   744   C0014442:Enzyme [Enzyme,Organic Chemical]
   744   C0522506:Downstream [Spatial Concept]
   744   C1457869:Defect [Functional Concept]
   744   C1861101:DEFECT [Disease or Syndrome]
   711   C0439851:Direct [Qualitative Concept]
   711   C1947931:Direct [Qualitative Concept]
Processing 00000000.tx.179: Because the majority FAO defects are associated with missense mutations compatible with the synthesis of a mutant protein with variable levels of residual enzyme activity (4), this rationale is potentially applicable to many, but not all, FAO-deficient individuals. 

Phrase: "Because"

Phrase: "the majority FAO defects"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   937   C1829742:Fatty acid oxidation defects [Disease or Syndrome]
   804   C0243067:defects [Functional Concept]
   771 E C1457869:Defect [Functional Concept]
   771 E C1861101:DEFECT [Disease or Syndrome]
   717   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "are"

Phrase: "associated with missense mutations"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   833   C0599155:Mutations, Missense [Genetic Function]
   770   C0026882:Mutations [Genetic Function]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1705285:Mutation [Cell or Molecular Dysfunction]
   737 E C1706221:Associate [Professional or Occupational Group]

Phrase: "compatible with the synthesis of a mutant protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0332290:compatible [Idea or Concept]
   744   C1524057:Compatible [Qualitative Concept]

Phrase: "with variable levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "of residual enzyme activity"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   901   C0243102:enzyme activity [Molecular Function]
   827   C0014442:Enzyme [Enzyme,Organic Chemical]
   827   C0205177:Activity [Functional Concept]
   827   C0439167:% activity [Quantitative Concept]
   827   C0441655:Activity [Activity]
   827   C1561536:*Activity [Idea or Concept]
   743 E C0014445:enzymes [Functional Concept]

Phrase: "(4"

Phrase: ")"

Phrase: ","

Phrase: "this rationale"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0392360:Rationale [Idea or Concept]
  1000   C2699007:Rationale [Idea or Concept]

Phrase: "is"

Phrase: "potentially applicable to many,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1272460:applicable [Qualitative Concept]
   770   C1706839:Applicable [Qualitative Concept]

Phrase: "but"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "all,"

Phrase: "FAO-deficient individuals."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   771   C0027361:Individual [Population Group]
   771   C0237401:Individual [Human]
   717   C1158366:fatty acid oxidation [Molecular Function]
Processing 00000000.tx.180: Furthermore, the ongoing development of new potent PPAR agonists for use in common metabolic diseases such as diabetes or obesity (15) may provide even better potential treatments for FAO disorders in the future. 

Phrase: "Furthermore,"

Phrase: "the ongoing development of new potent PPAR agonists"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   738   C0243107:development [Physiologic Function]
   738   C0678723:Development [Organism Function]
   738   C1527148:Development [Functional Concept]

Phrase: "for use"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0042153:use [Functional Concept]
  1000   C0457083:Use [Functional Concept]
  1000   C1947944:Use [Intellectual Product]

Phrase: "in common metabolic diseases"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   901   C0025517:Metabolic Diseases [Disease or Syndrome]
   827   C0012634:Diseases [Disease or Syndrome]
   827   C0311400:Metabolic [Functional Concept]
   827   C1524026:Metabolic [Cell Function]
   827   C2707259:Metabolic [Clinical Attribute]
   755 E C1836721:MALS [Finding]
   755 E C3538764:MALS [Gene or Genome]
   755 E C3540595:MAL [Gene or Genome]

Phrase: "such as diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "or"

Phrase: "obesity"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0028754:Obesity [Disease or Syndrome]
  1000   C1963185:Obesity [Finding]

Phrase: "(15"

Phrase: ")"

Phrase: "may"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "even better potential treatments for FAO disorders"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   742   C0087111:Treatments [Therapeutic or Preventive Procedure]
   708 E C0039798:treatment [Functional Concept]
   708 E C1522326:Treatment [Functional Concept]
   708 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   708 E C1705169:Treatment [Conceptual Entity]
   708 E C3538994:TREATMENT [Research Activity]

Phrase: "in the future."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016884:Future [Temporal Concept]
Processing 00000000.tx.181: Further screening of this class of drugs in different FAO disorders, with different genotypes and presentations, represents a new research track to address the legitimate demand for therapy of affected patients, augmenting progress made in understanding the origin and molecular basis of their diseases.  

Phrase: "Further screening of this class of drugs"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   774   C0373483:drugs screening [Laboratory Procedure]
   757 E C0013206:Drug Screening [Research Activity]
   748   C0220908:Screening [Health Care Activity]
   748   C0220909:screening [Functional Concept]
   748   C1698960:screening [Intellectual Product]
   748   C1710031:Screening [Diagnostic Procedure]
   748   C1710477:SCREENING [Research Activity]

Phrase: "in different FAO disorders,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0012634:Disorders [Disease or Syndrome]
   717   C1158366:fatty acid oxidation [Molecular Function]

Phrase: "with different genotypes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017431:Genotypes [Organism Attribute]

Phrase: "and"

Phrase: "presentations,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449450:presentations [Idea or Concept]

Phrase: "represents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "a new research"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0035168:research [Research Activity]
   861   C0242481:Research [Research Activity]

Phrase: "track"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040594:Track [Manufactured Object]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "address"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0376649:Address [Intellectual Product]
  1000   C1442065:Address [Spatial Concept]

Phrase: "the legitimate demand for therapy of affected patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0441516:Demand [Therapeutic or Preventive Procedure]
   744   C0699784:demand [Idea or Concept]

Phrase: "augmenting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0205217:augment [Quantitative Concept]

Phrase: "progress"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1272688:progress [Functional Concept]
  1000   C1280477:Progress [Functional Concept]

Phrase: "made in understanding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0162340:Understanding [Mental Process]
   756   C1881534:Make [Functional Concept]

Phrase: "the origin"
Meta Candidates (Total=16; Excluded=13; Pruned=0; Remaining=3)
  1000   C0079946:origin [Classification]
  1000   C0439659:Origin [Temporal Concept]
  1000   C1550512:origin [Intellectual Product]
   944 E C0017296:GENETIC [Therapeutic or Preventive Procedure]
   944 E C0314603:Genetic [Functional Concept]
   928 E C0205313:Original [Idea or Concept]
   928 E C2347409:Original [Occupational Activity]
   916 E C0005615:Birth [Organism Function]
   916 E C0035150:Reproduction [Organism Function]
   916 E C1550722:birth [Idea or Concept]
   916 E C3245487:birth [Intellectual Product]
   900 E C0454729:Natal [Geographic Area]
   900 E C0559522:Genital [Body System]
   900 E C0598240:originality [Mental Process]
   900 E C1546649:Genital [Intellectual Product]
   900 E C1550642:Genital [Body Substance]

Phrase: "and"

Phrase: "molecular basis of their diseases."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C1853126:MOLECULAR BASIS [Idea or Concept]
   760   C1527178:Basis [Functional Concept]
   760   C1874451:Basis [Pharmacologic Substance]
Processing 00000000.tx.182: MATERIALS AND METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  Patients Skin biopsies were performed from four VLCAD patients who carried the following mutations on VLCAD gene. 

Phrase: "MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Patients Skin biopsies"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
   867   C0150866:Skin biopsy [Diagnostic Procedure]
   867   C1546779:Biopsy, Skin [Intellectual Product]
   827   C0005558:biopsies [Diagnostic Procedure]
   827   C0444099:Skin [Body Substance]
   827   C1123023:Skin [Body System]
   827   C1278993:Skin [Body System]
   793 E C0220797:biopsy [Functional Concept]
   771 E C0221912:Cutaneous [Spatial Concept]
   771 E C0221928:Dermal [Qualitative Concept]
   771 E C1522447:Cutaneous [Functional Concept]
   704 E C0011646:Dermis [Tissue]

Phrase: "were"

Phrase: "performed from four VLCAD patients"
Meta Candidates (Total=20; Excluded=1; Pruned=0; Remaining=19)
   862   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   862   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   833   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   806   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   782   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   782   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   782   C1980013:Very long chain [Qualitative Concept]
   739   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   739   C0030705:Patients [Patient or Disabled Group]
   739   C0205166:Long [Qualitative Concept]
   739   C0205450:Four [Quantitative Concept]
   739   C0337112:Chain [Manufactured Object]
   739   C0442824:Very [Qualitative Concept]
   739   C0884358:Performed [Functional Concept]
   739   C1524075:Chain [Idea or Concept]
   739   C1706317:Long [Qualitative Concept]
   706 E C2947996:Perform [Pharmacologic Substance]

Phrase: "who"

Phrase: "carried"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:carried [Activity]
  1000   C0699809:carried [Finding]

Phrase: "the following mutations"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0026882:Mutations [Genetic Function]
   827 E C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "on VLCAD gene."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0017337:Gene [Gene or Genome]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.183: Patient 1 was homozygous for the missense mutation, G520A, in exon 7 that predicts a V134M amino acid change. 

Phrase: "Patient 1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "homozygous for the missense mutation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0019904:Homozygous [Organism Attribute]

Phrase: "G520A,"

Phrase: "in exon 7"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "that"

Phrase: "predicts"

Phrase: "a V134M amino acid change."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   923   C1953353:Amino acid change [Finding]
   812   C0392747:Change [Functional Concept]
   812   C0443172:change [Quantitative Concept]
   812   C1705241:Change [Quantitative Concept]
Processing 00000000.tx.184: This patient was symptomatic, with episodic rhabdomyolysis following exercise and other symptoms typically associated with the adult-onset, myopathic form of the disease. 

Phrase: "This patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "symptomatic,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0231220:Symptomatic [Functional Concept]

Phrase: "with episodic rhabdomyolysis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2675271:Rhabdomyolysis, episodic [Finding]
   861   C0035410:Rhabdomyolysis [Pathologic Function]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "exercise"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0015259:Exercise [Daily or Recreational Activity]
  1000   C1522704:Exercise [Therapeutic or Preventive Procedure]

Phrase: "and"

Phrase: "other symptoms typically"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0683368:symptoms [Functional Concept]
   861   C1457887:Symptoms [Sign or Symptom]

Phrase: "associated with the adult-onset,"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   806   C1836537:Adult onset [Finding]
   760   C0001675:Adult [Age Group]
   760   C0332162:Onset [Qualitative Concept]
   760   C1706450:Adult [Human]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]

Phrase: "myopathic form of the disease."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0348078:Form [Qualitative Concept]
   760   C0376315:Form [Manufactured Object]
   760   C1522492:Form [Functional Concept]
Processing 00000000.tx.185: Patients 2 and 3 were genotypically identical, with the same homozygous missense mutation, T848C, in exon 9 that predicts a V243A amino acid substitution. 

Phrase: "Patients 2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "were"

Phrase: "genotypically identical,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205280:Identical [Qualitative Concept]

Phrase: "with the same homozygous missense mutation,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0599155:Missense Mutation [Genetic Function]
   812   C0026882:Mutation [Genetic Function]
   812   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "T848C,"

Phrase: "in exon 9"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "that"

Phrase: "predicts"

Phrase: "a V243A amino acid substitution."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   923   C0525038:Amino Acid Substitution [Genetic Function,Molecular Biology Research Technique]
   812   C1555721:Substitution [Idea or Concept]
   812   C1706204:Substitution [Activity]
Processing 00000000.tx.186: Both patients were detected by newborn screening and are asymptomatic on dietary management, although patient 3 does have mildly elevated serum CPK. 

Phrase: "Both patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "detected by newborn screening"
Meta Candidates (Total=13; Excluded=2; Pruned=0; Remaining=11)
   833   C0027617:Newborn Screening [Diagnostic Procedure]
   770   C0021289:Newborn [Age Group]
   770   C0220908:Screening [Health Care Activity]
   770   C0220909:screening [Functional Concept]
   770   C0442726:Detected [Finding]
   770   C1511790:Detected [Therapeutic or Preventive Procedure]
   770   C1698960:screening [Intellectual Product]
   770   C1710031:Screening [Diagnostic Procedure]
   770   C1710477:SCREENING [Research Activity]
   770   C2239178:Newborn, NOS [Finding]
   770   C2939425:Newborn, NOS [Temporal Concept]
   737 E C1305399:screen [Functional Concept]
   737 E C1705053:Screen [Medical Device]

Phrase: "and"

Phrase: "are"

Phrase: "asymptomatic on dietary management,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0231221:Asymptomatic [Finding]

Phrase: "although"

Phrase: "patient 3"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "does"

Phrase: "have"

Phrase: "mildly elevated serum CPK."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   923   C0241005:Elevated serum CPK [Finding]
   875   C0151576:elevated cpk [Finding]
   861   C0750860:serum CPK [Laboratory Procedure]
Processing 00000000.tx.187: Patient 4 died suddenly in infancy and has the homozygous, missense mutation, A364G, in exon 6 that predicts an N81D substitution. 

Phrase: "Patient 4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "died"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
  1000   C0011065:Died [Organism Function]
  1000   C1546956:Died [Finding]
   928 E C0231800:Expired [Organ or Tissue Function]
   928 E C1704631:Expire [Idea or Concept]
   907 E C0184532:dying [Organism Function]
   907 E C1553404:terminated [Idea or Concept]
   907 E C2348570:Terminated [Functional Concept]

Phrase: "suddenly in infancy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0231330:Infancy [Temporal Concept]

Phrase: "and"

Phrase: "has"

Phrase: "the homozygous, missense mutation,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0599155:Missense Mutation [Genetic Function]
   827   C0026882:Mutation [Genetic Function]
   827   C1705285:Mutation [Cell or Molecular Dysfunction]

Phrase: "A364G,"

Phrase: "in exon 6"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0015295:Exon [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "that"

Phrase: "predicts"

Phrase: "an N81D substitution."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1555721:Substitution [Idea or Concept]
   861   C1706204:Substitution [Activity]
Processing 00000000.tx.188: This baby had a severe clinical presentation of VLCAD deficiency. 

Phrase: "This baby"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021270:Baby [Age Group]

Phrase: "had"

Phrase: "a severe clinical presentation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C2708283:Clinical presentation [Intellectual Product]
   827   C0449450:Presentation [Idea or Concept]

Phrase: "of VLCAD deficiency."
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.189: Informed consent was obtained from the parents of minors or from adult individuals. 

Phrase: "Informed consent"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
  1000   C0021430:Informed Consent [Regulation or Law]
   861   C1511481:Consent [Functional Concept]
   861   C1522154:Informed [Qualitative Concept]
   861   C1554192:consent [Idea or Concept]
   827 E C0537670:Inform [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827 E C0700287:inform [Health Care Activity]
   827 E C1552002:inform [Idea or Concept]

Phrase: "was"

Phrase: "obtained from the parents of minors"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   753   C0026193:Minors [Population Group]
   753   C0030551:Parents [Family Group]
   753   C0205165:minors [Qualitative Concept]
   753   C1301820:Obtained [Functional Concept]
   719 E C1706701:Obtain [Activity]
   719 E C2699423:Parent [Conceptual Entity]

Phrase: "or from adult individuals."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0001675:Adult [Age Group]
   770   C1706450:Adult [Human]
   737   C0027361:Individual [Population Group]
   737   C0237401:Individual [Human]
Processing 00000000.tx.190: Cell culture Human skin fibroblasts from normal and VLCAD-deficient individuals were cultured in Ham's F10 media (Invitrogen, Cergy-Pontoise, France) with glutamine, 12% fetal bovine serum (Invitrogen), 100U/ml penicillin and 0.1mg/ml streptomycin and incubated in a humidified CO2 incubator (5% CO2, 95% air) at 37C. 

Phrase: "Cell culture Human skin fibroblasts from normal"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   774   C0427861:cell human [Laboratory or Test Result]
   774   C0558145:Normal skin [Finding]
   774   C0814995:Skin cell [Cell]
   774   C1272578:fibroblasts skin [Cell]
   757   C0016030:fibroblast cell [Cell]
           Fibroblasts
   748   C0086418:Human [Human]
   748   C0444099:Skin [Body Substance]
   748   C1123023:Skin [Body System]
   748   C1278993:Skin [Body System]

Phrase: "and"

Phrase: "VLCAD-deficient individuals"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0027361:Individual [Population Group]
   760   C0237401:Individual [Human]
   756   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   756   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   723   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "were"

Phrase: "cultured in Ham's F10 media"
Meta Candidates (Total=12; Excluded=3; Pruned=0; Remaining=9)
   781   C0010454:Culture Media [Indicator, Reagent, or Diagnostic Aid]
   760   C0009458:Media [Intellectual Product]
   760   C0162867:Media [Tissue]
   760   C1254021:Media [Tissue]
   760   C1414497:F10 [Gene or Genome]
   726   C0010453:Culture [Idea or Concept]
   726   C0220814:culture [Functional Concept]
   726   C0430400:Culture [Laboratory Procedure]
   726 E C0439536:Medium [Quantitative Concept]
   726 E C1705217:Medium [Substance]
   726   C2242979:Culture [Laboratory Procedure]
   726 E C3244283:medium [Intellectual Product]

Phrase: "(Invitrogen,"

Phrase: "Cergy-Pontoise,"

Phrase: "France"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016674:France [Geographic Area]

Phrase: ")"

Phrase: "with glutamine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017797:Glutamine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "12% fetal bovine serum"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   812   C0007452:Bovine [Mammal]
   812   C0015965:Fetal [Embryonic Structure]
   812   C0229671:Serum [Body Substance]
   812   C0521457:Fetal [Functional Concept]
   812   C1140701:bovine [Mammal]
   812   C1546774:Serum [Intellectual Product]
   812   C1550100:Serum [Body Substance]

Phrase: "(Invitrogen"

Phrase: ")"

Phrase: ","

Phrase: "100U/ml penicillin"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0030842:Penicillin [Antibiotic,Organic Chemical]
   827   C0220892:Penicillin [Antibiotic,Organic Chemical]

Phrase: "and"

Phrase: "0.1mg/ml streptomycin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0038425:Streptomycin [Antibiotic,Carbohydrate]

Phrase: "and"

Phrase: "incubated in a humidified CO2 incubator"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0021178:Incubator [Manufactured Object]
   753   C1439852:Incubated [Laboratory Procedure]
   753   C2347816:Co2+ [Element, Ion, or Isotope]

Phrase: "(5% CO2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347816:Co2+ [Element, Ion, or Isotope]

Phrase: "95% air) at 37C."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0001861:Air [Substance]
   770   C3536832:Air [Inorganic Chemical,Pharmacologic Substance]
Processing 00000000.tx.191: For treatment, the media were removed, and the cells were subsequently incubated with fresh media containing bezafibrate (Sigma, Meylan, France) or fenofibric acid (kindly provided by FournierPharma, Dijon, France) or the equivalent amount of DMSO (vehicle) for 48h. 

Phrase: "For treatment,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "the media"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0009458:Media [Intellectual Product]
  1000   C0162867:Media [Tissue]
  1000   C1254021:Media [Tissue]
   966 E C0439536:Medium [Quantitative Concept]
   966 E C1705217:Medium [Substance]
   966 E C3244283:medium [Intellectual Product]

Phrase: "were"

Phrase: "removed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0849355:Removed [Qualitative Concept]
   966 E C1883720:Remove [Activity]
   966 E C3244314:remove [Functional Concept]

Phrase: ","

Phrase: "and"

Phrase: "the cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "subsequently"

Phrase: "incubated with fresh media"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   770   C0009458:Media [Intellectual Product]
   770   C0162867:Media [Tissue]
   770   C0443224:Fresh [Qualitative Concept]
   770   C1254021:Media [Tissue]
   770   C1439852:Incubated [Laboratory Procedure]
   770   C2827486:Fresh [Body Substance]
   737 E C0439536:Medium [Quantitative Concept]
   737 E C1705217:Medium [Substance]
   737 E C3244283:medium [Intellectual Product]

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "(Sigma,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1719918:Sigma [Intellectual Product]

Phrase: "Meylan,"

Phrase: "France"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016674:France [Geographic Area]

Phrase: ")"

Phrase: "or"

Phrase: "fenofibric acid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0060179:fenofibric acid [Organic Chemical,Pharmacologic Substance]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "(kindly"

Phrase: "provided by FournierPharma,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1999230:Provided [Activity]

Phrase: "Dijon,"

Phrase: "France"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016674:France [Geographic Area]

Phrase: ")"

Phrase: "or"

Phrase: "the equivalent amount of DMSO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1265611:Amount [Quantitative Concept]

Phrase: "(vehicle"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0042444:Vehicle [Biomedical or Dental Material]
  1000   C0348005:Vehicle [Manufactured Object]
   928 E C0445373:Vehicular [Functional Concept]

Phrase: ")"

Phrase: "for 48h."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1442464:48H [Temporal Concept]
Processing 00000000.tx.192: Fatty acid oxidation FAO was measured by quantifying the production of 3H2O from (9,10-3H) palmitate (Perkin Elmer, Courtaboeuf, France) as previously described in detail (23). 

Phrase: "Fatty acid oxidation FAO"

Phrase: "was"

Phrase: "measured by quantifying"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0444706:Measured [Qualitative Concept]
   790   C3541902:MEASURED [Diagnostic Procedure]
   756 E C0079809:Measure [Quantitative Concept]
   756 E C0242485:Measure [Functional Concept]
   756   C1709793:Quantify [Quantitative Concept]

Phrase: "the production of 3H2O"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0033268:production [Occupational Activity]

Phrase: "from"

Phrase: "(9,"

Phrase: "10-3H"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1442460:3H [Temporal Concept]

Phrase: ")"

Phrase: "palmitate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0030233:palmitate [Lipid]
  1000   C3503116:palmitate [Biomedical or Dental Material,Lipid]

Phrase: "(Perkin Elmer,"

Phrase: "Courtaboeuf,"

Phrase: "France"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016674:France [Geographic Area]

Phrase: ")"

Phrase: "as"

Phrase: "previously"

Phrase: "described in detail"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1522508:Detail [Qualitative Concept]
   790   C1552738:described [Idea or Concept]
   790   C1561567:detail [Functional Concept]

Phrase: "(23"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.193: The final concentration of palmitate was 125M, (60Ci/mmol) bound to fatty acid-free albumin. 

Phrase: "The final concentration of palmitate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0086045:Concentration [Mental Process]
   760   C1446561:Concentration [Quantitative Concept]

Phrase: "was"

Phrase: "125M,"

Phrase: "(60Ci/mmol)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439190:MMOLE [Quantitative Concept]

Phrase: "bound to fatty acid-free albumin."
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   820   C0015688:free fatty acid [Lipid]
   820   C2698488:Free Fatty Acid [Laboratory Procedure]
   790   C0015684:Fatty acid [Lipid]
   753   C0001128:Acid [Chemical]
   753   C0001924:Albumin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0202406:Acid [Laboratory Procedure]
   753   C0332296:free [Functional Concept]
   753   C0332297:bound [Spatial Concept]
   753   C1145667:Bound [Activity]
   753   C1167622:Bound [Molecular Function]
   753   C1689898:% bound [Quantitative Concept]
   753   C1880497:Free [Qualitative Concept]
   753   C1996904:Free [Qualitative Concept]
   753   C2349209:Bound [Conceptual Entity]
Processing 00000000.tx.194: We checked that the production of tritiated water was linear with respect to time between 0 and 180min in fibrate-treated and untreated cells as well. 

Phrase: "We"

Phrase: "checked"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1283174:Checked [Activity]

Phrase: "that"

Phrase: "the production of tritiated water"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0033268:production [Occupational Activity]

Phrase: "was"

Phrase: "linear with respect to time"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0205132:Linear [Spatial Concept]

Phrase: "between 0"

Phrase: "and"

Phrase: "180min in fibrate-treated"

Phrase: "and"

Phrase: "untreated cells as well."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   819   C2347578:Cells/well [Quantitative Concept]
   770   C0007634:Cells [Cell]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.195: Palmitate oxidation rates by fibroblasts were expressed as nanomoles of 3H-fatty acid (3H FA) oxidized per hour per milligrams of cell protein (nmol 3H-FAh1mg1 protein). 

Phrase: "Palmitate oxidation rates by fibroblasts"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0030011:Oxidation [Molecular Function]
   760   C0030233:palmitate [Lipid]
   760   C3503116:palmitate [Biomedical or Dental Material,Lipid]
   726   C0871208:Rate [Activity]
   726   C1521828:Rate [Quantitative Concept]

Phrase: "were"

Phrase: "expressed as nanomoles of 3H-fatty acid (3H FA)"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C0015684:Fatty acid [Lipid]
   748   C0001128:Acid [Chemical]
   748   C0202406:Acid [Laboratory Procedure]
   748   C0439191:Nanomole [Quantitative Concept]
   748   C1442460:3H [Temporal Concept]

Phrase: "oxidized per hour"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0439227:Hour [Temporal Concept]
   790   C0564385:/hour [Quantitative Concept]
   756   C0030011:oxidize [Molecular Function]

Phrase: "per milligrams"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439210:milligrams [Quantitative Concept]

Phrase: "of cell protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0007634:Cell [Cell]
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C1269647:Cell [Cell]
   861   C1704653:Cell [Medical Device]
   861   C1948049:Cell [Spatial Concept]

Phrase: "(nmol 3H-FAh1mg1 protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: ")."
Processing 00000000.tx.196: Enzyme activity VLCAD activity was measured as described elsewhere (24) using palmitoyl-CoA as substrate. 

Phrase: "Enzyme activity VLCAD activity"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   734   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   734   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   707   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]

Phrase: "was"

Phrase: "measured"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "elsewhere"

Phrase: "(24"

Phrase: ")"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "palmitoyl-CoA as substrate."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C0030239:Palmitoyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.197: The production of 2,3-unsaturated-palmitoyl-CoA and -hydroxypalmitoyl-CoA was quantified by HPLC and used to calculate acyl-CoA dehydrogenase activity. 

Phrase: "The production of 2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0033268:production [Occupational Activity]

Phrase: "3-unsaturated-palmitoyl-CoA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030239:Palmitoyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "and -"

Phrase: "hydroxypalmitoyl-CoA"

Phrase: "was"

Phrase: "quantified by HPLC"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0008562:HPLC [Laboratory Procedure]
   756   C1709793:Quantify [Quantitative Concept]

Phrase: "and"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "calculate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441506:Calculate [Activity]

Phrase: "acyl-CoA dehydrogenase activity."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C1151743:acyl-CoA dehydrogenase activity [Molecular Function]
           acyl dehydrogenase activity
   812   C0205177:Activity [Functional Concept]
   812   C0439167:% activity [Quantitative Concept]
   812   C0441655:Activity [Activity]
   812   C1561536:*Activity [Idea or Concept]
   756   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   756   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
Processing 00000000.tx.198: Western blot analysis Control and VLCAD fibroblasts were harvested in RIPA buffer (50mM Tris, pH 7.5, 150mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 0.1% SDS, 10g/ml leupeptin, 10g/ml aprotinin and 1mM phenylmethylsulfonyl fluoride) to prepare protein extracts. 

Phrase: "Western blot analysis Control"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0243148:control [Qualitative Concept]
   812   C1550141:Control [Substance]
   812   C1882979:Control [Conceptual Entity]
   812   C2587213:Control [Functional Concept]
   812   C3274648:Control [Qualitative Concept]
   756   C0949466:Western blot analysis [Laboratory Procedure]

Phrase: "and"

Phrase: "VLCAD fibroblasts"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   795   C0016030:Fibroblasts [Cell]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "were"

Phrase: "harvested in RIPA buffer"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   770   C0034584:RIPA [Laboratory Procedure]
   737   C1512335:Harvest [Health Care Activity]

Phrase: "(50mM Tris,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0041175:TRIS [Organic Chemical,Pharmacologic Substance]
   861   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   861   C0814229:TRI [Intellectual Product]

Phrase: "pH 7.5,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: "150mM NaCl,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037494:NaCl [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   861   C1959973:% NaCl [Quantitative Concept]

Phrase: "1% NP-40,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   901   C0044508:1-NP [Hazardous or Poisonous Substance,Organic Chemical]
   901   C0068941:NP-40 [Organic Chemical,Pharmacologic Substance]
   827   C0439509:/40 [Temporal Concept]
   827   C1706141:NP [Gene or Genome]
   827   C2827734:1+ [Quantitative Concept]
   827   C2981698:1+ [Classification]

Phrase: "0.25% sodium deoxycholate,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0037500:SODIUM DESOXYCHOLATE [Pharmacologic Substance,Steroid]
   812   C0037473:Sodium [Biologically Active Substance,Element, Ion, or Isotope]
   812   C0086123:Deoxycholate [Hormone,Pharmacologic Substance,Steroid]
   812   C0597484:Sodium+ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "0.1% SDS,"

Phrase: "10g/ml leupeptin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0064858:leupeptin [Amino Acid, Peptide, or Protein,Pharmacologic Substance]

Phrase: "10g/ml aprotinin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0003641:Aprotinin [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]

Phrase: "and"

Phrase: "1mM phenylmethylsulfonyl fluoride"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0031493:Phenylmethylsulfonyl Fluoride [Organic Chemical,Pharmacologic Substance]
   827   C0016327:Fluoride [Inorganic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "prepare"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1521827:Prepare [Functional Concept]

Phrase: "protein extracts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2828366:Extract [Substance]
Processing 00000000.tx.199: The lysates were centrifuged, and the supernatant was transferred to new vials. 

Phrase: "The lysates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1881488:Lysate [Physical Object]

Phrase: "were"

Phrase: "centrifuged"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0179834:centrifuge [Medical Device]

Phrase: ","

Phrase: "and"

Phrase: "the supernatant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1550101:Supernatant [Body Substance]

Phrase: "was"

Phrase: "transferred to new vials."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0184301:vials [Medical Device]
   770   C0205314:New [Temporal Concept]
   770   C0348011:transferred [Functional Concept]
   770   C1533199:Vials [Quantitative Concept]
   737 E C0040671:Transfer [Mental Process]
   737 E C1705822:Transfer [Activity]
   737 E C1706497:VIAL [Medical Device]
Processing 00000000.tx.200: Protein concentration was determined using the Bradford method. 

Phrase: "Protein concentration"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0427716:Protein concentration [Laboratory Procedure]
  1000   C1304757:Protein concentration [Laboratory or Test Result]
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "was"

Phrase: "determined"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the Bradford method."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0025663:Method [Intellectual Product]
   861   C0449851:Method [Functional Concept]
   861   C0871511:METHOD [Intellectual Product]
Processing 00000000.tx.201: About 20g of total protein per lane was resolved by 10% SDSPAGE and transferred to Hybond-P PVDF membrane (Amersham Biosciences, Freiburg, Germany). 

Phrase: "About 20g"

Phrase: "of total protein"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0555903:Total protein [Laboratory Procedure]
  1000   C1261360:total protein [Laboratory or Test Result]
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0439175:% total [Quantitative Concept]
   861   C0439810:Total [Qualitative Concept]

Phrase: "per lane"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1708639:Lane [Spatial Concept]

Phrase: "was"

Phrase: "resolved by 10% SDSPAGE"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1514893:Resolved [Idea or Concept]
   770   C2699488:Resolved [Conceptual Entity]

Phrase: "and"

Phrase: "transferred to Hybond-P PVDF membrane"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   753   C0025255:Membrane [Tissue]
   753   C0071710:PVDF [Organic Chemical]
   753   C0348011:transferred [Functional Concept]
   753   C0596901:Membrane [Cell Component]
   753   C1706182:Membrane [Manufactured Object]
   719 E C0040671:Transfer [Mental Process]
   719 E C1705822:Transfer [Activity]

Phrase: "(Amersham Biosciences,"

Phrase: "Freiburg,"

Phrase: "Germany"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]

Phrase: ")."
Processing 00000000.tx.202: The following antibodies were used: rabbit polyclonal anti-VLCAD and mouse monoclonal anti-actin (Chemicon International, Temecula, CA, USA). 

Phrase: "The following antibodies"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "were"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: ":"

Phrase: "rabbit polyclonal anti-VLCAD"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
   901   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   901   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   873   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   849   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   827   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   827   C1980013:Very long chain [Qualitative Concept]
   791   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   791   C0205166:Long [Qualitative Concept]
   791   C0337112:Chain [Manufactured Object]
   791   C0442824:Very [Qualitative Concept]
   791   C1524075:Chain [Idea or Concept]
   791   C1706317:Long [Qualitative Concept]

Phrase: "and"

Phrase: "mouse monoclonal anti-actin"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   812   C0001271:Actin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   741 E C0439681:Actinic [Qualitative Concept]

Phrase: "(Chemicon International, Temecula,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1555271:Temecula [Population Group]

Phrase: "CA,"

Phrase: "USA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: ")."
Processing 00000000.tx.203: The primary antibodies were used at a dilution of 1:2000 and detected using horseradish peroxidase-conjugated anti-rabbit or anti-mouse IgG and the chemiluminescent reagent, ECL (Amersham Biosciences). 

Phrase: "The primary antibodies"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   827 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "were"

Phrase: "used at a dilution of 1"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   767   C1524063:Use of [Functional Concept]
   753   C0079240:Dilution [Laboratory Procedure]
   753   C1273517:used [Finding]
   753   C1948037:Dilution [Functional Concept]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719 E C1947944:Use [Intellectual Product]

Phrase: ":"

Phrase: "2000"

Phrase: "and"

Phrase: "detected"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0442726:Detected [Finding]
  1000   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "horseradish peroxidase-conjugated anti-rabbit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0034493:Rabbit [Mammal]

Phrase: "or"

Phrase: "anti-mouse IgG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   913   C0051979:anti-IgG [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "and"

Phrase: "the chemiluminescent reagent,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0034760:Reagent [Indicator, Reagent, or Diagnostic Aid]

Phrase: "ECL (Amersham Biosciences"

Phrase: ")."
Processing 00000000.tx.204: Immunoreactive bands corresponding to the two protein antigens were scanned by densitometry with a computerized video densitometer. 

Phrase: "Immunoreactive bands"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0175723:Bands [Medical Device]
   827 E C0439645:Band [Spatial Concept]
   827 E C1521913:band [Cell Component]

Phrase: "corresponding to the two protein antigens"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   773   C1291777:Protein antigen [Immunologic Factor]
   753   C0003320:Antigens [Immunologic Factor]
   753   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C0205448:Two [Quantitative Concept]

Phrase: "were"

Phrase: "scanned by densitometry"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   805   C0011321:densitometric scan [Laboratory Procedure]
           Densitometry
   790   C0441633:scanned [Diagnostic Procedure]
   756 E C0034606:Scan [Diagnostic Procedure]
   756 E C2826292:SCAN [Finding]

Phrase: "with a computerized video densitometer."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0042655:Video [Manufactured Object]
   827   C0180321:Densitometer [Medical Device]
   827   C1706216:Densitometer [Medical Device]
   827   C3463807:Video [Intellectual Product]
Processing 00000000.tx.205: The results are characteristic of two independent experiments. 

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are"

Phrase: "characteristic of two independent experiments."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1521970:Characteristic [Qualitative Concept]
Processing 00000000.tx.206: Real-time quantitative PCR Total RNA was isolated by use of the Trizol reagent (Invitrogen), treated with DNAse (Ambion, UK) and transcribed into cDNA. 

Phrase: "Real-time quantitative PCR Total RNA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   700   C1709846:Real-Time PCR [Molecular Biology Research Technique]

Phrase: "was"

Phrase: "isolated by use of the Trizol reagent"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   778   C1524063:Use of [Functional Concept]
   748   C0034760:Reagent [Indicator, Reagent, or Diagnostic Aid]
   748   C0042153:use [Functional Concept]
   748   C0205409:Isolated [Functional Concept]
   748   C0457083:Use [Functional Concept]
   748   C0916178:trizol [Organic Chemical]
   748   C1548221:Isolated [Idea or Concept]
   748   C1947944:Use [Intellectual Product]
   714 E C0370215:Isolate [Substance]
   714 E C1875400:ISOLATE [Pharmacologic Substance]

Phrase: "(Invitrogen"

Phrase: ")"

Phrase: ","

Phrase: "treated with DNAse"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0011519:DNase [Amino Acid, Peptide, or Protein,Enzyme]
   790   C0011522:DNAase [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "(Ambion,"

Phrase: "UK"

Phrase: ")"

Phrase: "and"

Phrase: "transcribed into cDNA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0006556:cDNA [Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.207: Real-time quantitative PCR (RT-PCR) was performed using the SYBR Green I kit and the LightCycler instrument from Roche Diagnostics (Mannheim, Germany). 

Phrase: "Real-time quantitative PCR (RT-PCR)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   867   C1514628:Quantitative RTPCR [Molecular Biology Research Technique]
   827   C0599161:RT-PCR [Molecular Biology Research Technique]
   700   C1709846:Real-Time PCR [Molecular Biology Research Technique]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the SYBR Green I kit"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0812225:KIT [Medical Device]
   812   C1150635:KIT [Molecular Function]
   812   C1705212:Kit [Medical Device]
   812   C1705213:KIT [Medical Device]
   812   C3273202:Kit [Manufactured Object]
   756   C0386577:SYBR Green I [Indicator, Reagent, or Diagnostic Aid]

Phrase: "and"

Phrase: "the LightCycler instrument from Roche Diagnostics"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0348000:Instrument [Medical Device]

Phrase: "(Mannheim,"

Phrase: "Germany"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]

Phrase: ")."
Processing 00000000.tx.208: RT-PCR primers (Table 2) were designed using the sequences available in GenBank and spanned an intron/exon boundary. 

Phrase: "RT-PCR primers"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   793   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]
   734   C0599161:RT-PCR [Molecular Biology Research Technique]

Phrase: "(Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")"

Phrase: "were"

Phrase: "designed"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1707689:Design [Activity]
   966   C2983265:DESIGN [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the sequences"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0162326:Sequences [Nucleotide Sequence]
   966 E C0004793:Sequence [Nucleotide Sequence]
   966 E C0162327:Sequence [Nucleotide Sequence]
   966 E C1519249:Sequence [Functional Concept]
   916 E C1548958:Sequential [Idea or Concept]
   916 E C1705294:Sequential [Qualitative Concept]

Phrase: "available in GenBank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0470187:Available [Functional Concept]

Phrase: "and"

Phrase: "spanned"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1711300:Span [Conceptual Entity]
   966   C2700613:Span [Quantitative Concept]

Phrase: "an intron/exon boundary."
Processing 00000000.tx.209: Gene expression levels were compared in fibroblasts treated with either vehicle or bezafibrate for 48h. 

Phrase: "Gene expression levels"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   867   C3244092:expression level [Idea or Concept]
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]
   734   C0017262:Gene Expression [Genetic Function]

Phrase: "were"

Phrase: "compared in fibroblasts"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0016030:Fibroblasts [Cell]
   790   C1707455:Compared [Activity]

Phrase: "treated with either vehicle"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0042444:Vehicle [Biomedical or Dental Material]
   770   C0348005:Vehicle [Manufactured Object]
   770   C1522326:Treated [Functional Concept]
   737 E C1292734:TREAT [Functional Concept]

Phrase: "or"

Phrase: "bezafibrate for 48h."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.210: The amounts of the various mRNAs were normalized to the amount of -actin mRNA measured by quantitative RT-PCR in each sample. 

Phrase: "The amounts of the various mRNAs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1265611:amounts [Quantitative Concept]

Phrase: "were"

Phrase: "normalized to the amount of -actin mRNA"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0001271:Actin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   748   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   748   C1265611:Amount [Quantitative Concept]
   748   C1882115:Normalized [Research Activity]

Phrase: "measured by quantitative RT-PCR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   862   C1514628:Quantitative RTPCR [Molecular Biology Research Technique]
   806   C0599161:RT-PCR [Molecular Biology Research Technique]
   760   C0032520:PCR [Laboratory Procedure,Molecular Biology Research Technique]
   760   C0392762:Quantitative [Quantitative Concept]
   760   C0444706:Measured [Qualitative Concept]
   760   C0677874:pCR [Finding]
   760   C3541902:MEASURED [Diagnostic Procedure]
   726 E C0079809:Measure [Quantitative Concept]
   726 E C0242485:Measure [Functional Concept]

Phrase: "in each sample."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0370003:Sample [Substance]
  1000   C2347026:Sample [Conceptual Entity]
Processing 00000000.tx.211: The results are in arbitrary units and expressed as fold changes in mRNA levels in cells treated with bezafibrate relative to vehicle-treated controls. 

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "are in arbitrary units"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   799   C0439183:Arbitrary unit [Quantitative Concept]
   770   C0439148:Units [Quantitative Concept]
   770   C1264693:*Arbitrary [Quantitative Concept]
   770   C1519795:Units [Quantitative Concept]
   770   C1551058:Are [Quantitative Concept]
   737 E C1704753:Unit [Manufactured Object]
   737 E C1880519:Unit [Quantitative Concept]

Phrase: "and"

Phrase: "expressed as fold"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0332462:Fold [Spatial Concept]
   790   C1880834:FOLD [Phenomenon or Process]

Phrase: "changes in mRNA levels"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   770   C0035696:mRNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   770   C0392747:Change [Functional Concept]
   770   C0441889:Levels [Qualitative Concept]
   770   C0443172:change [Quantitative Concept]
   770   C1705241:Change [Quantitative Concept]
   737 E C0456079:Level [Classification]
   737 E C1547707:Level [Geographic Area]
   737 E C2946261:Level [Pharmacologic Substance]

Phrase: "in cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0007634:Cells [Cell]
  1000   C3282337:Cells [Cell]
   966 E C1269647:Cell [Cell]
   966 E C1704653:Cell [Medical Device]
   966 E C1948049:Cell [Spatial Concept]

Phrase: "treated with bezafibrate"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "relative to vehicle-treated controls."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0080103:Relative [Family Group]
   760   C0205345:Relative [Qualitative Concept]
   760   C1547039:*Relative [Quantitative Concept]
Processing 00000000.tx.212: View this table: [in this window] [in a new window]  Table2. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table2."
Processing 00000000.tx.213: Primers used for real-time quantitative PCR  ESI-MS-MS-based acylcarnitine analysis The method has been previously described in detail (25) with slight modifications. 

Phrase: "Primers"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0206415:Primer [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "for real-time quantitative PCR  ESI-MS-MS-based acylcarnitine analysis"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   874   C2733022:Quantitative PCR analysis [Laboratory Procedure]
   862   C0200931:PCR analysis [Laboratory Procedure]
   787   C0002778:Analysis [Laboratory Procedure]
   787   C0936012:Analysis [Research Activity]
   787   C1524024:analysis [Functional Concept]

Phrase: "The method"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025663:Method [Intellectual Product]
  1000   C0449851:Method [Functional Concept]
  1000   C0871511:METHOD [Intellectual Product]

Phrase: "has"

Phrase: "been"

Phrase: "previously"

Phrase: "described in detail"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1522508:Detail [Qualitative Concept]
   790   C1552738:described [Idea or Concept]
   790   C1561567:detail [Functional Concept]

Phrase: "(25"

Phrase: ")"

Phrase: "with slight modifications."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0392747:Modification [Functional Concept]
   827   C1554963:modification [Qualitative Concept]
Processing 00000000.tx.214: Briefly, at 100% confluency, fibroblasts were detached with trypsin, counted, plated (20x105 cells per well in 24-well microplates) and settled to form a cell monolayer. 

Phrase: "Briefly,"

Phrase: "at 100% confluency,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   789   C0205200:Confluent [Qualitative Concept]

Phrase: "fibroblasts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016030:Fibroblasts [Cell]

Phrase: "were"

Phrase: "detached with trypsin,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0041236:TRYPSIN [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   790   C0687118:Detached [Functional Concept]
   790   C1561504:detached [Idea or Concept]

Phrase: "counted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0750480:Count [Activity]
   966   C1705566:Count [Quantitative Concept]

Phrase: ","

Phrase: "plated"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005971:Plate [Medical Device]
   966   C1139930:plate [Medical Device]
   966   C3537155:Plate [Manufactured Object]

Phrase: "(20x105 cells per well"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   898   C2347578:Cell per Well [Quantitative Concept]
           Cells/well
   770   C0007634:Cells [Cell]
   770   C3282337:Cells [Cell]
   737 E C1269647:Cell [Cell]
   737 E C1704653:Cell [Medical Device]
   737 E C1948049:Cell [Spatial Concept]

Phrase: "in 24-well microplates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C1709027:Microplate [Research Device]

Phrase: ")"

Phrase: "and"

Phrase: "settled"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1266099:SETTLE [Neoplastic Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "form"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "a cell monolayer."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0872351:monolayer [Clinical Drug]
Processing 00000000.tx.215: The medium was then removed, and 1ml of Ham's F10 medium containing palmitate bound to BSA (4:1 molar ratio, 200M) and L-carnitine (400M) was added. 

Phrase: "The medium"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0009458:Medium [Intellectual Product]
  1000   C0439536:Medium [Quantitative Concept]
  1000   C1705217:Medium [Substance]
  1000   C3244283:medium [Intellectual Product]

Phrase: "was"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "removed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0849355:Removed [Qualitative Concept]
   966 E C1883720:Remove [Activity]
   966 E C3244314:remove [Functional Concept]

Phrase: ","

Phrase: "and"

Phrase: "1ml of Ham's F10 medium containing palmitate"

Phrase: "bound to BSA (4"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0332297:bound [Spatial Concept]
   770   C1145667:Bound [Activity]
   770   C1167622:Bound [Molecular Function]
   770   C1689898:% bound [Quantitative Concept]
   770   C2349209:Bound [Conceptual Entity]

Phrase: ":"

Phrase: "1 molar ratio,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C2825550:Molar Ratio [Quantitative Concept]
   827   C0456603:Ratio [Quantitative Concept]
   827   C1547037:Ratio [Intellectual Product]

Phrase: "200M"

Phrase: ")"

Phrase: "and"

Phrase: "L-carnitine"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0007258:L-Carnitine [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
           Carnitine
  1000   C0087163:L-Carnitine [Organic Chemical,Pharmacologic Substance,Vitamin]
           Carnitine
   861   C0439394:l's [Quantitative Concept]
   861   C1706495:L- [Intellectual Product]
   861   C3642217:/L [Quantitative Concept]

Phrase: "(400M"

Phrase: ")"

Phrase: "was"

Phrase: "added."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1524062:Added [Functional Concept]
   966 E C1883712:Add [Functional Concept]
Processing 00000000.tx.216: After incubation at 37C for 72h, the reaction medium in each well was collected, and the cell monolayer was retained for protein quantification. 

Phrase: "After incubation"

Phrase: "at 37C"

Phrase: "for 72h,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292423:72H [Temporal Concept]

Phrase: "the reaction medium in each well"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0009458:Medium [Intellectual Product]
   753   C0439536:Medium [Quantitative Concept]
   753   C1705217:Medium [Substance]
   753   C3244283:medium [Intellectual Product]

Phrase: "was"

Phrase: "collected"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1516695:Collected [Idea or Concept]
  1000   C1516698:Collected [Functional Concept]

Phrase: ","

Phrase: "and"

Phrase: "the cell monolayer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0872351:monolayer [Clinical Drug]

Phrase: "was"

Phrase: "retained for protein quantification."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   770   C0333118:Retained [Functional Concept]
   770   C1709793:Quantification [Quantitative Concept]
Processing 00000000.tx.217: The acylcarnitines in the reaction mixture were analyzed using an API3000 triple quadrupole mass spectrometer (Sciex, Applied Biosystem, USA) detecting the precursors of an m/z of 85 and quantitated by comparison with added, internal, deuterated standards. 

Phrase: "The acylcarnitines in the reaction mixture"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0368608:acylcarnitines [Organic Chemical]

Phrase: "were"

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "an API3000 triple quadrupole mass spectrometer"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   840   C0183396:Mass Spectrometer [Medical Device]
   804   C0183395:Spectrometer [Medical Device]
   804   C0205174:Triple [Quantitative Concept]
   804   C0577559:Mass [Finding]
   804   C1306372:*Mass [Quantitative Concept]
   804   C1710143:Spectrometer [Manufactured Object]
   804   C2347727:Quadrupole [Research Device]
   804   C3152252:Mass [Quantitative Concept]

Phrase: "(Sciex,"

Phrase: "Applied Biosystem,"

Phrase: "USA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0041703:USA [Geographic Area]

Phrase: ")"

Phrase: "detecting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0442726:detect [Finding]

Phrase: "the precursors of an"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   737   C1709634:Precursor [Idea or Concept]

Phrase: "m/"

Phrase: "z of 85"

Phrase: "and"

Phrase: "quantitated by comparison with added, internal, deuterated standards."
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   744   C0038137:standards [Intellectual Product]
   744   C0175675:Standards [Qualitative Concept]
   744   C0205102:Internal [Spatial Concept]
   744   C1524062:Added [Functional Concept]
   744   C1553872:Internal [Intellectual Product]
   744   C1619620:Internal [Intellectual Product]
   744   C1707455:Comparison [Activity]
   711 E C1442989:Standard [Qualitative Concept]
   711 E C1883712:Add [Functional Concept]
   711 E C2828392:Standard [Intellectual Product]
Processing 00000000.tx.218: Statistical analysis Data are expressed as meanSD. 

Phrase: "Statistical analysis Data"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C2828391:statistical data [Quantitative Concept]
   827   C1511726:Data [Idea or Concept]
   827   C3245479:data [Medical Device]
   734   C0871424:statistical analysis [Research Activity]

Phrase: "are"

Phrase: "expressed as meanSD."
Processing 00000000.tx.219: Differences between vehicle and treated cells were analyzed by one-way analysis of variance (ANOVA) and the Fisher's test; 

Phrase: "Differences between vehicle"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   756   C1705241:*Difference [Quantitative Concept]
   756   C1705242:Difference [Qualitative Concept]
   706 E C0443199:Differential [Qualitative Concept]

Phrase: "and"

Phrase: "treated cells"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0007634:Cells [Cell]
   861   C3282337:Cells [Cell]
   827 E C1269647:Cell [Cell]
   827 E C1704653:Cell [Medical Device]
   827 E C1948049:Cell [Spatial Concept]

Phrase: "were"

Phrase: "analyzed by one-way analysis of variance (ANOVA)"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   897   C1709320:One-way Analysis of Variance [Quantitative Concept]
   814   C0002780:Analysis of Variance [Quantitative Concept]
           Variance Analysis
   748   C0002778:Analysis [Laboratory Procedure]
   748   C0205447:One [Quantitative Concept]
   748   C0936012:Analysis [Research Activity]
           Analyzed
   748   C1524024:analysis [Functional Concept]
   748   C1711260:Variance [Qualitative Concept]
   748   C2348152:Variance [Quantitative Concept]

Phrase: "and"

Phrase: "the Fisher's test"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C1708064:Fisher's Test [Intellectual Product]
   861   C0022885:Test [Laboratory Procedure]
   861   C0039593:Test [Functional Concept]
   861   C0392366:test [Intellectual Product]

Phrase: ";"
Processing 00000000.tx.220: P<0.05 was considered significant.  

Phrase: "P<0.05"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "was"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "significant."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0237881:significant [Quantitative Concept]
  1000   C0750502:Significant [Idea or Concept]
  1000   C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.221: ACKNOWLEDGEMENTS  This work was supported by grants from the Association Franaise contre les Myopathies (AFM). 

Phrase: "ACKNOWLEDGEMENTS"

Phrase: "This work"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043227:Work [Occupational Activity]

Phrase: "was"

Phrase: "supported by grants"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0018173:Grants [Quantitative Concept]
   790   C1521721:Supported [Conceptual Entity]
   756 E C0183683:Support [Medical Device]
   756 E C1548284:Grant [Idea or Concept]

Phrase: "from the Association Franaise contre les Myopathies (AFM)."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0026848:Myopathies [Disease or Syndrome]
Processing 00000000.tx.222: We thank Dr D. 

Phrase: "We"

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "Dr D."
Processing 00000000.tx.223: Pruneau for providing the fenofibric acid and Dr S. 

Phrase: "Pruneau for providing"

Phrase: "the fenofibric acid"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0060179:fenofibric acid [Organic Chemical,Pharmacologic Substance]
   861   C0001128:Acid [Chemical]
   861   C0202406:Acid [Laboratory Procedure]

Phrase: "and"

Phrase: "Dr S."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]
Processing 00000000.tx.224: Olpin for advices. 

Phrase: "Olpin for advices."
Processing 00000000.tx.225: Conflict of Interest statement. 

Phrase: "Conflict of Interest statement."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C1710187:Statement [Idea or Concept]
   756   C0079152:Conflict of Interest [Idea or Concept]
Processing 00000000.tx.226: None declared.  

Phrase: "None"

Phrase: "declared."
Processing 00000000.tx.227: REFERENCES TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS REFERENCES  Rinaldo, P., Matern, D. and Bennett, M.J. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "TOP ABSTRACT INTRODUCTION RESULTS DISCUSSION MATERIALS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0520510:Materials [Substance]

Phrase: "AND"

Phrase: "METHODS"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0025663:Methods [Intellectual Product]
  1000   C0025664:methods [Intellectual Product]
  1000   C0449851:Methods [Functional Concept]
   966 E C0871511:METHOD [Intellectual Product]

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Rinaldo,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Matern,"

Phrase: "D."

Phrase: "and"

Phrase: "Bennett,"

Phrase: "M."

Phrase: "J."
Processing 00000000.tx.228: (2002) Fatty acid oxidation disorders. 

Phrase: "(2002"

Phrase: ")"

Phrase: "Fatty acid oxidation disorders."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0012634:Disorders [Disease or Syndrome]
   756   C1158366:fatty acid oxidation [Molecular Function]
Processing 00000000.tx.229: Annu. 

Phrase: "Annu."
Processing 00000000.tx.230: Rev. 

Phrase: "Rev."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347961:Rev. [Professional or Occupational Group]
Processing 00000000.tx.231: Physiol, 64, 477502.[CrossRef][ISI][Medline] Andresen, B.S., Olpin, S., Poorthuis, B.J., Scholte, H.R., Vianey-Saban, C., Wanders, R., Ijlst, L., Morris, A., Pourfarzam, M., Bartlett, K. etal. 

Phrase: "Physiol,"

Phrase: "64,"

Phrase: "477502."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Andresen,"

Phrase: "B.S.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347469:/B [Quantitative Concept]

Phrase: "Olpin,"

Phrase: "S."

Phrase: ","

Phrase: "Poorthuis,"

Phrase: "B.J.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347469:/B [Quantitative Concept]

Phrase: "Scholte,"

Phrase: "H.R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Vianey-Saban,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Wanders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0233569:wander [Finding]

Phrase: ","

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Ijlst,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Morris,"

Phrase: "A.,"

Phrase: "Pourfarzam,"

Phrase: "M."

Phrase: ","

Phrase: "Bartlett,"

Phrase: "K. etal."
Processing 00000000.tx.232: (1999) Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. 

Phrase: "(1999"

Phrase: ")"

Phrase: "Clear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2963144:Clear [Qualitative Concept]

Phrase: "correlation of genotype"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707520:Correlation [Qualitative Concept]

Phrase: "with disease phenotype"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0031437:Phenotype [Organism Attribute]
   861   C1285572:Phenotype [Laboratory Procedure]

Phrase: "in very-long-chain acyl-CoA dehydrogenase deficiency."
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
  1000   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0220711:Long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   877   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   787   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
   787   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   747   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   724 E C1636779:% deficient [Quantitative Concept]
   710   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.233: Am. 

Phrase: "Am."
Processing 00000000.tx.234: J. 

Phrase: "J."
Processing 00000000.tx.235: Hum. 

Phrase: "Hum."
Processing 00000000.tx.236: Genet., 64, 479494.[CrossRef][ISI][Medline] Gregersen, N., Andresen, B.S., Corydon, M.J., Corydon, T.J., Olsen, R.K., Bolund, L. and Bross, P. 

Phrase: "Genet.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]

Phrase: "64,"

Phrase: "479494."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Gregersen,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Andresen,"

Phrase: "B.S.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347469:/B [Quantitative Concept]

Phrase: "Corydon,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1827933:Corydon [Bird]

Phrase: "M."

Phrase: "J.,"

Phrase: "Corydon,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1827933:Corydon [Bird]

Phrase: "T.J.,"

Phrase: "Olsen,"

Phrase: "R.K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Bolund,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "and"

Phrase: "Bross,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.237: (2001) Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotypephenotype relationship. 

Phrase: "(2001"

Phrase: ")"

Phrase: "Mutation analysis in mitochondrial fatty acid oxidation defects"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0796357:mutation analysis [Laboratory Procedure]
   744   C0002778:Analysis [Laboratory Procedure]
   744   C0936012:Analysis [Research Activity]
   744   C1524024:analysis [Functional Concept]

Phrase: ":"

Phrase: "exemplified by acyl-CoA dehydrogenase deficiencies,"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   871   C0268635:Acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   833   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   833   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   790   C0001374:Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
   773   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   753   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   719   C0011155:Deficiency [Functional Concept]
   719   C0162429:Deficiency [Disease or Syndrome]
   719   C1623416:deficiency [Qualitative Concept]

Phrase: "with special focus"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205234:Focus [Spatial Concept]
   861   C1285542:focus [Functional Concept]

Phrase: "on genotypephenotype relationship."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0439849:Relationship [Qualitative Concept]
   861   C1705630:Relationship [Idea or Concept]
   861   C1706279:Relationship [Idea or Concept]
   861   C3540605:Relationship [Intellectual Product]
Processing 00000000.tx.238: Hum. 

Phrase: "Hum."
Processing 00000000.tx.239: Mutat., 18, 169189.[CrossRef][ISI][Medline] Gregersen, N., Bross, P. and Andresen, B.S. 

Phrase: "Mutat.,"

Phrase: "18,"

Phrase: "169189."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Gregersen,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Bross,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "and"

Phrase: "Andresen,"

Phrase: "B.S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.240: (2004) Genetic defects in fatty acid beta-oxidation and acyl-CoA dehydrogenases. 

Phrase: "(2004"

Phrase: ")"

Phrase: "Genetic defects in fatty acid beta-oxidation"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   831   C1829742:Fatty acid oxidation defects [Disease or Syndrome]
   751   C0000768:Birth Defects [Congenital Abnormality]
   751   C0220810:birth defects [Functional Concept]
   748   C0017296:GENETIC [Therapeutic or Preventive Procedure]
   748   C0243067:defects [Functional Concept]
   748   C0314603:Genetic [Functional Concept]
   734 E C1737329:Birth defect [Congenital Abnormality]
   714 E C1457869:Defect [Functional Concept]
   714 E C1861101:DEFECT [Disease or Syndrome]

Phrase: "and"

Phrase: "acyl-CoA dehydrogenases."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085744:Acyl CoA Dehydrogenases [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   983 E C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C0030016:Dehydrogenases [Amino Acid, Peptide, or Protein,Enzyme]
   734   C0001374:Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.241: Molecular pathogenesis and genotypephenotype relationships. 

Phrase: "Molecular pathogenesis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0543483:pathogenesis [Functional Concept]
   861   C0699748:Pathogenesis [Pathologic Function]

Phrase: "and"

Phrase: "genotypephenotype relationships."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0439849:Relationships [Qualitative Concept]
   827 E C1705630:Relationship [Idea or Concept]
   827 E C1706279:Relationship [Idea or Concept]
   827 E C3540605:Relationship [Intellectual Product]
Processing 00000000.tx.242: Eur. 

Phrase: "Eur."
Processing 00000000.tx.243: J. 

Phrase: "J."
Processing 00000000.tx.244: Biochem., 271, 470482.[Abstract/Free FullText] Vianey-Saban, C., Divry, P., Brivet, M., Nada, M., Zabot, M.T., Mathieu, M. and Roe, C. 

Phrase: "Biochem.,"

Phrase: "271,"

Phrase: "470482."

Phrase: "[Abstract/Free FullText"

Phrase: "] Vianey-Saban,"

Phrase: "C.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "Divry,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Brivet,"

Phrase: "M."

Phrase: ","

Phrase: "Nada,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347069:NADA [Functional Concept]

Phrase: "M."

Phrase: ","

Phrase: "Zabot,"

Phrase: "M.T.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Mathieu,"

Phrase: "M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Roe,"

Phrase: "C."
Processing 00000000.tx.245: (1998) Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency: clinical characteristics and diagnostic considerations in 30 patients. 

Phrase: "(1998"

Phrase: ")"

Phrase: "Mitochondrial very-long-chain acyl-coenzyme A dehydrogenase deficiency"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   964   C0342784:Very Long Chain Acyl-Coenzyme A Dehydrogenase Deficiency [Disease or Syndrome]
   931   C0220711:Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency [Disease or Syndrome]
   807   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   791   C0011155:Deficiency [Functional Concept]
   791   C0162429:Deficiency [Disease or Syndrome]
   791   C1623416:deficiency [Qualitative Concept]
   734   C0065170:Long-Chain-Acyl-Coenzyme A Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   720 E C1636779:% deficient [Quantitative Concept]

Phrase: ":"

Phrase: "clinical characteristics"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0683325:clinical characteristics [Clinical Attribute]
   861   C1521970:Characteristics [Qualitative Concept]

Phrase: "and"

Phrase: "diagnostic considerations in 30 patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0518609:considerations [Finding]
Processing 00000000.tx.246: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.247: Chim. 

Phrase: "Chim."
Processing 00000000.tx.248: Acta, 269, 4362.[CrossRef][ISI][Medline] Shen, J.J., Matern, D., Millington, D.S., Hillman, S., Feezor, M.D., Bennett, M.J., Qumsiyeh, M., Kahler, S.G., Chen, Y.T. and Van Hove, J.L. 

Phrase: "Acta,"

Phrase: "269,"

Phrase: "4362."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Shen,"

Phrase: "J.J.,"

Phrase: "Matern,"

Phrase: "D."

Phrase: ","

Phrase: "Millington,"

Phrase: "D.S.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Hillman,"

Phrase: "S."

Phrase: ","

Phrase: "Feezor,"

Phrase: "M.D.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1512018:M.D. [Intellectual Product]
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Bennett,"

Phrase: "M."

Phrase: "J.,"

Phrase: "Qumsiyeh,"

Phrase: "M."

Phrase: ","

Phrase: "Kahler,"

Phrase: "S.G.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439267:g% [Quantitative Concept]
   861   C2603362:S' [Clinical Attribute]

Phrase: "Chen,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0999213:Chen [Bird]

Phrase: "Y.T."

Phrase: "and"

Phrase: "Van Hove,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0264488:heave [Disease or Syndrome]

Phrase: "J.L."
Processing 00000000.tx.249: (2000) Acylcarnitines in fibroblasts of patients with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and other fatty acid oxidation disorders. 

Phrase: "(2000"

Phrase: ")"

Phrase: "Acylcarnitines in fibroblasts of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0368608:acylcarnitines [Organic Chemical]

Phrase: "with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency"
Meta Candidates (Total=12; Excluded=1; Pruned=0; Remaining=11)
  1000   C0342786:Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency [Disease or Syndrome]
   954   C0126155:Long-chain-3-hydroxyacyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   954   C1415460:long-chain-3-hydroxyacyl-CoA dehydrogenase [Gene or Genome]
           LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE
   902   C0443557:Long chain hydroxyacyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   845   C1415458:hydroxyacyl-CoA dehydrogenase [Gene or Genome]
   818   C1291311:dehydrogenase deficiency [Disease or Syndrome]
   795   C0011155:Deficiency [Functional Concept]
   795   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   795   C0162429:Deficiency [Disease or Syndrome]
   795   C1623416:deficiency [Qualitative Concept]
   724 E C1636779:% deficient [Quantitative Concept]

Phrase: "and"

Phrase: "other fatty acid oxidation disorders."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0012634:Disorders [Disease or Syndrome]
   756   C1158366:fatty acid oxidation [Molecular Function]
Processing 00000000.tx.250: J. 

Phrase: "J."
Processing 00000000.tx.251: Inherit. 

Phrase: "Inherit."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439660:inherit [Functional Concept]
Processing 00000000.tx.252: Metab. 

Phrase: "Metab."
Processing 00000000.tx.253: Dis., 23, 2744.[CrossRef][ISI][Medline] Sim, K.G., Hammond, J. and Wilcken, B. 

Phrase: "Dis.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0451119:DIS [Intellectual Product]
  1000   C1444662:DIS [Finding]

Phrase: "23,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "2744."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Sim,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1420068:SIM [Gene or Genome]

Phrase: "K.G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Hammond,"

Phrase: "J."

Phrase: "and"

Phrase: "Wilcken,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.254: (2002) Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. 

Phrase: "(2002"

Phrase: ")"

Phrase: "Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   738   C0679199:strategies [Mental Process]
Processing 00000000.tx.255: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.256: Chim. 

Phrase: "Chim."
Processing 00000000.tx.257: Acta, 323, 3758.[CrossRef][ISI][Medline] Carpenter, K.H. and Wiley, V. 

Phrase: "Acta,"

Phrase: "323,"

Phrase: "3758."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Carpenter,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0336362:Carpenter [Professional or Occupational Group]

Phrase: "K.H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Wiley,"

Phrase: "V."
Processing 00000000.tx.258: (2002) Application of tandem mass spectrometry to biochemical genetics and newborn screening. 

Phrase: "(2002"

Phrase: ")"

Phrase: "Application of tandem mass spectrometry"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0185125:Application [Health Care Activity]
   760   C1947919:Application [Intellectual Product]
   760   C2347934:Application [Intellectual Product]
   760   C3539080:APPLICATION [Quantitative Concept]

Phrase: "to biochemical genetics"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0017401:Genetics, Biochemical [Biomedical Occupation or Discipline]
   861   C0017398:Genetics [Biomedical Occupation or Discipline]
   861   C0017399:genetics [Biologic Function]
   861   C0205474:Biochemical [Functional Concept]

Phrase: "and"

Phrase: "newborn screening."
Meta Candidates (Total=11; Excluded=2; Pruned=0; Remaining=9)
  1000   C0027617:Newborn Screening [Diagnostic Procedure]
   861   C0021289:Newborn [Age Group]
   861   C0220908:Screening [Health Care Activity]
   861   C0220909:screening [Functional Concept]
   861   C1698960:screening [Intellectual Product]
   861   C1710031:Screening [Diagnostic Procedure]
   861   C1710477:SCREENING [Research Activity]
   861   C2239178:Newborn, NOS [Finding]
   861   C2939425:Newborn, NOS [Temporal Concept]
   827 E C1305399:screen [Functional Concept]
   827 E C1705053:Screen [Medical Device]
Processing 00000000.tx.259: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.260: Chim. 

Phrase: "Chim."
Processing 00000000.tx.261: Acta, 322, 110.[CrossRef][ISI][Medline] Spiekerkoetter, U., Sun, B., Zytkovicz, T., Wanders, R., Strauss, A.W. and Wendel, U. 

Phrase: "Acta,"

Phrase: "322,"

Phrase: "110."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Spiekerkoetter,"

Phrase: "U.,"

Phrase: "Sun,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0038817:Sun [Natural Phenomenon or Process]
  1000   C0376223:Sun [Geographic Area]

Phrase: "B.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "Zytkovicz,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Wanders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0233569:wander [Finding]

Phrase: ","

Phrase: "R.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "Strauss,"

Phrase: "A.W."

Phrase: "and"

Phrase: "Wendel,"

Phrase: "U."
Processing 00000000.tx.262: (2003) MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. 

Phrase: "(2003"

Phrase: ")"

Phrase: "MS/MS-based newborn"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0021289:Newborn [Age Group]
   812   C2239178:Newborn, NOS [Finding]
   812   C2939425:Newborn, NOS [Temporal Concept]

Phrase: "and"

Phrase: "family screening"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0220908:Screening [Health Care Activity]
   861   C0220909:screening [Functional Concept]
   861   C1698960:screening [Intellectual Product]
   861   C1710031:Screening [Diagnostic Procedure]
   861   C1710477:SCREENING [Research Activity]

Phrase: "detects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442726:detect [Finding]

Phrase: "asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0030705:Patients [Patient or Disabled Group]
   726   C0342784:Very long chain acyl-CoA dehydrogenase deficiency [Disease or Syndrome]
Processing 00000000.tx.263: J Pediatr., 143, 335342.[CrossRef][ISI][Medline] Saudubray, J.M., Martin, D., de Lonlay, P., Touati, G., Poggi-Travert, F., Bonnet, D., Jouvet, P., Boutron, M., Slama, A., Vianey-Saban, C. etal. 

Phrase: "J"

Phrase: "Pediatr.,"

Phrase: "143,"

Phrase: "335342."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Saudubray,"

Phrase: "J."

Phrase: "M."

Phrase: ","

Phrase: "Martin,"

Phrase: "D."

Phrase: ","

Phrase: "de Lonlay,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Touati,"

Phrase: "G.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Poggi-Travert,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Bonnet,"

Phrase: "D."

Phrase: ","

Phrase: "Jouvet,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "Boutron,"

Phrase: "M."

Phrase: ","

Phrase: "Slama,"

Phrase: "A.,"

Phrase: "Vianey-Saban,"

Phrase: "C. etal."
Processing 00000000.tx.264: (1999) Recognition and management of fatty acid oxidation defects: a series of 107 patients. 

Phrase: "(1999"

Phrase: ")"

Phrase: "Recognition"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0524637:Recognition [Mental Process]

Phrase: "and"

Phrase: "management of fatty acid oxidation defects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0001554:Management [Occupational Activity]
   753   C0376636:management [Health Care Activity]
   753   C1273870:Management [Occupational Activity]
   753   C3273539:Management [Occupation or Discipline]
   716   C1829742:Fatty acid oxidation defects [Disease or Syndrome]

Phrase: ":"

Phrase: "a series of 107 patients."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205549:Series [Quantitative Concept]
   760   C2348044:Series [Intellectual Product]
Processing 00000000.tx.265: J. 

Phrase: "J."
Processing 00000000.tx.266: Inherit. 

Phrase: "Inherit."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439660:inherit [Functional Concept]
Processing 00000000.tx.267: Metab. 

Phrase: "Metab."
Processing 00000000.tx.268: Dis., 22, 488502.[ISI][Medline] Roe, C.R., Sweetman, L., Roe, D.S., David, F. and Brunengraber, H. 

Phrase: "Dis.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0451119:DIS [Intellectual Product]
  1000   C1444662:DIS [Finding]

Phrase: "22,"

Phrase: "488502."

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Roe,"

Phrase: "C.R.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0722969:c r [Organic Chemical,Pharmacologic Substance]
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Sweetman,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Roe,"

Phrase: "D.S.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "David,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "and"

Phrase: "Brunengraber,"

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.269: (2002) Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. 

Phrase: "(2002"

Phrase: ")"

Phrase: "Treatment of cardiomyopathy"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0039798:treatment [Functional Concept]
   790   C0087111:Treatment [Therapeutic or Preventive Procedure]
   790   C1522326:Treatment [Functional Concept]
   790   C1533734:Treatment [Therapeutic or Preventive Procedure]
   790   C1705169:Treatment [Conceptual Entity]
   790   C3538994:TREATMENT [Research Activity]

Phrase: "and"

Phrase: "rhabdomyolysis in long-chain fat oxidation disorders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0035410:Rhabdomyolysis [Pathologic Function]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "an anaplerotic odd-chain triglyceride."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0041004:Triglyceride [Biologically Active Substance,Lipid]
Processing 00000000.tx.270: J. 

Phrase: "J."
Processing 00000000.tx.271: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.272: Invest., 110, 259269.[Abstract/Free FullText] Lee, C.H., Olson, P. and Evans, R.M. 

Phrase: "Invest.,"

Phrase: "110,"

Phrase: "259269."

Phrase: "[Abstract/Free FullText"

Phrase: "] Lee,"

Phrase: "C.H.,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]
   861   C1553033:[c] [Quantitative Concept]

Phrase: "Olson,"

Phrase: "P."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "and"

Phrase: "Evans,"

Phrase: "R.M."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0694746:r m [Immunologic Factor,Pharmacologic Substance]
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.273: (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. 

Phrase: "(2003"

Phrase: ")"

Phrase: "Minireview"

Phrase: ":"

Phrase: "lipid metabolism,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0598783:Lipid Metabolism [Molecular Function]
  1000   C1517898:Lipid Metabolism [Molecular Function]
   861   C0023779:Lipid [Lipid]
   861   C0025519:Metabolism [Organism Function]
   861   C0025520:metabolism [Functional Concept]

Phrase: "metabolic diseases,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C0025517:Metabolic Diseases [Disease or Syndrome]
   861   C0012634:Diseases [Disease or Syndrome]
   861   C0311400:Metabolic [Functional Concept]
   861   C1524026:Metabolic [Cell Function]
   861   C2707259:Metabolic [Clinical Attribute]
   789 E C1836721:MALS [Finding]
   789 E C3538764:MALS [Gene or Genome]
   789 E C3540595:MAL [Gene or Genome]

Phrase: "and"

Phrase: "peroxisome proliferator-activated receptors."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0166418:Peroxisome Proliferator-Activated Receptors [Amino Acid, Peptide, or Protein,Receptor]
   988 E C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]
Processing 00000000.tx.274: Endocrinology, 144, 22012207.[Abstract/Free FullText] Berger, J. and Moller, D.E. 

Phrase: "Endocrinology,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0014137:Endocrinology [Biomedical Occupation or Discipline]
   928 E C0694557:endocrinologic [Functional Concept]

Phrase: "144,"

Phrase: "22012207."

Phrase: "[Abstract/Free FullText"

Phrase: "] Berger,"

Phrase: "J."

Phrase: "and"

Phrase: "Moller,"

Phrase: "D."

Phrase: "E."
Processing 00000000.tx.275: (2002) The mechanisms of action of PPARs. 

Phrase: "(2002"

Phrase: ")"

Phrase: "The mechanisms of action of PPARs."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   779   C0031327:mechanism of action [Physiologic Function]
   779   C1524059:mechanism of action [Functional Concept]
   742   C0441712:Mechanisms [Functional Concept]
   708 E C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.276: Annu. 

Phrase: "Annu."
Processing 00000000.tx.277: Rev. 

Phrase: "Rev."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347961:Rev. [Professional or Occupational Group]
Processing 00000000.tx.278: Med., 53, 409435.[CrossRef][ISI][Medline] Vamecq, J. and Latruffe, N. 

Phrase: "Med.,"

Phrase: "53,"

Phrase: "409435."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Vamecq,"

Phrase: "J."

Phrase: "and"

Phrase: "Latruffe,"

Phrase: "N."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]
Processing 00000000.tx.279: (1999) Medical significance of peroxisome proliferator-activated receptors. 

Phrase: "(1999"

Phrase: ")"

Phrase: "Medical significance of peroxisome proliferator-activated receptors."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0237881:Significance [Quantitative Concept]
   748   C0750502:Significance [Idea or Concept]
Processing 00000000.tx.280: Lancet, 354, 141148.[CrossRef][ISI][Medline] Evans, R.M., Barish, G.D. and Wang, Y.X. 

Phrase: "Lancet,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0777169:Lancet [Medical Device]

Phrase: "354,"

Phrase: "141148."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Evans,"

Phrase: "R."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205090:R- [Spatial Concept]
  1000   C0684010:R. [Professional or Occupational Group]
  1000   C2603358:R' [Clinical Attribute]

Phrase: "M."

Phrase: ","

Phrase: "Barish,"

Phrase: "G.D."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439417:g d [Quantitative Concept]

Phrase: "and"

Phrase: "Wang,"

Phrase: "Y.X."
Processing 00000000.tx.281: (2004) PPARs and the complex journey to obesity. 

Phrase: "(2004"

Phrase: ")"

Phrase: "PPARs"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
  1000   C0166418:Peroxisome Proliferator-Activated Receptors [Amino Acid, Peptide, or Protein,Receptor]
   988 E C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   861   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   812   C0597357:receptors [Amino Acid, Peptide, or Protein,Receptor]
   812   C0752063:Peroxysome [Cell Component]
   812   C1879547:Activated [Activity]
   812   C2984308:Peroxisome [Functional Concept]
   779 E C1515877:Activate [Functional Concept]
   741 E C3546463:peroxisomal [Cell Component]

Phrase: "and"

Phrase: "the complex journey to obesity."
Processing 00000000.tx.282: Nat. 

Phrase: "Nat."
Processing 00000000.tx.283: Med., 10, 355361.[CrossRef][ISI][Medline] Roe, C.R. and Roe, D.S. 

Phrase: "Med.,"

Phrase: "10,"

Phrase: "355361."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Roe,"

Phrase: "C.R."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0722969:c r [Organic Chemical,Pharmacologic Substance]
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "and"

Phrase: "Roe,"

Phrase: "D.S."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.284: (1999) Recent developments in the investigations of inherited metabolic disorders using cultured human cells. 

Phrase: "(1999"

Phrase: ")"

Phrase: "Recent developments in the investigations of inherited metabolic disorders"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   720   C0008073:DEVELOPMENTAL DISORDERS [Mental or Behavioral Dysfunction]
   708   C0243107:development [Physiologic Function]
   708   C0678723:Development [Organism Function]
   708   C1527148:Development [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "cultured human cells."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   913   C0007600:cultured cells [Cell]
   913   C0007635:Cultured Cells [Cell]
   913   C3282338:Cells, Cultured [Cell]
   901   C0427861:Human cells [Laboratory or Test Result]
   827   C0007634:Cells [Cell]
   827   C3282337:Cells [Cell]
   793 E C1269647:Cell [Cell]
   793 E C1704653:Cell [Medical Device]
   793 E C1948049:Cell [Spatial Concept]
Processing 00000000.tx.285: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.286: Genet. 

Phrase: "Genet."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]
Processing 00000000.tx.287: Metab., 68, 243257.[CrossRef][ISI][Medline] Giak Sim, K., Carpenter, K., Hammond, J., Christodoulou, J. and Wilcken, B. 

Phrase: "Metab.,"

Phrase: "68,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450387:68 [Intellectual Product]

Phrase: "243257."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Giak Sim,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1420068:SIM [Gene or Genome]

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Carpenter,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0336362:Carpenter [Professional or Occupational Group]

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Hammond,"

Phrase: "J.,"

Phrase: "Christodoulou,"

Phrase: "J."

Phrase: "and"

Phrase: "Wilcken,"

Phrase: "B."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]
Processing 00000000.tx.288: (2002) Quantitative fibroblast acylcarnitine profiles in mitochondrial fatty acid beta-oxidation defects: phenotype/metabolite correlations. 

Phrase: "(2002"

Phrase: ")"

Phrase: "Quantitative fibroblast acylcarnitine profiles in mitochondrial fatty acid beta-oxidation defects"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   704   C1979963:Profile [Laboratory Procedure]
   704   C2003903:Profile [Functional Concept]

Phrase: ":"

Phrase: "phenotype/metabolite correlations."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C1707520:Correlation [Qualitative Concept]
Processing 00000000.tx.289: Mol. 

Phrase: "Mol."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0027960:Mole [Neoplastic Process]
  1000   C0324740:Mole [Mammal]
  1000   C0439189:Mole [Quantitative Concept]
  1000   C1456781:mole [Neoplastic Process]
  1000   C1824986:mol [Gene or Genome]
   916 E C0026367:Molar [Body Part, Organ, or Organ Component]
   900 E C0027962:moles [Neoplastic Process]
Processing 00000000.tx.290: Genet. 

Phrase: "Genet."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0325074:Genet [Mammal]
Processing 00000000.tx.291: Metab., 76, 327334.[CrossRef][ISI][Medline] Eacho, P.I. and Foxworthy, P.S. 

Phrase: "Metab.,"

Phrase: "76,"

Phrase: "327334."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Eacho,"

Phrase: "P.I."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: "and"

Phrase: "Foxworthy,"

Phrase: "P.S."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0234833:P s [Organ or Tissue Function]
  1000   C0722388:P & S [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.292: (1988) Inhibition of hepatic fatty acid oxidation by bezafibrate and bezafibroyl CoA. 

Phrase: "(1988"

Phrase: ")"

Phrase: "Inhibition of hepatic fatty acid oxidation"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2250059:inhibition of fatty acid oxidation [Cell Function]
   753   C0021467:Inhibition [Mental Process]
   753   C0021469:Inhibition [Molecular Function]
   753   C1628982:% inhibition [Quantitative Concept]
   753   C3463820:Inhibition [Activity]

Phrase: "by bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "bezafibroyl CoA."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0635744:bezafibroyl-CoA [Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
Processing 00000000.tx.293: Biochem. 

Phrase: "Biochem."
Processing 00000000.tx.294: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.295: Res. 

Phrase: "Res."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347379:RES [Finding]
Processing 00000000.tx.296: Commun., 157, 11481153.[CrossRef][ISI][Medline] Aoyama, T., Peters, J.M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T. and Gonzalez, F.J. 

Phrase: "Commun.,"

Phrase: "157,"

Phrase: "11481153."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Aoyama,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Peters,"

Phrase: "J."

Phrase: "M."

Phrase: ","

Phrase: "Iritani,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Nakajima,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Furihata,"

Phrase: "K.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
  1000   C1708601:K' [Quantitative Concept]

Phrase: "Hashimoto,"

Phrase: "T."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "and"

Phrase: "Gonzalez,"

Phrase: "F.J."
Processing 00000000.tx.297: (1998) Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). 

Phrase: "(1998"

Phrase: ")"

Phrase: "Altered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0392747:Altered [Functional Concept]

Phrase: "constitutive expression of fatty acid-metabolizing enzymes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0185117:Expression [Therapeutic or Preventive Procedure]

Phrase: "in mice"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025914:Mice [Mammal]
  1000   C0025929:mice [Mammal]
  1000   C0026809:Mice [Mammal]

Phrase: "lacking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332268:Lacking [Qualitative Concept]

Phrase: "the peroxisome proliferator-activated receptor alpha (PPARalpha)."
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
  1000   C0166415:Peroxisome Proliferator-Activated Receptor alpha [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA [Gene or Genome]
           PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0439095:Alpha [Intellectual Product]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1879547:Activated [Activity]
   804   C2003941:Alpha [Intellectual Product]
   804   C2350010:Alpha [Qualitative Concept]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]
Processing 00000000.tx.298: J. 

Phrase: "J."
Processing 00000000.tx.299: Biol. 

Phrase: "Biol."
Processing 00000000.tx.300: Chem., 273, 56785684.[Abstract/Free FullText] Peters, J.M., Aoyama, T., Burns, A.M. and Gonzalez, F.J. 

Phrase: "Chem.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0201682:CHEM [Laboratory Procedure]

Phrase: "273,"

Phrase: "56785684."

Phrase: "[Abstract/Free FullText"

Phrase: "] Peters,"

Phrase: "J."

Phrase: "M."

Phrase: ","

Phrase: "Aoyama,"

Phrase: "T.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2603360:T' [Clinical Attribute]

Phrase: "Burns,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0006434:Burns [Injury or Poisoning]
   966 E C1550619:Burn [Substance]

Phrase: "A.M."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C2346751:A/m [Quantitative Concept]
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "and"

Phrase: "Gonzalez,"

Phrase: "F.J."
Processing 00000000.tx.301: (2003) Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. 

Phrase: "(2003"

Phrase: ")"

Phrase: "Bezafibrate"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]

Phrase: "is"

Phrase: "a dual ligand for PPARalpha"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   762   C1621296:receptor ligand [Molecular Function]
   742   C0023688:Ligand [Chemical]

Phrase: "and"

Phrase: "PPARbeta"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0287592:PPAR-beta [Amino Acid, Peptide, or Protein,Receptor]
  1000   C0379275:PPAR-Beta [Amino Acid, Peptide, or Protein,Receptor]
  1000   C1418778:PPAR-BETA [Gene or Genome]

Phrase: ":"

Phrase: "studies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0947630:studies [Laboratory Procedure]
   966 E C0557651:Study [Manufactured Object]
   966 E C2603343:Study [Research Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "null mice."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   983   C0206745:Null Mouse [Mammal]
   861   C0025914:Mice [Mammal]
   861   C0025929:mice [Mammal]
   861   C0026809:Mice [Mammal]
Processing 00000000.tx.302: Biochim. 

Phrase: "Biochim."
Processing 00000000.tx.303: Biophys. 

Phrase: "Biophys."
Processing 00000000.tx.304: Acta, 1632, 8089.[ISI][Medline] Zhang, L.F., Ding, J.H., Yang, B.Z., He, G.C. and Roe, C. 

Phrase: "Acta,"

Phrase: "1632,"

Phrase: "8089."

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Zhang,"

Phrase: "L.F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Ding,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1419419:DING [Gene or Genome]

Phrase: "J.H.,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Yang,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945617:yang [Idea or Concept]

Phrase: "B.Z.,"

Phrase: "He,"

Phrase: "G.C."

Phrase: "and"

Phrase: "Roe,"

Phrase: "C."
Processing 00000000.tx.305: (2003) Characterization of the bidirectional promoter region between the human genes encoding VLCAD and PSD-95. 

Phrase: "(2003"

Phrase: ")"

Phrase: "Characterization of the bidirectional promoter region"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1880022:Characterization [Activity]

Phrase: "between the human genes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   983   C0314604:Human gene [Gene or Genome]
   861   C0017337:Genes [Gene or Genome]

Phrase: "encoding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1547699:Encoding [Idea or Concept]
  1000   C2700640:Encoding [Activity]

Phrase: "VLCAD"
Meta Candidates (Total=16; Excluded=0; Pruned=0; Remaining=16)
  1000   C0065170:Very-Long-Chain Acyl-CoA Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Long-Chain-Acyl-CoA Dehydrogenase
  1000   C1412110:ACYL-CoA DEHYDROGENASE, VERY LONG-CHAIN [Gene or Genome]
   947   C1439272:ACYL-CoA DEHYDROGENASE, LONG-CHAIN [Gene or Genome]
   901   C0001374:Long-Chain Acyl CoA [Biologically Active Substance,Lipid,Nucleic Acid, Nucleoside, or Nucleotide]
           Acyl CoA
   861   C0050688:acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0085744:Acyl-CoA dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
           Acyl dehydrogenase
   861   C1980013:Very long chain [Qualitative Concept]
   799   C0030016:Dehydrogenase [Amino Acid, Peptide, or Protein,Enzyme]
   799   C0205166:Long [Qualitative Concept]
   799   C0337112:Chain [Manufactured Object]
   799   C0442824:Very [Qualitative Concept]
   799   C1524075:Chain [Idea or Concept]
   799   C1706317:Long [Qualitative Concept]

Phrase: "and"

Phrase: "PSD-95."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0900627:PSD-95 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
  1000   C1333226:PSD-95 [Gene or Genome]
  1000   C1705335:PSD-95 [Gene or Genome]
   861   C1418591:PSD [Gene or Genome]
   861   C1418984:PSD [Gene or Genome]
Processing 00000000.tx.306: Genomics, 82, 660668.[CrossRef][ISI][Medline] Djouadi, F., Bonnefont, J.P., Thuillier, L., Droin, V., Kadhom, N., Munnich, A. and Bastin, J. 

Phrase: "Genomics,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0887950:Genomics [Biomedical Occupation or Discipline]

Phrase: "82,"

Phrase: "660668."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Djouadi,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Bonnefont,"

Phrase: "J.P.,"

Phrase: "Thuillier,"

Phrase: "L.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]

Phrase: "Droin,"

Phrase: "V.,"

Phrase: "Kadhom,"

Phrase: "N.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441922:N+ [Intellectual Product]
  1000   C1553036:[n] [Quantitative Concept]

Phrase: "Munnich,"

Phrase: "A."

Phrase: "and"

Phrase: "Bastin,"

Phrase: "J."
Processing 00000000.tx.307: (2003) Correction of fatty acid oxidation in carnitine palmitoyl transferase II-deficient cultured skin fibroblasts by bezafibrate. 

Phrase: "(2003"

Phrase: ")"

Phrase: "Correction of fatty acid oxidation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1705565:CORRECTION [Intellectual Product]
   760   C1947976:Correction [Functional Concept]

Phrase: "in carnitine palmitoyl transferase II-deficient cultured skin fibroblasts"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   812   C0450138:Cultured skin [Body Part, Organ, or Organ Component]
   793   C0016030:Fibroblasts [Cell]
   793   C0444099:Skin [Body Substance]
   793   C1123023:Skin [Body System]
   793   C1278993:Skin [Body System]
   779   C1272578:Skin fibroblast [Cell]
   737 E C0221912:Cutaneous [Spatial Concept]
   737 E C0221928:Dermal [Qualitative Concept]
   737 E C1522447:Cutaneous [Functional Concept]

Phrase: "by bezafibrate."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0005330:Bezafibrate [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.308: Pediatr. 

Phrase: "Pediatr."
Processing 00000000.tx.309: Res., 54, 446451.[Abstract/Free FullText] Manning, N.J., Olpin, S.E., Pollitt, R.J. and Webley, J. 

Phrase: "Res.,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347379:RES [Finding]

Phrase: "54,"

Phrase: "446451."

Phrase: "[Abstract/Free FullText"

Phrase: "] Manning,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0024554:MAN [Finding]
   966   C0025266:Man [Population Group]
   966   C0086418:Man [Human]

Phrase: "N.J.,"

Phrase: "Olpin,"

Phrase: "S."

Phrase: "E.,"

Phrase: "Pollitt,"

Phrase: "R.J."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "and"

Phrase: "Webley,"

Phrase: "J."
Processing 00000000.tx.310: (1990) A comparison of [9,10-3H]palmitic and [9,10-3H]myristic acids for the detection of defects of fatty acid oxidation in intact cultured fibroblasts. 

Phrase: "(1990"

Phrase: ")"

Phrase: "A comparison of [9,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1707455:Comparison [Activity]

Phrase: "10-3H"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1442460:3H [Temporal Concept]

Phrase: "]palmitic"

Phrase: "and ["

Phrase: "9,"

Phrase: "10-3H"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1442460:3H [Temporal Concept]

Phrase: "]myristic acids for the detection of defects of fatty acid oxidation"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   770   C1158366:acids fatty oxidation [Molecular Function]
   756   C0027139:Myristic Acids [Lipid]
   754   C0015684:Fatty Acids [Lipid]
   738   C0001128:Acids [Chemical]
   722 E C0027138:Myristic Acid [Biologically Active Substance,Lipid]
   704 E C0202406:Acid [Laboratory Procedure]

Phrase: "in intact cultured fibroblasts."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0016030:Fibroblasts [Cell]
Processing 00000000.tx.311: J. 

Phrase: "J."
Processing 00000000.tx.312: Inherit. 

Phrase: "Inherit."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439660:inherit [Functional Concept]
Processing 00000000.tx.313: Metab. 

Phrase: "Metab."
Processing 00000000.tx.314: Dis., 13, 5868.[CrossRef][ISI][Medline] Wanders, R.J., Vreken, P., den Boer, M.E., Wijburg, F.A., van Gennip, A.H. and Ijlst, L. 

Phrase: "Dis.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0451119:DIS [Intellectual Product]
  1000   C1444662:DIS [Finding]

Phrase: "13,"

Phrase: "5868."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "Wanders"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0233569:wander [Finding]

Phrase: ","

Phrase: "R.J.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Vreken,"

Phrase: "P.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C2603361:P' [Clinical Attribute]

Phrase: "den Boer,"

Phrase: "M."

Phrase: "E.,"

Phrase: "Wijburg,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "A.,"

Phrase: "van Gennip,"

Phrase: "A.H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "and"

Phrase: "Ijlst,"

Phrase: "L."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439394:l's [Quantitative Concept]
  1000   C1706495:L- [Intellectual Product]
  1000   C3642217:/L [Quantitative Concept]
Processing 00000000.tx.315: (1999) Disorders of mitochondrial fatty acyl-CoA beta-oxidation. 

Phrase: "(1999"

Phrase: ")"

Phrase: "Disorders of mitochondrial fatty acyl-CoA beta-oxidation."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C0751651:Mitochondrial Disorders [Disease or Syndrome]
   744   C0012634:Disorders [Disease or Syndrome]
Processing 00000000.tx.316: J. 

Phrase: "J."
Processing 00000000.tx.317: Inherit. 

Phrase: "Inherit."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439660:inherit [Functional Concept]
Processing 00000000.tx.318: Metab. 

Phrase: "Metab."
Processing 00000000.tx.319: Dis., 22, 442487.[CrossRef][ISI][Medline] Djouadi, F., Aubey, F., Schlemmer, D. and Bastin, J. 

Phrase: "Dis.,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0451119:DIS [Intellectual Product]
  1000   C1444662:DIS [Finding]

Phrase: "22,"

Phrase: "442487."

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[ISI][Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Djouadi,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Aubey,"

Phrase: "F.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "Schlemmer,"

Phrase: "D."

Phrase: "and"

Phrase: "Bastin,"

Phrase: "J."
Processing 00000000.tx.320: (2005) Peroxisome proliferator activated receptor (PPAR) agonist but not PPAR corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells. 

Phrase: "(2005"

Phrase: ")"

Phrase: "Peroxisome proliferator activated receptor (PPAR) agonist"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C2987634:Agonist [Pharmacologic Substance]
   771   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   771   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]

Phrase: "but"

Phrase: "not PPAR"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   937   C0166418:peroxisome proliferator activated receptor [Amino Acid, Peptide, or Protein,Receptor]
   937   C1418776:PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR [Gene or Genome]
   840   C0600434:peroxisome proliferator [Hazardous or Poisonous Substance]
   804   C0597357:receptor [Amino Acid, Peptide, or Protein,Receptor]
   804   C0752063:Peroxysome [Cell Component]
   804   C1879547:Activated [Activity]
   804   C2984308:Peroxisome [Functional Concept]
   771 E C1515877:Activate [Functional Concept]
   733 E C3546463:peroxisomal [Cell Component]

Phrase: "corrects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2349182:Correct [Qualitative Concept]

Phrase: "carnitine palmitoyl transferase 2 deficiency in human muscle cells."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   849   C0342790:Carnitine palmitoyl transferase 2 deficiency [Disease or Syndrome]
   829   C2874243:Muscle carnitine palmitoyltransferase deficiency [Disease or Syndrome]
   810   C0268639:Carnitine palmitoyltransferase deficiency [Disease or Syndrome]
   781   C0268637:Muscle carnitine deficiency [Disease or Syndrome]
   762   C0342788:Carnitine Deficiency [Disease or Syndrome]
   762   C1142132:Carnitine deficiency [Disease or Syndrome]
   762   C1291317:deficiency transferase [Disease or Syndrome]
   742   C0011155:Deficiency [Functional Concept]
   742   C0162429:Deficiency [Disease or Syndrome]
   742   C1623416:deficiency [Qualitative Concept]
Processing 00000000.tx.321: J. 

Phrase: "J."
Processing 00000000.tx.322: Clin. 

Phrase: "Clin."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]
Processing 00000000.tx.323: Endocrinol. 

Phrase: "Endocrinol."
Processing 00000000.tx.324: Metab., 90, 17911797.[Abstract/Free FullText] This Article Abstract Full Text (PDF) All Versions of this Article: 14/18/2695 most recent ddi303v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to citation manager Request Permissions Google Scholar Articles by Djouadi, F. 

Phrase: "Metab.,"

Phrase: "90,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439083:>90 [Quantitative Concept]
  1000   C0439087:<90 [Quantitative Concept]

Phrase: "17911797."

Phrase: "[Abstract/Free FullText"

Phrase: "]"

Phrase: "This Article Abstract Full Text"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C1527021:Text [Intellectual Product]
   812   C1554111:Text [Idea or Concept]
   812   C1705606:Text [Intellectual Product]
   812   C3541382:Text [Intellectual Product]

Phrase: "(PDF)"

Phrase: "All Versions of this Article"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0333052:versions [Functional Concept]
   726 E C2607870:Version [Spatial Concept]

Phrase: ":"

Phrase: "14/18/2695 most recent ddi303v1"

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me"

Phrase: "when"

Phrase: "this article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "is"

Phrase: "cited"

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me"

Phrase: "if"

Phrase: "a correction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1705565:CORRECTION [Intellectual Product]
  1000   C1947976:Correction [Functional Concept]

Phrase: "is"

Phrase: "posted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0687676:Post [Temporal Concept]
   966   C1704687:Post [Manufactured Object]

Phrase: "Services"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0557854:Services [Occupational Activity]
   966 E C2825316:Service [Manufactured Object]
   966 E C3245478:service [Idea or Concept]

Phrase: "Email"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]

Phrase: "this article to a friend Similar articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1706852:Article [Intellectual Product]

Phrase: "in this journal Similar articles"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   896   C0282420:Journal Article [Intellectual Product]
   793   C1706852:Article [Intellectual Product]

Phrase: "in ISI Web"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0282111:Web [Manufactured Object]

Phrase: "of Science Similar articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C1706852:Article [Intellectual Product]

Phrase: "in PubMed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1138432:PubMed [Intellectual Product]

Phrase: "Alert"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0239110:ALERT [Finding]

Phrase: "me to new issues of the journal"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0162443:Journal [Intellectual Product,Manufactured Object]
   748   C0205314:New [Temporal Concept]
   714   C0033213:Issue [Finding]
   714   C1706387:Issue [Intellectual Product]

Phrase: "Add to My Personal Archive Download"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0003738:archive [Manufactured Object]
   753   C0024552:MY [Geographic Area]
   753   C1519021:Personal [Organism Attribute]
   753   C1554162:Archive [Idea or Concept]
   753   C1883712:Add [Functional Concept]

Phrase: "to citation manager Request Permissions Google Scholar Articles"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   762   C1706852:Article [Intellectual Product]

Phrase: "by Djouadi,"

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.325: Articles by Bastin, J. 

Phrase: "Articles by Bastin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1706852:Article [Intellectual Product]

Phrase: "J."
Processing 00000000.tx.326: PubMed PubMed Citation Articles by Djouadi, F. 

Phrase: "PubMed PubMed Citation Articles by Djouadi,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   719   C1706852:Article [Intellectual Product]

Phrase: "F."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]
Processing 00000000.tx.327: Articles by Bastin, J. 

Phrase: "Articles by Bastin,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1706852:Article [Intellectual Product]

Phrase: "J."
Processing 00000000.tx.328: Online ISSN 1460-2083 - Print ISSN 0964-6906 Copyright  2006 Oxford University Press Oxford Journals Oxford University Press Site Map Privacy Policy Frequently Asked Questions Other Oxford University Press sites: Oxford University Press American National Biography Booksellers' Information Service Children's Fiction and Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights and Permissions Science School Books Social Sciences Very Short Introductions World's Classics

Phrase: "Online ISSN 1460-2083 - Print ISSN 0964-6906 Copyright  2006 Oxford University Press Oxford Journals Oxford University Press Site Map Privacy Policy Frequently"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   788   C2735290:Privacy policy [Intellectual Product]
   782   C0242456:Policy [Intellectual Product]

Phrase: "Asked"

Phrase: "Questions"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1522634:Question [Intellectual Product]

Phrase: "Other Oxford University Press sites"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C0205145:Sites [Spatial Concept]
   779 E C1515974:Site [Body Location or Region]
   779 E C2825164:Site [Spatial Concept]

Phrase: ":"

Phrase: "Oxford University Press American National Biography Booksellers' Information Service Children's Fiction"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   788   C0887933:fiction [Intellectual Product]

Phrase: "and"

Phrase: "Poetry Children's Reference Corporate & Special Sales Dictionaries Dictionary"

Phrase: "of National Biography Digital Reference English Language Teaching Higher Education Textbooks Humanities International Education Unit Law Medicine Music Online Products Oxford English Dictionary Reference Rights"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   852   C0947619:Finger.right [Body Part, Organ, or Organ Component]
   782   C0035621:Rights [Qualitative Concept]
   782   C0205090:Right [Spatial Concept]

Phrase: "and"

Phrase: "Permissions Science School Books Social Sciences Very Short Introductions World's Classics"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   788   C0439658:classics [Qualitative Concept]
   755 E C0439858:Classic [Qualitative Concept]

